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Abbreviations and terminology
OMV outer membrane vesicles
dOMV detergent-extracted OMV (using deoxycholate)
nOMV native OMV, detergent-free extraction with a chelating agent (EDTA)
sOMV spontaneously released OMV, no extraction (detergent-free)
LPS lipopolysaccharide (endotoxin)
DOC deoxycholate
EDTA ethylenediaminetetraacetic acid (chelates Ca2+ and Mg2+ ions)
lpxL1 mutation prevents biosynthesis of acyl chain in lipid A (attenuates LPS toxicity)
rmpM mutation disrupts membrane anchor protein (expected to improve OMV yield)
next-generation OMV OMV from strain with lpxL1-LPS, produced with a detergent-free 
process
PorA outer membrane porin A protein
fHbp factor H binding protein
CPS capsular polysaccharide
PL phospholipid
PTAG phospho-tag reagent (glyceraldehyde-3-phosphate)
TiO2 titanium dioxide (captures PTAG)
SBA serum bactericidal activity (measures functional immunogenicity)
MAT IL-6 monocyte activation test (measures in vitro toxicity)
QbD Quality by Design
DoE Design of Experiments
Thesis abstract
Only vaccines containing outer membrane vesicles (OMV) have successfully stopped Neisseria 
meningitidis serogroup B epidemics. The OMV vaccines, however, provide limited coverage and 
are difficult to produce. This is caused by an obligatory detergent treatment, which removes 
lipopolysaccharide (LPS), a toxic OMV component. This thesis explored an alternative approach, 
based on OMV with attenuated lpxL1-LPS and a detergent-free process. The alternative approach 
is referred to as ‘next-generation OMV’ and provided vaccines with improved immunological and 
biochemical properties. In addition, quantitative proteomics demonstrated a preferred protein 
composition. This provided justification for further development towards clinical trials. After 
optimization of specific process steps, an improved pilot-scale production process was developed. 
The quality of OMV from this optimized process was stable and within pre-set specifications for 
nine consecutive batches. Studies in mice and rabbits suggested that next-generation OMV are 
immunogenic and safe for parenteral use in humans. Therefore these vaccines are now ready for 
clinical evaluation. Several groups are developing broadly protective OMV vaccines against N. 
meningitidis serogroup B, but also against other serogroups and other pathogens. OMV therefore 
have the potential to become a versatile technology platform for prophylactic and therapeutic 
vaccines. Such a platform requires a reliable production process to generate substantial quantities 
of high quality product. The process described in this thesis is well-suited for this purpose. The 
results encourage technology transfer to a commercial partner, with the goal to translate next-
generation OMV technology into actual vaccines and improve global public health.

Chapter 1
General introduction
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Background
The Health Council of the Netherlands recognized that the development of a serogroup B 
meningococcal disease vaccine is of major importance for national public health [1]. At present 
only vaccines containing outer membrane vesicles (OMV) have proven efficacy against specific 
serogroup B strains. These vaccines however do not provide broad coverage and are difficult to 
produce [2, 3]. To facilitate progress, the Institute for Translational Vaccinology (Intravacc, until 
recently part of the National Institute for Public Health and the Environment (RIVM)) received 
public funding to remove existing bottlenecks with a dedicated research program. Since the late 
1990’s this program has provided a vaccine concept with broad serogroup B coverage and a high-
yield synthetic growth medium for meningococci. A gene mutation that attenuates toxic OMV 
components was also discovered and is expected to allow a more straightforward production 
process [4-7]. This thesis explores the benefits of such an alternative production strategy. New 
tools for product characterization and a novel pilot-scale production process for next-generation 
OMV vaccines were developed. The next-generation OMV vaccines are now ready for clinical 
evaluation. Relevance of this thesis for the broader field of vaccinology is discussed.
Meningococcal disease
Neisseria meningitidis is a gram-negative β-proteobacterium and member of the Neisseriaceae family 
[8]. It was identified as the causative agent of bacterial meningitis by Anton Weichselbaum in 
1887 [9]. Meningococci reside in the nasopharyngeal mucosa of their human host. Approximately 
8–20% of the adult population is colonized by meningococci, but most individuals will never 
develop symptoms of disease [10, 11]. Through a poorly understood mechanism, virulent N. 
meningitidis bacteria sometimes cross the mucosa to enter the bloodstream and cause invasive 
disease [12-14]. There are several different serogroups of N. meningitidis based on characteristics 
of its capsular polysaccharide. Six serogroups (A, B, C, W, X, and Y) are more virulent and cause 
the vast majority of life-threatening disease [14, 15]. The highest incidence occurs in young 
children under the age of four. Another incidence peak is observed among teenagers, most likely 
caused by increased exposure to risk factors like smoking or a high frequency of intimate contacts 
[16, 17]. Invasive meningococcal disease has devastating consequences caused by highly acute 
meningitis and septicemia. Fatality rates vary from 5–10% in industrialized countries up to 20% 
in developing countries. In addition about 10–20% of survivors have permanent health damage 
such as amputated of limbs, epilepsy, mental disabilities or deafness [18]. 
Epidemic outbreaks of meningococcal disease have been described in Europe since 1805 and 
for more than 100 years in sub-Saharan Africa, known as the ‘African meningitis belt‘ (Figure 1) 
[18, 19]. Incidence rates of invasive meningococcal disease vary from very rare to 100–1000 cases 
per 100,000 inhabitants per year in specific regions during an epidemic outbreak. N. meningitidis 
serogroup A causes the highest disease incidence, as illustrated by repeated outbreaks in the 
African meningitis belt every 5–10 years and to a lesser extent in Russia and China over the past 
few decades [19, 20]. Serogroup B is predominant in industrialized countries, where it 
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accounts for 30–40% of all cases in North America and up to 80% in European countries [21, 22]. 
Even though serogroup B is associated with lower incidence rates than serogroup A, prolonged 
outbreaks have caused a substantial number of cases [23, 24]. The other virulent serogroups also 
have a high incidence and a distinct geographical distribution (Figure 1) [14]. The severity and 
global character of meningococcal disease emphasizes the need for an effective vaccine prevention 
strategy [24]. 
The first vaccines against N. meningitidis contained purified capsular polysaccharide (CPS) of 
serogroups A and C. They were safe and moderately effective in preventing serogroup C disease 
in the U.S. military and in controlling serogroup A epidemics in the African meningitis belt [25, 
26]. After the emergence of serogroup W, a quadravalent vaccine was developed, containing CPS 
from serogroups A, C, W and Y [25, 27]. Unfortunately, purified CPS vaccines proved to be poorly 
immunogenic in young infants and failed to induce long-term immunological memory [18, 28]. 
Based on experience with conjugate vaccines against Haemophilus influenzae, meningococcal 
CPS was chemically conjugated to toxoid carrier protein. These CPS–protein conjugate vaccines 
were safe, had a greatly improved immunogenicity in young infants and were able to induce 
Figure 1. Epidemiology of meningococcal disease.
(A) Worldwide distribution of meningococcal disease by serogroup. Countries with epidemic outbreaks are 
depicted in dark grey. The predominant serogroups are shown for each continent (adapted from [24]). (B) 
The number of WHO reported cases of meningococcal disease in the African meningitis belt countries from 
1970 to 2010. Devastating epidemic outbreaks occur approximately every ten years with local incidences 
of 100–1000 reported cases per 100,000 inhabitants, with a mortality rate of approximately 20% (source: 
www.who.int).
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immunological memory in toddlers and adolescents [29-31]. Conjugated vaccines have now 
been used in routine vaccination programs for several years, which decreased the number of 
deaths and clinical cases with more than 90%. Disease incidence in non-vaccinated individuals 
also decreased due to herd immunity [32-35]. Despite the major successes with other serogroups, 
conjugate vaccines containing serogroup B capsular polysaccharide had a poor immunogenicity 
[36]. The suspected cause was a structural similarity with sialic acid in glycoproteins from human 
neural tissue [37]. An attempt to solve this problem by replacing the N-acetyl groups of sialic acid 
residues yielded a conjugate vaccine that was safe in phase I clinical trials, but unable to induce 
functional immunogenicity [38, 39].
Outer membrane vesicle vaccines
Disappointing results with the conjugate approach shifted serogroup B research towards 
surface-exposed subcapsular antigens of the outer membrane. Like Escherichia coli or Vibrio 
cholerae, meningococci released outer membrane vesicles (OMV) containing proteins, CPS, 
lipopolysaccharide (LPS), phospholipids (PL) and periplasmic constituents [40-42]. The OMV 
were immunologically similar to the N. meningitidis outer membrane, since they contained all 
major membrane proteins in their native conformation (Figure 2) [43]. OMV induced good 
functional immunogenicity in humans, but detergent-extraction was necessary to ensure safety 
[44-46]. The detergent removed most of the LPS from the vesicles, which would otherwise have 
a highly endotoxic effect [47, 48]. After development of a production process by the Norwegian 
Institute for Public Health (NIPH), detergent-extracted OMV vaccines were used to control 
epidemic outbreaks in several different countries [49]. To date, these are the only interventions 
with proven efficacy against serogroup B meningococcal disease [3]. Efficacy was demonstrated 
in Chile, Cuba, Norway, Brazil and New-Zealand, where one specific strain had caused epidemic 
outbreaks for several decades [50-54]. The excellent safety record and high efficacy were a major 
milestone for the application of OMV in vaccinology. 
Detergent-extracted OMV vaccines are well-suited for the control of epidemic outbreaks due to a 
high strain specificity [3]. A significant limitation however is that the immune response is almost 
exclusively directed against the immuno-dominant porin A antigen (PorA), especially in young 
infants and children [55-57]. PorA is variable between circulating serogroup B strains, which 
complicates development of a broadly protective vaccine [58]. To increase coverage, Intravacc 
developed recombinant strains with multiple PorA subtypes. The cps locus was also deleted to 
improve biosafety and remove the undesired CPS antigen of serogroup B [7, 37, 59]. This multivalent 
OMV concept initially consisted of two trivalent vaccine strains (HexaMen) and provided broad 
functional immunogenicity in phase II clinical trials [60, 61]. Potential European coverage was 
further increased to 80% of circulating strains by adding a third trivalent strain (NonaMen) [5, 
62]. Other groups have improved vaccine coverage by complementing multiple PorA’s with 
other immunogenic antigens, like factor H binding protein (fHbp) or iron-regulated proteins (e.g. 
FetA) [63, 64]. In addition OMV were used in a vaccine containing purified recombinant proteins 
(Novartis, Bexsero). The recombinant proteins were discovered by ‘reverse vaccinology’ [65], but 
the presence of detergent-extracted OMV was required for sufficient immunogenicity [66-68]. 
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In addition to a limited coverage, LPS removal with detergents caused production problems 
like aggregation. OMV aggregates interfere with sterile filtration, leaving the use of potentially 
toxic preservatives (i.e. thiomersalate) as the only remaining option to ensure sterility. Residual 
detergent in the OMV vaccine can stabilize aggregates, but deoxycholate is a component of animal 
origin [2, 61]. These challenges complicate compliance to current regulatory requirements, which 
has delayed the late-phase development and registration of detergent-extracted OMV vaccines 
[69]. Intravacc succeeded to attenuate LPS by introducing the lpxL1 mutation, rather than 
physically remove it with deoxycholate (Figure 3) [6]. The attenuated LPS had a highly reduced 
endotoxic activity, which enabled the development of next-generation OMV vaccines for human 
use [70, 71]. Next-generation OMV are produced completely detergent-free, which preserves the 
native (attenuated) LPS content and retains protective lipoproteins like fHbp. This is expected 
to improve immunogenicity and cross-protection [72-74]. Therefore the development of next-
generation OMV vaccines may resolve the disadvantages associated with detergent-extraction.
Figure 2. Vesiculation from the cell envelope of Neisseria meningitidis.
N. meningitidis can release outer membrane vesicles (OMV) through vesiculation [76]. OMV are spherical 
particles with a diameter of 50-200 nm, containing outer membrane proteins in their natural conformation, 
capsular polysaccharide (CPS), lipopolysaccharide (LPS), phospholipid (PL) and periplasmic constituents. 
OMV can be used as a vaccine since they are immunologically similar to the pathogen. PorA was identified 
as the immuno-dominant antigen of OMV vaccines that successfully stopped serogroup B epidemics 
in Norway, New Zealand, Cuba, Brazil and Chile [50-54]. Wild-type LPS of N. meningitidis however is 
endotoxic and must be removed with detergent-extraction to obtain a safe vaccine. Alternatively, it can 
be attenuated with the ΔlpxL1 mutation (see Figure 3). RmpM is an anchor protein, which connects the 
outer membrane to a rigid peptidoglycan layer. Therefore ΔrmpM strains have a higher OMV yield. For 
N. meningitidis serogroup B vaccines, Δcps capsule deletion mutants are used to prevent suspected cross-
reactivity with human neural tissue [37].
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Figure 3. Lipopolysaccharide of N. meningitidis.
Wild-type lipopolysaccharide (LPS) of N. meningitidis has a strong endotoxic effect in humans. Therefore 
the production of OMV vaccines requires LPS removal with detergents, which complicates processing [2, 
61]. Alternatively, LPS toxicity can be attenuated by introducing the lpxL1 mutation which may enable 
a detergent-free production process [6]. The strains that were used in this thesis had an additional galE 
truncation in the oligosaccharide part of the LPS, resulting from deletion of the cps capsule locus [59]. 
*Biosynthesis of the outlined secondary acyl chain of lipid A is prevented by lpxL1 gene deletion.  
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Objectives and thesis outline
After many years of extensive fundamental and applied research, broadly protective OMV 
vaccines against serogroup B meningococcal disease are now on the horizon [71]. Production and 
quality issues related to LPS removal with detergent have prevented successful introduction of 
promising vaccine concepts for humans use, like HexaMen [7, 61]. This thesis explores the use of 
next-generation OMV vaccines as an improved alternative for detergent-extracted vaccines. The 
designation ‘next-generation OMV’ refers to the combination of vaccine strains with attenuated 
lpxL1-LPS and a detergent-free process. These changes may have a profound impact on process 
and vaccine characteristics. Therefore, the central question of this thesis is:
Do next-generation OMV vaccines provide improved quality and process robustness? 
With the central research question in mind, five hypotheses were formulated and tested in this 
thesis:
1)  Next-generation OMV vaccines provide improved quality compared to detergent-extracted 
OMV.
2)  Biomass extraction during processing changes the immunogenic protein content of OMV 
vaccines.
3)  Biological stimuli can trigger OMV release by N. meningitidis and can be applied to improve 
vaccine production.
4)  Next-generation OMV vaccines allow a more consistent and efficient large-scale production 
process.
5)  Despite a high LPS content, next-generation OMV vaccines are safe for parenteral use in 
humans.
The hypotheses were tested in different chapters of this thesis, as outlined in Figure 4. Chapter 2 
compared the properties of detergent-extracted reference OMV with detergent-free alternatives. 
This was done at small-scale, in the context of vaccine strains with systematic combinations of 
two different gene deletions. The ΔlpxL1 mutation was used to attenuate LPS [6] and the ΔrmpM 
mutation was expected to improve yield [75]. Biochemical composition, yield and functional 
properties of the resulting OMV vaccines were analyzed with the goal to identify the best 
combination of strain and process for further scale-up (hypothesis 1).
In chapter 3 and 4, the effect of different production processes on the protein content of OMV 
vaccines was assessed with proteomics. Chapter 3 is a qualitative study, which demonstrated that 
a newly developed affinity tag (PTAG) can be used to reduce sample complexity while preserving 
the original proteome fingerprint. The relevance of such an approach for the analysis of complex 
protein products like OMV vaccines, is substantiated. Chapter 4 added a robust quantification 
method to the PTAG protocol, based on stable isotope labeling of free amino groups. This method 
was used to quantify the protein content of OMV vaccines from different production processes, 
followed by functional annotation of differentially expressed proteins (hypothesis 2).
16
Based on the results of chapters 2, 3 and 4, a ΔlpxL1-ΔrmpM mutant strain was selected and 
combined with a detergent-free process for further process development. A central step in this new 
process was biomass extraction with a chelating agent (detergent-free). Chapter 5 systematically 
optimized this step by measuring the impact of five potentially critical process parameters on 
OMV quality with Design of Experiments (DoE) [77, 78]. Two critical process parameters were 
identified, which were tuned to optimize the detergent-free extraction step. 
In E. coli, different biological stimuli for the spontaneous release of OMV have been identified, 
including nutrient starvation [41, 79-81]. It was hypothesized that such stimuli can trigger OMV 
release in N. meningitidis as well and improve the yield of an OMV production process. The 
results of chapter 5 already pointed in this direction since one of the critical process parameters 
was related to both nutrient starvation and increased OMV yield, but this observation required 
additional experimental validation. This was done in chapter 6, which identified cysteine as the 
limiting medium component for growth. Next, the impact of cysteine depletion on spontaneous 
OMV release was measured and an underlying mechanism was proposed. The added value of 
such an approach for production of next-generation OMV vaccine was also assessed (hypothesis 
3). 
In parallel with chapters 5 and 6, a pilot-scale GMP production process was developed based 
on three different ΔlpxL1-ΔrmpM strains expressing multiple recombinant PorA antigens (next-
generation NonaMen vaccine [5, 70]). Chapter 7 evaluated process robustness and consistency of 
replicate cultivations at 40 L scale. GMP quality control was performed to assess if OMV product 
quality was within preset preliminary specifications. In addition, yield and reproducibility of the 
new detergent-free process was compared with published reference processes (hypothesis 4). 
Figure 4. Thesis outline.
The central research question and hypotheses were tested in different chapters of this thesis. Chapter 3 and 
4 describe the development of a novel quantitative proteomics method for characterization of OMV protein 
content. The other research chapters describe the process development of next-generation OMV vaccine.
17
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Chapter 7 demonstrated that next-generation NonaMen vaccine met all preset specifications, 
therefore the vaccine was tested for preclinical immunogenicity and toxicology (mice and 
rabbits; chapter 8). Since next-generation NonaMen has a high attenuated LPS content compared 
to detergent-extracted vaccines, safety and toxicity testing is of special importance. Chapter 8 
verified whether in vitro observed LPS attenuation after lpxL1 deletion translates to low toxicity 
in rabbits (hypothesis 5). 
This thesis covers all major aspects of preclinical vaccine development, from concept evaluation 
to pilot-scale GMP production. Preclinical toxicology and immunogenicity testing in chapter 8 
provides justification for future clinical trials. Therefore this thesis represents an important step 
towards the introduction of next-generation OMV vaccine for human use. The scope of these 
results is discussed, since the new production process is not necessarily restricted to NonaMen 
and may be applicable for other meningococcal serogroups or other gram-negative pathogens 
like Vibrio cholerae or Bordetella pertussis [82-84]. Such a technology platform facilitates the 
development and clinical evaluation of new OMV concepts and supports the ongoing global 
effort to fight infectious diseases through vaccination. 
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20
Abstract
The use of detergent-extracted outer membrane vesicles (OMV) is an established approach 
for development of a multivalent PorA vaccine against N. meningitidis serogroup B. Selective 
removal of lipopolysaccharide (LPS) decreases toxicity, but promotes aggregation and narrows 
the immune response. Detergent-free OMV vaccines retain all LPS, which preserves the native 
vesicle structure, but results in high toxicity and lower yield. The present study assesses the 
effects of gene mutations that attenuate LPS toxicity (lpxL1) or improve OMV yield (rmpM) in 
combination with the available OMV purification processes. The results substantiate that OMV 
from a strain with both mutations, produced with a detergent-free process provide better vaccine 
characteristics than the traditional detergent-based approach. With comparable toxicity and 
yield, no aggregation and cross-protection against other PorA subtypes, these OMV vaccines are 
potentially safe and effective for parenteral use in humans.
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Introduction
Neisseria meningitidis is a human pathogen that can cause acute meningitis and septicemia, with 
fatality rates around 15% [18]. Serogroup B meningitis accounts for 30-40% of meningitis cases 
in North America [21, 85] and up to 80% in some European countries [22, 86], yet a broadly 
protective vaccine is not available. Effective vaccines against other serogroups have been 
developed based on capsular polysaccharide conjugated to a carrier protein [31]. This approach 
was not feasible for serogroup B, due to poor immunogenicity [87] and concerns for vaccination-
induced autoimmunity [37]. To date, vaccines based on outer membrane vesicles (OMV) are the 
only vaccines that successfully controlled serogroup B epidemics with examples in Norway, 
Cuba, and New Zealand [49-51, 53, 88].
OMV are released from the outer membrane of gram negative bacteria and consist of a 
phospholipid (PL) bilayer that contains outer membrane proteins, lipopolysaccharide (LPS) 
and periplasmic constituents [89]. PorA protein was identified as the major protective antigen 
in OMV, but is highly variable between the circulating serogroup B strains which complicates 
vaccine development [57, 90]. For this reason, the Netherlands Vaccine Institute (Bilthoven, The 
Netherlands) developed an OMV vaccine based on genetically modified N. meningitidis strains 
that express multiple PorA subtypes. This multivalent OMV vaccine was initially made with 
2 trivalent PorA strains, expressing a total of 6 PorA subtypes [7, 61] and provided functional 
immunogenicity in phase II clinical trials [60]. To ensure sufficient coverage for serogroup B 
strains circulating globally, a third trivalent strain was added [5]. 
OMV vaccines are traditionally prepared with detergent extraction (dOMV purification process) 
to remove LPS and increase vesicle release. The LPS of N. meningitidis is highly toxic, but residual 
amounts (approx. 1%) are needed to maintain vesicle structure and adjuvate the immune 
response against PorA [91-93]. With balanced detergent concentrations the dOMV purification 
process provides these requirements, however there are major disadvantages. Along with LPS, 
detergent removes PL and also lipoproteins that contribute to immunogenicity, such as factor 
H binding protein [73, 94]. The resulting immune response is directed against a specific PorA 
subtype, without eliciting cross-protection [87, 95]. In addition, selective removal of LPS and 
PL changes the native vesicle structure and promotes aggregation [3, 96]. Detergent treatment 
is necessary to decrease LPS toxicity, but has detrimental side effects that complicate vaccine 
development.
Detergent-free OMV purification processes retain all LPS, resulting in a preserved native vesicle 
structure, but also in vaccines that are inherently toxic when used for parenteral immunization [3]. 
Two detergent-free purification processes have been described. The native OMV (nOMV) process 
[44] is similar to dOMV except for a detergent-free extraction step and the spontaneous OMV 
(sOMV) process [97-99] utilizes ultrafiltration or ultracentrifugation to purify spontaneously 
released OMV’s from the culture supernatant, without extraction. nOMV vaccines produced 
encouraging results in animals and humans, but high LPS content limited applicability of the 
vaccine to intranasal administration [100-103]. Preclinical data on sOMV vaccines includes a 
study in mice, reporting cross-protection against a panel of serogroup B strains that was not found 
22
with dOMV, but potential differences in toxicity were not addressed [104]. Other studies with 
sOMV vaccines in mice and rhesus monkeys also reported a broad immunogenicity [73, 94, 190]. 
The sOMV process however imposes an additional challenge, since it produces OMV yields that 
are too low for  feasible process development [97, 98, 104]. To date, a direct and comprehensive 
comparison of the available OMV purification processes has not been made. 
Discovery of lpxL1 mutant strains provided a solution for the LPS toxicity issue [6]. Deletion 
of lpxL1 attenuated LPS toxicity, while preserving the adjuvant activity needed for the immune 
response [6, 72, 94]. It was established that the immunogenicity of OMV from LPS deficient strains 
could be restored by adding external lpxL1 LPS [105, 106]. In addition, rmpM deletion mutants 
were found to have a loosely attached outer membrane which could increase OMV release [107]. 
Absence of RmpM did not affect immunogenicity or bacterial growth characteristics [108], but 
to date the effect on OMV yield has not been scrutinized. In theory, a combination of lpxL1 and 
rmpM mutations could solve the toxicity and yield problems associated with detergent-free OMV 
vaccines. The present study provides the first comprehensive analysis of N. meningitidis serogroup 
B vaccine performance, using OMV from the available purification processes (dOMV, nOMV and 
sOMV) in combination with lpxL1 and rmpM genetic modifications (Figure 1). The OMV vaccines 
were analyzed for yield, toxicity, functional immunogenicity and aggregation with the objective 
to select the best approach for vaccine development. Beneficial effects were found for both gene 
mutations, enabling the use of detergent-free methods as the better alternative to traditional, 
detergent-based OMV purification processes.
Figure 1. Experimental outline. 
From a shared genetic background (H44/76), four bacterial strains were constructed expressing three PorA 
subtypes and combinations of lpxL1 and rmpM gene mutations (wt, ΔR, ΔL and ΔRΔL strains). The strains 
were processed with three different purification processes (dOMV, nOMV and sOMV) producing eight OMV 
vaccines with distinct characteristics. The detergent-based dOMV process was used to reduce toxicity of 
strains with normal LPS (detergent extraction of wt and ΔR), while the detergent-free nOMV process was 
exclusively used for strains with attenuated LPS toxicity (EDTA extraction of ΔL and ΔRΔL). The detergent-
free sOMV process was used on all four strains, providing two inherently toxic control vaccines (marked with 
asterikses) and two sOMV vaccines with attenuated LPS toxicity.
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Materials and methods
Bacterial strains and growth conditions
All N. meningitidis strains that were used are recombinant non-encapsulated variants of the 
group B isolate H44/76 [109], combining one wild type and two recombinant PorA subtypes 
(trivalent PorA: subtypes P1.7,16, P1.5-1,2-2 and P1.19,15) with a non-functional porB gene [7] and 
truncated galE LPS [110]. Additional mutations in lpxL1 and/or rmpM genes are strain-specific 
and summarized in Figure 1, resulting in 4 different strains (wt, ΔR, ΔL and ΔRΔL). Inactivation 
of lpxL1 resulted in loss of the secondary acyl chain of lipid A, which was verified by mass 
spectrometry [6]. All bacterial cultures were grown in chemically defined medium. Disposable, 
baffled 500 mL erlenmeyer shake flasks with vented closure (Nalgene, Rochester, New York, 
U.S.A.) containing 150 mL medium, were inoculated with 10 mL working seedlot (cells at OD590 = 
1.00 ± 0.05; stored at -135°C with 17.4% (v/v) glycerol) and incubated at 35°C, 200 rpm. Glucose 
concentration of the medium was monitored at-line with a YSI-2700 analyzer (Yellow Springs 
Instruments, Yellow Springs, Ohio, U.S.A.). Cells were harvested for OMV purification during 
late-exponential growth phase, at a residual glucose concentration of 5 mM.
OMV purification processes
The dOMV purification process utilizes deoxycholate (DOC) extraction of the bacterial outer 
membrane in the presence of EDTA, as described previously [61]. The nOMV process was 
based on the method described by Zollinger et. al. [44]. In this study, the consecutive steps of 
the nOMV process were identical to dOMV, however without DOC. OMV release is stimulated 
using EDTA alone, which is a chelating agent that destabilizes the bacterial outer membrane 
[111]. Supernatants from the initial harvesting step of the dOMV and nOMV processes were 
used as starting material for the sOMV purification process. After 0.2 μm filtration (Millipore, 
Billerica, Massachusetts, U.S.A.), OMV were concentrated and diafiltrated in Tris-sucrose buffer 
(10 mM Tris-HCl, pH 7.4; 3% sucrose (w/v)), using 100 kD ultrafiltration units (Millipore) driven 
by centrifugal force (3000 xg; 4°C). Additional purification and concentration of OMV in the 
retentate was done by ultracentrifugation (60 minutes at 125000 xg; 4°C). The final OMV pellets 
were homogenized in Tris-sucrose buffer and diluted to a total protein concentration of 0.5 mg/
mL. All OMV purification processes were performed at small-scale (<0.5 L).
OMV vaccines
Bacterial strains with lpxL1 and rmpM genetic modifications were systematically combined with 
OMV purification processes to obtain 8 OMV vaccines with distinct characteristics (Figure 1). 
The dOMV process was used to decrease toxicity of OMV vaccines with normal LPS (wt and ΔR 
strains), while the detergent-free nOMV process was exclusively used for strains with attenuated, 
non-toxic LPS (ΔL and ΔRΔL). These restrictions were used, because there should be no need 
for detergents when an OMV vaccine contains non-toxic LPS. To obtain inherently toxic OMV 
vaccines that were needed as controls for the toxicity analysis, the detergent-free sOMV process 
was used for all 4 bacterial strains, including those with toxic LPS.
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Biochemical composition and OMV yield
Total protein concentration of OMV vaccines was measured using the Peterson’s method [112]. 
PorA and ‘other protein’ content was measured with quantitative SDS gel electrophoresis under 
denaturing conditions [112, 113]. Per lane, 4 μg total protein from OMV vaccines was loaded. 
Gels were stained with Novex Colloidal Blue (Invitrogen, Carlsbad, California, U.S.A.) and PorA 
and ‘other protein’ was quantified as a percentage of total protein using TL100 1D gel analysis 
software (Totallab, Newcastle upon Tyne, U.K.). Residual DNA in the OMV vaccines was 
quantified with fluorescence spectroscopy using ethidium bromide (MP Biochemicals, Illkirch, 
France) as described before [4, 114]. Fatty acid composition was analyzed to quantify LPS and 
PL content, using a modified gas chromatography method [115, 116]. LPS was isolated by hot 
phenol-water extraction as  described  before [117]  and quantified using  the peak height of 
C14:0-3OH with C12:0-2OH as the internal standard (two C14:0-3OH residues per LPS), while 
PL was quantified using the peak heights sum of C16:0, C16:1, C18:0 and C18:1 with C15:0 as the 
internal standard. Specific protein yields (µg total protein and µg trivalent PorA per 1010 bacteria) 
were used to estimate OMV yield. Optical density was measured to calculate the number of 
harvested bacteria (1 OD unit at 590 nm corresponds to 4.4 x 109 cfu/mL).
Immunizations and functional immunogenicity
Immunizations were performed with 4 groups consisting of 15 female BALB/c mice per group, 
which were 6 to 8 weeks old. Group 1 mice received ΔR-dOMV vaccine, group 2 mice were 
immunized with ΔRΔL-nOMV vaccine and group 3 mice received ΔRΔL-sOMV vaccine. Group 4 
received mock immunizations. All OMV vaccines were administered in a 0.3 mL dose, containing 
AlPO4 as an adjuvant. Vaccines were prepared less than 24 hours before immunization by mixing 
OMV containing 1.5 μg PorA per subtype per dose (4.5 μg trivalent PorA per dose) with 0.45 
mg AlPO4 overnight at 4°C. Immunizations were given twice, subcutaneously on days 0 and 28, 
and serum was collected on day 42. Functional immunogenicity was determined by measuring 
serum bactericidal activity (SBA) as described before [118]. Statistical analysis of the obtained 
non-parametric data was done using the Kruskal-Wallis test to compare titers for each PorA 
subtype between the experimental groups (unpaired observations). P-values below 0.05 were 
considered to be significant.
Toxicity
The toxicity of the OMV vaccines was measured as described before for B. pertussis [119]. 
Stimulation of IL-6 production was tested with the human macrophage cell line MM6 [120]. 
Macrophages were seeded in 24-wells plates (2.5 x 105 cells/well) in 400 μl of IMDM medium 
(Invitrogen, Breda, The Netherlands) supplemented with penicillin, streptomycin, L-glutamine 
and fetal calf serum. The cells were stimulated with 100 μl of OMV in fivefold dilution series. The 
stimulation lasted 16 to 18 h at 37°C in a humid atmosphere with 5% CO2. Following stimulation, 
IL-6 concentrations in the culture supernatants were quantified using an ELISA against human IL-6 
according to the manufacturers’ instructions (PeliKine Compact, Amsterdam, The Netherlands). 
One-way ANOVA statistical analysis with post-testing was used to detect significant p-values 
between any of the OMV vaccines.
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OMV size and aggregation
Vesicle size distribution of OMV vaccines was measured by dynamic light scattering (DLS) at 
25°C with a Malvern 4700 system equipped with a 488 nm Argon ion laser (Uniphase, San José, 
California, U.S.A.) and PCS software version 1.35 (Malvern Ltd., Malvern, UK). For refractive 
index and viscosity the values of pure water were used. The vesicle size distribution was reflected 
in the polydispersity index (PdI), which ranges between 0.0 (mono-dispersed) and 1.0 (entirely 
hetero-dispersed). OMV aggregation was quantified by comparing the total protein content of 
OMV starting material with the total protein content of the OMV pellet after centrifugation at 
low RCF. Starting material (1 mL) was centrifuged at 5000 xg for 10 minutes, 4°C and the pellet 
was resuspended in 1 mL buffer (10mM Tris-HCl, pH 7.4, 3% sucrose (w/v)) and analyzed for 
total protein content. Aggregation was calculated by expressing the total protein content of the 
pellet as a percentage of total protein in the starting material. Measurements were performed one 
month after purification of the OMV, before formulation with adjuvant.
26
Results
Biochemical composition and OMV yield
The effect of purification process type on the biochemical composition of OMV vaccines was 
quantified by measuring PorA, other protein, PL, LPS and DNA content. The results are shown 
in Table 1. The major biochemical components of dOMV vaccines was PorA protein (63.0 ± 2.0% 
(weight %)) and other protein (29.4 ± 2.2%). Protein content of detergent-free nOMV and sOMV 
vaccines was lower, due to increased amounts of LPS and PL. In sOMV vaccines LPS and PL 
content was highest (24.3 ± 6.6% and 33.7 ± 8.1%, respectively) and detergent-treatment in dOMV 
vaccines selectively removed both molecules, resulting in 2.8 ± 0.4% LPS and 2.5 ± 0.3% PL (p < 
0.001). Residual DNA was low for all three purification processes due to efficient removal during 
ultracentrifugation. Protein composition analysis of OMV vaccines (Figure 2B) designated PorA 
as the most abundant protein (66.6 ± 0.4% of total protein) and confirmed absence of RmpM in 
deletion mutant strains (ΔR and ΔRΔL). Specific protein yields of total protein and PorA were 
used to estimate OMV yield (Figure 2A). RmpM mutant strains had higher OMV yields than 
strains with functional RmpM. Strain ΔRΔL had 4.2 ± 0.4 fold higher yield than ΔL and strain ΔR 
had a 2.1 ± 0.4 fold higher yield than wt (combined averages of OMV from different purification 
processes). In addition, a purification process effect was found. For all bacterial strains, sOMV 
vaccines had significantly lower yields than the corresponding nOMV or dOMV vaccines (p < 
0.05). The lpxL1 mutation had a negative effect on yield (2.6 ± 1.0 fold reduction).
Toxicity and functional immunogenicity
To predict toxicity in humans, high yield OMV vaccines were tested for their ability to stimulate 
IL-6 production in a human macrophage cell line. In OMV with normal LPS there is a known 
correlation between IL-6 production and toxicity [119, 120]. This was confirmed by ΔR-dOMV 
and ΔR-sOMV vaccines with low and high toxicity, respectively. In OMV vaccines with attenuated 
LPS (ΔRΔL strain) such correlation was not found. Despite high LPS content (comparable to ΔR-
Table 1.
Biochemical composition (weight %) of OMV vaccines from three purification processes. OMV’s were 
extracted from concentrated bacterial cells using detergent extraction (dOMV) or EDTA extraction (nOMV), 
or harvested directly from the culture supernatant (sOMV). The content of five major biochemical compounds 
of OMV vaccines was analyzed: trivalent PorA, other protein, phospholipid (PL), lipopolysaccharide (LPS) 
and residual DNA. Detergent in the dOMV process selectively removed PL and LPS from the OMV’s. Similar 
observations were made for the nOMV process, however to a lesser extent than for dOMV. Error margins 
represent standard deviations.
dOMV (detergent-extraction) nOMV (EDTA extraction) sOMV (spontaneous OMV)
trivalent PorA 63.0 ± 2.0% 31.9 ± 6.9% 21.9 ± 11.9%
other protein 29.4 ± 2.2% 25.2 ± 7.6% 15.7 ± 4.8%
PL 2.5 ± 0.3% 27.5 ± 0.7% 33.7 ± 8.1%
LPS 2.8 ± 0.4% 13.3 ± 0.7% 24.3 ± 6.6%
residual DNA 2.4 ± 0.4% 2.2 ± 0.3% 4.4 ± 1.5%
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sOMV), IL-6 levels were comparable to ΔR-dOMV (Figure 3A). Functional immunogenicity was 
determined by measuring SBA titers in mice sera. All OMV vaccines combined the same 3 PorA 
subtypes (P1.7,16; P1.5-1,2-2 and P1.19,15-1) and were tested against a panel of 8 monovalent 
H44/76-derived bacterial strains each expressing a single PorA subtype, or no PorA at all (ΔPorA 
strain). Table 2 shows the SBA titers of three high yield OMV vaccines with low toxicity. The fourth 
high yield vaccine (ΔR-sOMV) was not tested in mice, due to inherent toxicity (see Figure 3A). 
Two PorA subtypes that were included in the vaccines (P1.7,16 and P1.5-1,2-2) confirmed high 
bactericidal titers against their monovalent target strains, with 94.4% of the mice responding to 
immunization. Titers against P1.5-1,2-2 were higher for ΔRΔL-sOMV than for the other vaccines 
(p < 0.05). Only 15.6% of the mice responded to the third subtype (P1.19,15-1), with no responders 
Figure 2.
(A) OMV yields of eight vaccines, estimated with the specific total protein yield (black bars) and the specific, 
trivalent PorA yield (grey bars). Increased yield was found for strains with non-functional RmpM (ΔR and 
ΔRΔL). Error bars represent standard deviations from triplicate experiments. (B) Absence of RmpM was 
confirmed with SDS gel electrophoresis. Molecular weight standard (left) indicates protein weight and 
protein names are indicated on the right. wt-dOMV was included as a control for presence of RmpM. All 
OMV vaccines were trivalent PorA (subtypes P1.7,16; P1.5-1,2-2 and P1.19,15-1).
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at all for the ΔR-dOMV vaccine and low titers with few responders for ΔRΔL-nOMV and ΔRΔL-
sOMV (detergent-free). Analysis of bactericidal titers against PorA subtypes that were not 
included in the vaccines confirmed that ΔR-dOMV (detergent-treatment) did not induce cross-
protection. Remarkably, ΔRΔL-sOMV (detergent-free) did elicit broad cross-protection against 
all monovalent PorA strains, including three responders against the ΔPorA strain. Improved 
cross-protection was also observed for ΔRΔL-nOMV (detergent-free), however less pronounced 
with a few responders against 2 out of 6 non-included PorA subtypes (P12-1,13 and P1.7,1-1; not 
significantly higher than ΔR-dOMV).
OMV size and aggregation
Vesicle size analysis of OMV vaccines from high yield strains (ΔR and ΔRΔL) revealed that vesicle 
size was dependent on purification process type (Figure 3B). Both sOMV vaccines had identical 
vesicle sizes (80.2 ± 2.2 nm) and formed a near-homogeneous population with low polydispersity 
index (PdI) of 0.143 ± 0.017. The nOMV vaccine was also near-homogeneous, but with a larger 
average size of 106.5 ± 1.7 nm (p < 0.001 when compared to sOMV). In contrast, the dOMV vaccine 
formed a heterogeneous population, with high PdI (0.460 ± 0.112). Within this population, vesicle 
size varied between 550 and 5500 nm. In concordance with these observations, OMV aggregation 
percentage was low for all detergent-free vaccines, with averages of 6.9 ± 3.0% and significantly 
higher for dOMV vaccines (95.5 ± 1.0%; p < 0.001).
Table 2.
Bactericidal titers (SBA) against a panel of monovalent PorA strains after immunization with trivalent PorA 
vaccines that combined high yield with low toxicity. Three groups of 15 mice were immunized with either 
ΔR-dOMV, ΔRΔL-nOMV or ΔRΔL-sOMV vaccine. PorA subtypes that were not included in the vaccines 
were used to assess cross-protection, which was restricted to detergent-free OMV vaccines (especially ΔRΔL-
sOMV). Total number of responders is listed for each group (max. 15). Mean SBA titers (>90% killing) of 
responders are summarized on a 2log scale and error margins represent standard deviation. Statistically 
significant results (p < 0.05) are marked with asteriskses for the comparison with ΔR-dOMV (*) or ΔRΔL-
nOMV (‡). 
monovalent 
PorA strain
PorA 
included in 
vaccine
mean SBA titer responders number of responders
ΔR-dOMV ΔRΔL-nOMV ΔRΔL-sOMV ΔR-dOMV ΔRΔL-nOMV ΔRΔL-sOMV
P1.7,16 yes 10.8 ± 1.5 11.0 ± 1.1 11.2 ± 1.2 14 14 15
P1.5-1,2-2 yes 12.2 ± 2.3 12.5 ± 1.8 15.0 ± 1.7*‡ 13 14 15
P1.19,15-1 yes 0.0 5.3 ± 2.8 8.3 ± 2.1* 0 2 5
P1.5-2,10 no 0.0 0.0 12.2 ± 3.9*‡ 0 0 14
P12-1,13 no 0.0 7.7 ± 1.2 12.4 ± 2.3*‡ 0 3 15
P1.7-2,4 no 0.0 0.0 9.5 ± 1.4*‡ 0 0 12
P1.22,14 no 0.0 0.0 9.7 ± 1.0*‡ 0 0 12
P1.7-1,1 no 0.0 6.3 ± 0.0 9.3 ± 2.1*‡ 0 2 14
ΔporA no 0.0 0.0 10.3 ± 0.0 0 0 3
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Figure 3.
(A) Toxicity and LPS content of OMV vaccines from high yield strains (ΔR and ΔRΔL). OMV’s with attenuated 
LPS (ΔRΔL strain) had low toxicity despite high LPS content. Black bars represent the average IL-6 induction 
from 5log dilution series, normalized per μg PorA (predictor of toxicity) and grey bars indicate LPS content as 
weight percentage of the PorA content. Error bars represent standard deviations from triplicate experiments. 
(B) The vesicle size distribution was measured. ΔRΔL-sOMV (black line), ΔR-sOMV (grey line), ΔRΔL-nOMV 
(black intersected line) and ΔR-dOMV (grey intersected line) are depicted, corresponding to the OMV vaccines 
in Figure 3A. Detergent-free OMV’s (nOMV and sOMV) had defined size distributions around 90 nm, while 
the dOMV vaccine had an undefined distribution, caused by detergent-induced vesicle aggregation.
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Discussion
The use of N. meningitidis outer membrane vesicles (OMV) as a delivery vehicle for immuno-
dominant PorA protein is a well-established approach for the development of a vaccine against 
N. meningitidis serogroup B [7, 60, 61]. In the present study, three different OMV purification 
processes are systematically combined with bacterial strains containing lpxL1 and rmpM genetic 
modifications, with the objective to select the best approach for vaccine development (Figure 1). 
The resulting OMV vaccines have distinct characteristics regarding yield, toxicity, immunogenicity 
and aggregation. 
RmpM-related yield improvement has been found for all three small-scale OMV purification 
processes in this study. This is especially important for feasibility of the sOMV process, since 
it does not involve extraction to increase OMV release. RmpM is proposed to act as an anchor 
protein containing domains that interact with outer membrane proteins and the peptidoglycan 
layer, providing stability to the bacterial cell wall [121-123]. RmpM deletion mutants have been 
associated with a loosely attached outer membrane and an effect on OMV yield was hypothesized 
[107]. The data in this study (Figure 2A) now provide clear evidence for the link between non-
functional RmpM protein and increased OMV yield. 
To predict toxicity in humans, OMV vaccines from high yield, rmpM mutant strains have been used 
to stimulate IL-6 production in macrophage cells (Figure 3A). Vaccines with normal LPS confirm 
the relation between LPS content and toxicity. This relation has not been found in detergent-free 
vaccines with attenuated LPS, which produce IL-6 levels comparable to ΔR-dOMV (low toxicity), 
despite high LPS content. This beneficial effect of the lpxL1 mutation is supported by the results 
of other studies [72, 94]. The remaining IL-6 induction of OMV vaccines with attenuated LPS 
can be caused by non-LPS components, such as lipoproteins, which are known TLR-2 activators 
[124]. IL-6 induction by human macrophage cells is increasingly used as predictor of clinical 
toxicity [125], therefore OMV vaccines with attenuated LPS are potentially safe for parenteral use 
in humans. 
Functional immunogenicity of high yield, trivalent PorA vaccines with low toxicity has been 
measured (Table 2). One PorA subtype that was included in the immunizations (P1.19,15-1) is 
known to produce low bactericidal titers in mice [5, 61, 118, 126], but induces sufficient titers in 
rabbits [5] and humans [60]. Functional immunogenicity against P1.5-1,2-2 is higher for detergent-
free sOMV vaccine (ΔRΔL-sOMV) than for the other two vaccines. In addition, this vaccine elicits 
cross-protection against the complete panel of monovalent PorA strains. Similar results have been 
found before [104], but toxicity was not addressed despite presence of toxic LPS. The sOMV 
vaccine in this study combines broad cross-protection with confirmed low toxicity. The low cross-
protection observed for ΔRΔL-nOMV and ΔR-dOMV can be caused by decreased amounts of 
bactericidal lipoproteins with low antigenic variability, like factor H binding protein or GNA2132 
[73, 94, 127, 128]. Detergent treatment of ΔR-dOMV removes all lipoproteins from the vaccine, 
while EDTA extraction (ΔRΔL-nOMV) destabilizes the outer membrane [111]. This destabilization 
causes loss of LPS (as confirmed in table 1) [129], but may also decrease lipoprotein content. It is 
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established that ΔRΔL-sOMV has improved overall functional immunogenicity, however with a 
lower OMV yield than ΔRΔL-nOMV.
In addition to yield, toxicity and immunogenicity, OMV aggregation is an important criterion 
for selection of a preferred vaccine development strategy. To obtain regulatory approval it is 
required to ensure consistent product quality throughout the manufacturing lifetime [130]. Due 
to lack of homogeneity, aggregated OMV vaccines are likely to impose difficulties. One month 
after purification, aggregation percentages were low for vaccines from detergent-free processes 
(nOMV and sOMV) resulting in well-defined vesicle size, while detergent extraction (dOMV 
process) resulted in outer membrane aggregates with significant size heterogeneity (Figure 3B). 
Such aggregation has not been reported for dOMV vaccines that were used to control epidemics 
in Norway, Cuba and New Zealand [50, 51, 53], however these vaccines were produced with 
large-scale, optimized processes. dOMV aggregates can be separated from intact vesicles with a 
filtration step, but this results in major yield loss. The observed aggregation can be explained with 
the data in Table 1, where detergent treatment selectively removes negatively charged LPS and 
PL molecules. This is likely to promote aggregation, since neutralization of OMV surface charge 
eliminates electrostatic repulsion [96, 131, 132]. The aggregation effect is not fully understood 
nor controlled, resulting in a dOMV vaccine that is less attractive for process development than 
nOMV or sOMV vaccines. Another argument to avoid using DOC in the dOMV process is its 
animal origin. 
OMV vaccines from a detergent-based purification process (dOMV vaccines) give adequate 
protection in humans [50, 51, 53, 88] however the present work indicates that detergent-free 
alternatives provide highly reduced OMV aggregation and comparable yield and toxicity. In 
addition, improved cross-protection is observed. The use of detergent-free OMV purification 
processes is enabled by the lpxL1 mutation, which genetically attenuates LPS toxicity [6]. OMV 
yield of all purification processes improves significantly by introducing the rmpM deletion, which 
increases feasibility of the sOMV process for further process development. The presented results 
substantiate that OMV from a bacterial strain with both genetic modifications (lpxL1 and rmpM), 
made with a detergent-free purification process (either nOMV or sOMV) are the best available 
approachs for vaccine development. It may provide vaccines that are broadly protective against 
N. meningitidis serogroup B and potentially safe for parenteral use in humans. 
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Unbiased selective isolation of 
protein N-terminal peptides from 
complex proteome samples using 
phospho tagging (PTAG) and TiO
2
-
based depletion
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Abstract
A positional proteomics strategy for global N-proteome analysis is presented based on phospho 
tagging (PTAG) of internal peptides followed by depletion by titanium dioxide (TiO2) affinity 
chromatography. N-terminal and lysine amino groups are initially completely dimethylated with 
formaldehyde at the protein level, after which the proteins are digested and the newly formed 
internal peptides modified with the PTAG reagent glyceraldhyde-3-phosphate in nearly perfect 
yields (> 99%). The resulting phospho-peptides are depleted through binding onto TiO2, keeping 
exclusively a set of N-acetylated and/or N-dimethylated terminal peptides for analysis by LC-
MS/MS. Analysis of peptides derivatized with differentially labeled isotopic analogues of the 
PTAG reagent reveals a high depletion efficiency (> 95%). The method enables identification 
of 753 unique N-terminal peptides (428 proteins) in N. meningitidis and 928 unique N-terminal 
peptides (572 proteins) in S. cerevisiae. These include verified neo-N-termini from subcellular-
relocalized membrane and mitochondrial proteins. The presented PTAG approach is therefore 
a novel versatile and robust method for mass spectrometry-based N-proteome analysis and 
identification of protease-generated cleavage products.
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Introduction
In shotgun proteomics, proteins are digested into peptides, typically using trypsin as protease, 
separated by liquid chromatography and analyzed by online-coupled tandem mass spectrometry 
(LC-MS/MS). Identifying significant portions of all proteins present in complex samples by LC-
MS remains a major challenge, even for advanced proteomics workflows [133]. To address the 
challenges, new concepts in sample preparation have been proposed, aiming at reduction of 
sample complexity while preserving the proteome fingerprint [134-136]. The most useful methods 
for this purpose yield a single, positional-defined peptide for each individual protein. McDonald 
and Beynon argued that the two most obvious positional locations within every protein are the 
extreme ends, thus the N-terminal and the C-terminal peptides (positional proteomics) [134]. 
As a result of drastic sample simplification, positional proteomics analysis provides insights in 
a variety of post translational modification (PTM) processes and proteolytic processing which 
proteins may undergo at their N-terminal and C-terminal ends [137, 138].
Positional proteomics strategies rely on the ability to differentiate between the N- or C-terminal 
parts of a protein and the internal counterparts [139, 140]. Protocols for targeted enrichment of 
C-terminal peptides have only recently been introduced [141, 142], mainly due to lower chemical 
reactivity of C-terminal carboxyl groups compared to N-terminal amino groups. Gevaert et 
al. [136, 143] introduced the well-established combined fractional diagonal chromatography 
(COFRADIC) technology. In their method, N-terminal sequences are distinguished and separated 
from the internal peptides by differential labeling of protein N-terminal amino groups on the one 
hand and the a-amino groups of internal proteolytic peptides on the other hand such that the 
latter obtain a shift in retention on reversed phase chromatography. To prevent the discriminative 
retention shift for N-terminal amino acid sequences, free amino groups of protein N-termini 
(a-amino) and lysine side chains (a-amino group) are protected by acetylation prior to digestion. 
Another negative selection approach, proposed by McDonald et al. [134, 135] involves the 
protective blocking of amino groups at the protein level followed by digestion and subsequent 
depletion of internal peptides by reaction with an amine reactive scavenger resin. Kleifeld et al. 
[144, 145] have developed terminal amine isotope labeling of substrates (TAILS) for the negative 
selection of N-terminal peptides and identification and quantification of proteolytic events. They 
used a novel water-soluble aldehyde polymer for the selective binding of a-amine containing 
internal peptides [146]. 
Positive selection methods employ a reversed approach [147]. These protocols are based on the 
incorporation of an affinity group (e.g. biotin) to the protein N-terminal amino groups, followed 
by digestion and enrichment of the modified N-terminal peptides [148, 149]. Unwanted cross-
reaction with the side chain amino group of lysines is prevented by guanidination (lysine to 
homo-arginine conversion) at the protein level. Selective and complete lysine labeling on the 
protein level can be problematic, hence the group of Wells introduced an enzymatic approach to 
selectively label the protein N-terminal amino group in a single step [150]. A severe drawback 
of positive selection approaches is the loss of N-terminal peptides for proteins having naturally 
acetylated or otherwise modified N-termini, because these termini do not react with the affinity 
labeling agents. 
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Selective enrichment of N-terminal peptides constitutes a major challenge due to the consecutive 
sample preparation steps (i.e. protective labeling, purification and enrichment), each prone to 
side reactivity and sample losses. Moreover, tryptic protein digests contain many more internal 
peptides than N-terminal peptides, therefore posing high demands on the efficiency of depletion 
to prevent significant contamination of the final sample fraction with internal peptides [147]. 
For example, Timmer et al. [148] used NHS-activated biotin for the positive selection of protein 
N-termini, however it was stated that a substantial portion of positive identifications were 
observed as a result of nonspecific biotinylation [137]. In case of amine-reactive scavenger beads, 
multiple incubation steps were needed for effective coupling of internal peptides [135, 151]. 
Zhang et al. reported specific loss of histidine-containing N-terminal peptides when using NHS-
activated sepharose [151]. In addition, histidine- and arginine-containing N-terminal peptides 
are generally underrepresented in N-terminomics when SCX is used for pre-enrichment prior to 
depletion of internal peptide [152]. N-acetylated N-termini, widely present in higher eukaryotes, 
can be enriched more easily using SCX fractionation (without derivatization chemistry), but 
unfortunately such approaches are blind for unmodified protein N-termini [153-155]. TAILS, 
however, used water-soluble aldehyde polymer for effective coupling and depletion of internal 
peptides in a single-step, thereby minimizing possible sample losses [144].
In view of the challenges associated with the enrichment of N-terminal peptides, a novel 
positional proteomics strategy was developed. The strategy utilizes a highly selective PTAG-
labeling reagent for the modification of internal peptides, after initial protection of protein 
N-termini and lysine side chains. PTAG-derivatized peptides have similar properties as naturally 
phosphorylated peptides in terms of binding to titanium dioxide (TiO2). Hence, the flow-through 
fraction of TiO2 affinity chromatography is highly enriched in N-terminal peptides and could be 
directly analyzed by LC-MS/MS. It is demonstrated that PTAG is a straightforward and efficient 
N-proteome enrichment strategy due to the use of highly selective derivatization chemistry, 
both at the protein and peptide level, in combination with robust and easy-to-implement TiO2 
technology. 
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Materials and Methods
Cell culture 
Neisseria meningitidis strain used in this study is a recombinant non-encapsulated variant of the 
group B isolate H44/76, with a nonfunctional porB gene and truncated galE-LPS [156]. Bacterial 
cultures were grown at 35 °C in a chemically defined medium (150 mL) in disposable, baffled 
500-mL erlenmeyer shake flasks with vented closure (Nalgene, Rochester, NY, U.S.A.) by shaking 
at 200 rpm [156]. Cells were harvested by centrifugation at 13,000xg for 2 min at 4 °C and 
resuspended in TE buffer (0.1 M EDTA, 1 M Tris-HCl pH 8.0, Sigma Aldrich, Zwijndrecht, The 
Netherlands) containing 0.5 mg/ml lysozyme (Sigma Aldrich, Zwijndrecht, The Netherlands) 
and incubated at 4 °C for 3 minutes in this medium. Next, proteins were extracted with Trizol 
(Invitrogen, Blijswijk, The Netherlands) according to the manufacturer’s protocol and stored at 
-80 °C prior to use. Outer membrane vesicles (OMV) from N. meningitidis (grown as described 
above) were released by adding EDTA extraction buffer (0.01M EDTA, 0.1M Tris-HCl pH 8.6) and 
further purified by consecutive centrifugation and ultracentrifugation steps, as described by van 
de Waterbeemd et al. (NOMV protocol) [156]. Concentrated OMV (approximately 100 µl sample, 
containing 1 mg total protein) were mixed with 1 mL Trizol reagent and proteins were extracted 
and stored as described above. Saccharomyces cerevisiae strain BJ5460 (LGC Standards, Almere, 
The Netherlands) was cultured in 150 mL YPD medium in baffled 500-mL erlenmeyer shake 
flasks with vented closure (Nalgene, Rochester, NY, U.S.A.) at 30 °C, by shaking at 200 rpm. Cells 
were harvested from 300 mL culture (OD590=1.7) by centrifugation at 2,000xg for 5 min. Cells were 
washed three times with PBS and resuspended in 200 µL lysis buffer (2 M guanidine hydrochloride, 
12 mM EDTA, 50 mM Tris-HCl, pH 7.5 (Sigma Aldrich, Zwijndrecht, The Netherlands) to which 5 
mL protease inhibitor cocktail (Sigma Aldrich, Zwijndrecht, The Netherlands) was added. The cell 
suspension was subjected to three rounds of freeze-thaw cycles. Next, cleaned glass beads were 
added and cells were further disrupted by 6 vortex cycles with intermediate cooling steps (at 4 
°C). Supernatants after each cycle were pooled and centrifuged at 2,000xg at 4 °C for 10 min. The 
resulting supernatant was incubated overnight with a 4-fold excess of acetone (v/v) at -20 °C and 
proteins were subsequently pelleted at 13,000xg at 4 °C for 10 min. The protein pellet was washed 
twice with acetone/water 4/1 (v/v), pelleted after each wash step as described before and dried 
for 5 min by vacuum centrifugation at room temperature.
Dimethylation of primary amines 
The protocol for dimethylation of primary amines was adopted from Boersema et al. [157]. An 
aliquot corresponding to 100 µg of protein was dissolved in 100 mM KH2PO4 (the pH adjusted 
to 7.5) containing 4 M guanidine hydrochloride. Disulfide bridges were reduced by adding 
dithiotreitol (Sigma Aldrich, Zwijndrecht, The Netherlands) to a final concentration of 20 mM 
and incubated 37 °C for 30 min. Free thiol groups were alkylated by adding iodoacetamide 
(Sigma Aldrich, Zwijndrecht, The Netherlands) to a final concentration of 100 mM and incubation 
at room temperature for 30 min in the dark. Excess reagent was exhausted by the addition of 
dithiotreitol at a final concentration of 100 mM (incubated at 37 °C for 30 min). The free N-terminal 
and lysine amino groups were dimethylated by formaldehyde at a final concentration of 180 
mM (CH2O, Sigma Aldrich, Zwijndrecht, The Netherlands) in the presence of 30 mM freshly 
prepared sodium cyanoborohydride (NaCNBH3, Sigma Aldrich, Zwijndrecht, The Netherlands) 
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at room temperature. Freshly prepared sodium cyanoborohydride at a final concentration of 30 
mM was added after 1-h and 2-h time intervals and the sample was further incubated overnight. 
Subsequently, the mixture was diluted 4 times with water to decrease the guanidine hydrochloride 
concentration to less than 1 M and proteins were extracted by acetone precipitation as described 
above. Precipitated proteins were reconstituted in 15 µL of 100 mM KH2PO4 (pH 7.5) containing 
4 M guanidine hydrochloride. Excess formaldehyde was exhausted by the addition 50 µL of 1 M 
ammonia hydroxide (Zwijndrecht, The Netherlands) and incubation at room temperature for 1 h. 
Ammonium hydroxide was removed by vacuum centrifugation at room temperature till dryness. 
Protein digestion
Dimethylated proteins were (parallel) digested in 50µl 100 mM KH2PO4 (pH 7.5) and guanidine 
hydrochloride with a concentration of less than 1 M with either chymotrypsin (Roche, Woerden, 
The Netherlands) in 4 mM calcium chloride (Sigma Aldrich, Zwijndrecht, The Netherlands) at 37 
°C, trypsin (Promega, Leiden, The Netherlands) at 37 °C or endoprotease GluC (Roche, Woerden, 
The Netherlands) at room temperature, all with an enzyme/protein ratio of 1/20 (w/w). After 
1 h, digest mixtures were diluted twice with 100 mM KH2PO4 (pH 7.5) to reduce to guanidine 
concentration to less than 0.5 M. Fresh enzyme was added at a enzyme/protein ratio of 1/20 
w/w and the mixture was further incubated overnight at similar temperature conditions as 
described above.
Removal of pyroglutamate
N-terminal glutamine was enzymatically cyclized by glutamine cyclotransferase (Qcyclase, 
Qiagen, Venlo, The Netherlands) and the formed pyroglutamyl moiety was subsequently cleaved 
by the aminopeptidase pGAPase (Qiagen, Venlo, The Netherlands). This protocol was adapted 
from Staes et al. [152], with adjustment of the incubation time to 2 h at 37 °C.
Preparation of PTAG derivates 
The free amino groups of the internal peptides were PTAG derivatized in 100 mM KH2PO4 (pH 7.5) 
with DL-glyceraldehyde-3-phosphate (Sigma Aldrich, Zwijndrecht, The Netherlands) at a final 
concentration of 90 mM and freshly prepared sodium cyanoborohydride in a final concentration 
of 30 mM at room temperature. Freshly prepared sodium cyanoborohydride was added at 1h 
and 2h intervals and the reaction mixture was further incubated overnight. Following PTAG 
derivatization, peptide mixtures were extensively purified by C18 solid phase extraction (SPE) 
chromatography (column dimensions 5 cm (L) x 200 mm inner diameter (ID), in-house packed 
with 5 mm Reprosil Pur C18-AQ, (Dr Maisch, Ammerbuch-Entringen, Germany). 
Depletion of PTAG-peptides 
PTAG-peptides were depleted by TiO2 affinity chromatography, essentially as previously 
described [158, 159]. Briefly, SPE-purified samples were evaporated to dryness, reconstituted in 
0.1 M acetic acid in water (pH 2.7) and loaded onto a short TiO2 column at a flow rate of 5 µl/
min (100 ml injection loop). The short TiO2 column comprises of a 1-mm ID PEEK tubing with an 
Upchurch (Oak Harbor, U.S.A.) 360-mm ID adapter at the front and end for connection to (fritted) 
micro-capillary tubing and is slurry-packed with a 10-mm (L) bed of 5 µm Titansphere particles 
(10 mg) (GL Sciences, Tokyo, Japan). Unretained peptides were collected in the void volume. Next, 
the TiO2 column was extensively washed with a 100-µl plug (3 column volumes) of acetonitrile/
39
Chapter 3
water/dimethyl sulfoxide in 0.1 M acetic acid (45/45/10/, v/v/v) (Sigma Aldrich, Zwijndrecht, 
The Netherlands). The TiO2 flow-through fraction and the wash fraction were pooled, evaporated 
to dryness by vacuum centrifugation and reconstituted in formic acid/DMSO in water (5/5, v/v) 
and stored at -20 °C until analysis.
LC-MS/MS analysis 
N-terminal peptides-enriched samples (TiO2 flow-through fraction) were pre-fractionated offline 
(6-14 fractions) using a mixed bed anion-cation column as described by Motoyama et al. [160] 
or directly analyzed on an LTQ-Orbitrap XL instrument (Thermo Fisher Scientific, Bremen, 
Germany) and Agilent 1100 HPLC system (Agilent, Amstelveen, The Netherlands) modified 
for nanoflow LC separations as described previously by Meiring et al. [161]. All columns were 
packed in house. The trap column was a 100-µm ID fritted micro-capillary packed with 20 mm, 5 
µm particle size Reprosil Pur C18-AQ particles (Dr. Maisch, Ammerbuch-Entringen, Germany). 
The analytical column was a 50-µm ID microcapillary packed with 31 cm 3 µm particle size 
Reprosil Pur C18-AQ, with an integral-pulled tip and operated at a flow rate of 125 nL/min. 
ESI voltage, typically 1.8 kV, was applied by liquid junction at the top of the column. Solvent 
A consisted of 0.1 M acetic acid (Sigma Aldrich, Zwijndrecht, The Netherlands) in deionized 
water (Milli-Q, Millipore, Amsterdam, The Netherlands) and solvent B of 0.1 M acetic acid in 
acetonitrile (Biosolve, Valkenswaard, The Netherlands). Gradients were as follows: 100% solvent 
A during sample loading (0-10 min, flow rate 5 µL/min), 7% to 26% solvent B in 160 minutes 
followed by an increase to 60% solvent B in 20 minutes and reconditioning with solvent A for 
10 min (total runtime 200 min). The mass spectrometer was set to acquire full MS spectra (m/z 
350 to 1,500) for mass analysis in the Orbitrap at 60,000 resolution (FWHM) followed by data-
dependent MS/MS analysis (LTQ) for the top 5 or 7 abundant precursor ions above a threshold 
value of 10,000 counts. The normalized collision energy was set to 35%, isolation width to 2.0 Da, 
activation Q to 0.250 and activation time to 30 ms. The maximum ion time (dwell time) for MS 
scans was set to 200 ms and for MS/MS scans to 2500 s. Charge state screening and preview mode 
were enabled. Precursor ions with unknown and +1 charge states were excluded for subsequent 
MS/MS analysis. Dynamic exclusion was enabled (exclusion size list 500) with repeat set to 1 and 
an exclusion duration of 180 s. The background ion at m/z 391.284280 was used as lock mass for 
internal mass calibration. 
Data analysis
The analysis of mass spectrometric RAW data was carried out using Proteome Discoverer 1.2 
software (Thermo Fisher Scientific, Bremen, Germany) applying standard settings unless 
otherwise noted. MS/MS scans were searched against the N. meningitidis strain MC58 database 
(containing 2,003 entries, 2010, Uniprot) or the S. cerevisiae SGD database (http://www.
yeastgenome.org, 2010, containing 5,821 entries) using SEQUEST (Proteome Discoverer 1.2, 
Thermo Fisher Scientific, Bremen, Germany). Precursor ion and MS/MS tolerances were set to 10 
ppm and 0.8 Da, respectively. Decoy database searches were performed with False Discovery Rate 
(FDR) tolerances set to 5% and 1% for modest and high confidence filtering settings, respectively. 
The data were searched separately with either no enzyme, C-terminal trypsin cleavage specificity, 
C-terminal chymotrypsin cleavage specificity or C-terminal GluC cleavage specificity allowing 
five miss-cleavages because lysine cleavage is prevented by dimethyl modification. Cysteine 
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carbamidomethyl, N-terminal dimethylation and lysine dimethylation were set as fixed 
modifications while aspargine deamidation and methionine oxidation were set as variable 
modifications. Similar searches were performed for alternative modifications by substituting 
N-terminal dimethylation modification with acetylation, ammonia loss, no modification, 
glyceraldehyde-3-phosphate, and monomethylation (Supplemental Tables 3-5). N-terminal 
dimethylated, N-terminal acetylated and N-terminal monomethylated proline-starting peptide 
sequences with high confidence (Xcorr values > 2.2, false discovery rates < 1%), rank no. 1 and 
linear sequences within the first 70 amino acids were considered for manual data analysis. 
Peptides possessing charge states of 6+ and higher were excluded. True N-terminal peptides 
(initiator methionine and methionine cleavage) were kept in the final dataset as well as proteins 
with signal peptide or transit peptide cleavage sites. Peptidase cleavages sites were verified by 
prediction software [162] or previous data [163] (Supplemental Table 6-7). Annotated spectra are 
provided for proteins with only a single confident peptide identification (Supplemental spectra 
1-2). The raw data files and protocols associated with this manuscript are available to the reader 
upon request.
Assessment of binding efficiency of PTAG-peptides
Synthesis of isotopically deuterium-labeled PTAG reagents was started from either D0-
tetrahydrofuran or D8-tetrahydrofuran (Sigma Aldrich, Zwijndrecht, The Netherlands). 
4-bromobutyl acetate was obtained by ring-opening of tetrahydrofuran and nucleophilic 
substitution (into the acetate ester) by incubation with 33% hydrobromic acid in acetic acid (Sigma 
Aldrich, Zwijndrecht, The Netherlands) at room temperature for 1 h. Tetramethylammonium 
salt of dibenzylphosphate was prepared from the drop wise addition of tetramethylammonium 
hydroxide into a solution of dibenzylphosphate in methanol/acetone 1/1 (v/v) (Sigma Aldrich, 
Zwijndrecht, The Netherlands) at -10 °C. Tetramethylammonium salt of dibenzylphosphate 
was refluxed with 4-bromobutyl acetate for 5 h in dioxane (Sigma Aldrich, Zwijndrecht, The 
Netherlands). The resulting dibenzyl-4-acetatebutyl phosphate was purified on silica and 
hydrogenated into dibenzyl-4-hydroxybutyl phosphate with 0.4 M sodium carbonate (Sigma 
Aldrich, Zwijndrecht, The Netherlands) in 1/1 (v/v) ethanol/water at room temperature for 
24 h. The product was extracted from the ethanol/water mixture with dichloromethane and 
subsequently dried on anhydrous magnesium sulphate (Baker, Deventer, The Netherlands). 
Dibenzyl-4-hydroxybutyl phosphate was oxidized into dibenzyl-4-oxobutyl phosphate by 
the incubation with a catalytic amount of pyridinium chlorochromate (PCC, Sigma Aldrich, 
Zwijndrecht, The Netherlands) in dichloromethane at room temperature for 1 h. Dibenzyl-
4-oxobutyl phosphate was purified on silica gel and the dibenzylphosphate functionality was 
reduced by a catalytic amount of 10% palladium on carbon (Sigma Aldrich, Zwijndrecht, The 
Netherlands) under a hydrogen atmosphere at room temperature for 1 h. The structure of the final 
products, D0-4-oxobutyl dihydrogen phosphate and D5-4-oxobutyl dihydrogen phosphate, were 
verified by NMR (JEOL (400 Mhz), Tokyo, Japan). Partial hydrogen/deuterium exchange was 
observed as a result of enolization of the deuterated carbonyl functionality. After equilibration 
of the enolization reaction (storage in water), a ∆M = 5.0 Da between the isotopic variants was 
obtained. The TiO2 binding efficiencies of the PTAG-peptides were evaluated using the in-house-
synthesized, isotopically-labeled PTAG-reagents. An aliquot corresponding to 100 µg of protein 
from the OMV fraction of N. meningitidis was dimethylated as described above. Proteins were 
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digested with trypsin and free a-amines of internal peptides were PTAG derivatized with an 
equimolar mixture of D0-4-oxobutyl dihydrogen phosphate and D5-4-oxobutyl dihydrogen 
phosphate and the addition of freshly prepared sodium cyanoborohydride (as described above). 
Peptide mixtures were subjected to TiO2 affinity chromatography (as described above) and the 
flow-through fraction was analyzed by LC-MS. Raw data files were converted to the NetCDF 
file format and imported into MsXelerator software package (v.2.9, MsMetrix, Maarssen, The 
Netherlands). Co-eluting mass spectral doublets with a ∆M of 5.0306 (PTAG-peptides) were 
extracted by the search algorithm as previously described by Meiring et al. [164]. 
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Results
General description of N-proteome enrichment 
A schematic overview of phospho tagging (PTAG) for global N-proteome analysis is depicted 
in Figure 1. The strategy starts with the denaturation of proteins by reduction and alkylation of 
cysteines to enhance the accessibility of amino groups for chemical labeling and erratic depletion 
of cysteine linkages in N-terminal peptides. Reductive dimethylation of primary amines using 
formaldehyde and sodium cyanoborohydride simultaneously blocks the free a-amines of protein 
N-termini, except when they are already in vivo blocked by N-acetylation, as well as e-amines 
of the lysine side chains [157]. Subsequently, trypsination of the proteome will result in an 
Figure 1. Workflow for recovery of N-terminal peptides with the PTAG strategy. 
Protein samples are denaturated, cysteines reduced and alkylated, following by the reductive dimethylation 
of free a- and e-amines (double grey dot) (day 1). Proteins are purified from excess reagent by acetone 
precipitation and remaining residual amounts are quenched by ammonium hydroxide. After proteolytic 
digestion (day 2), peptides with an N-terminal glutamine are enzymatically converted into pyroglutamate 
by Qcyclase and subsequently cleaved by pGAPase. Protein internal peptides are Phospho-tagged (PTAG) 
by the reaction with DL-glyceraldehyde-3-phosphate (GAP3) in the presence of cyanoborohydride (day 
3). Peptide mixtures are subsequently desalted and excess reagents were removed by C18 solid phase 
extraction (SPE) chromatography. PTAG-peptides are depleted by TiO2 affinity chromatography (day 4) for 
enrichment of dimethylated (grey double dot) and naturally acetylated (open triangle) in the flow-through 
fraction.
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ArgC like digestion pattern as lysine cleavage is prevented due to the dimethyl modification, as 
previously shown [144]. The free N-terminal a-amines of the, upon digestion, newly generated 
internal peptides are susceptible for tagging with the PTAG reagent glyceraldehyde-3-phoshate 
(GAP3) (Figure 2). PTAG-labeled peptides are subsequently depleted through binding to TiO2, 
with the flow-through fraction being highly enriched in N-acetylated and N-dimethylated 
peptides is analyzed by LC-MS/MS (Supplemental Figure 1). Confident protein assignment may 
be problematic in N-terminal peptide enrichment strategies because identification is inherently 
based on a single peptide, referred to as ‘one-hit wonders’ [165]. For this reason, parallel replicates 
of each proteome sample were digested with three different proteases (trypsin, endoprotease 
GluC and chymotrypsin) to generate overlapping N-terminal peptides with different lengths. In 
addition, N-proteome coverage is increased by the parallel use of proteases, because trypsin alone 
may generate N-terminal peptides of inappropriate length or poor ionization and fragmentation 
properties to be identified by LC-MS/MS [134, 154]. Despite the multiple digestion strategy, 
many proteins are expected to be identified based on a single peptide. To enhance confidence in 
protein assignment for these single peptide identifications, offline ion exchange pre-fractionation 
(typically 6 fractions) was performed in combination with high accurate MS analysis using an 
LTQ-Orbitrap to increase the number of MS/MS identification of a single peptide from technical 
replicates, different charge states and deamidation or oxidation states [144]. Also, stringent 
database search criteria were used (false discovery rates < 1%) to obtain high confidence in 
sequence assignment and annotated spectra for proteins with a single peptide identification are 
provided (Supplemental spectra 1-2). 
Dimethyl labeling on the protein level 
High efficiency in reductive dimethylation of N-termini and lysine side chains is critical to 
minimize erratic depletion of N-terminal peptides [145]. Protective labeling of these amino 
groups with formaldehyde was investigated for the standard protein Cytochrome C. Progress 
of the reaction was determined on the 6 available e-amine groups of the chymotryptic acetylated 
N-terminal peptide Ac-GDVEKGKKIF. At 3-hour, the reaction yielded an incorporation of 5.9 
methyl groups (98%) (Supplemental Figure 2). The reaction was driven to essentially quantitative 
by the addition of freshly prepared cyanoborohydride after 1-h and 2-h points followed by 
overnight incubation (data not shown).
Phospho tagging (PTAG) of internal peptides
PTAG-labeling of proteolytically generated internal peptides should reach completion to 
minimize co-purification of unmodified internal peptides in the final sample mixture. Evaluation 
of the derivatization reaction for the internal peptides generated from chymotryptic digestion 
Figure 2. Phospho-tagging reaction scheme. 
N-terminal a-amines of proteolytically generated peptides react with glyceraldehyde-3-phosphate (GAP3) 
into Schiffs bases that are rapidly reduced in the presence of cyanoborohydride. Note, e-amines of lysine 
side chains are protected by dimethylation with formaldehyde and cyanoborohydride on the protein level. 
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of Cytochome C yielded > 99% efficiency without any side reactions. Similar results were 
found for a more complex (100 mg) trypsinated outer membrane vesicle (OMV) fraction from N. 
meningitidis. OMV are nano-sized spherical protein-lipid vesicles which can be used as a vaccine 
against serogroup B meningitis [3]. The main antigen present in OMV is the outer membrane 
porin A protein (PorA), which constitutes approximately 70% of the total protein content. For 
proteolytically digested OMV proteome, with abundances spanning several orders of magnitude, 
PTAG derivatization chemistry was nearly quantitative (> 99%). Despite the high labeling yields, 
unmodified residues could still be detected however at greatly reduced abundances (< 1%) 
compared to their PTAG-labeled analogues (Supplemental Figure 3). Slow and/or incomplete 
reactivity of proline-starting internal peptides, as reported by others [136, 152], was not observed 
for the PTAG reagent. 
Depletion efficiency of PTAG-peptides 
The most critical step in positional proteomics is the effective depletion of internal peptides while 
maintaining maximum recovery of N-terminal peptides. The depletion efficiency of internal 
peptides for the PTAG strategy was evaluated for the chymotryptic digest of Cytochrome C 
(Supplemental Figure 4). The naturally acetylated N-terminal peptide of Cytochrome C (Ac-
GDVEKGKKIF) was detected as the most predominant ion trace in the flow-through fraction.
For the N-proteome analysis of complex proteome samples, a high capacity, offline TiO2 affinity 
chromatography column was prepared in-house (slurry packed). Stringent washing conditions 
were applied to minimize nonspecific binding [166] (Supplemental Table 2). A 100-µg proteolytic 
digest of OMV was subjected to TiO2 affinity chromatography (10 mg beads) and effective 
depletion of PTAG peptides was established in less than 20 minutes at a 1:100 peptide-to-beads 
ratio (w/w). This is illustrated by the substantial sample simplification of a proteolytic digest 
Figure 3. 
LC-MS maps of proteolytic peptides (GluC) of N. meningitidis outer membrane vesicle (OMV) fraction 
before (A) and after (B) enrichment of N-terminal peptides. The protein composition of OMV is dominated 
by the outer membrane PorA protein, accounting for approximately 75% of the total protein content. 
N-terminal peptides of several proteins, including the high abundant N-terminus of PorA were recovered 
as predominant ion trace in the enriched sample fraction (B and C), indicating effective depletion of internal 
peptides.
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of OMV fraction of N. meningitidis (Figure 3). After depletion of internal peptides, N-termini of 
several low abundant proteins were recovered as the most predominant base peak traces in the 
chromatogram along with the high abundant N-terminus of PorA. Evaluation of MS/MS-data 
revealed that PTAG-peptides with poor binding affinity were occasionally identified in the final 
sample (data not shown). However, identification of these peptides by data-dependent MS/
MS analysis may not reflect the total fraction because identification is hampered by substantial 
neutral loss of phosphate during CID fragmentation [167]. For this purpose, D0- and D5-labeled 
analogues of the PTAG reagent were synthesized in-house and employed to discriminate PTAG 
peptides by their unique 5-Da mass difference (doublets) from N-terminal peptides (singlets). In 
a single LC-MS/MS analysis of a N-terminally enriched OMV sample, approximately 5% of all 
peptides ions were assigned as poorly retained PTAG peptides (Supplemental Figure 5), thereby 
again demonstrating the high efficiency in depletion even for complex and high dynamic range 
proteome samples.
Figure 4. 
Venn diagram comparing the number of identified unique N-terminal peptides (A, C) and assigned proteins 
(B, D) in N. meningitidis (combined OMV and whole cells fraction) and S. cerevisiae, respectively, by the 
(parallel) use of different proteases in the PTAG protocol. Both in N. meningitidis and S. cerevisiae the largest 
number of confident sequence assignments was obtained for trypsin with little overlap between GluC and 
chymotrypsin. Parallel digestion with GluC added approximately 25% unique N-terminal peptides and 
a 15% increase in proteome coverage, while the additional use of chymotrypsin may be superfluous for 
global N-proteome analysis.
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Peptide modifications 
The results of the PTAG strategy applied to a tryptic whole cell lysate of N. meningitidis are 
summarized in Table 1. In total, 645 unique N-terminal dimethylated peptides were identified 
by offline ion exchange pre-fractionation (6 fractions) of the TiO2 flow-through fraction and 
subsequent LC-MS/MS analysis. Of these N-terminal-dimethylated peptides, 423 peptides (312 
proteins) were annotated as true protein N-terminal peptides with initiator methionine residues, 
methionine cleavage sites and proteins with signal peptide cleavage sites. Redundancy was 
especially observed for high abundant proteins. Multiple unique N-terminal peptides per protein 
were identified as a result of incomplete initiator methionine or signal peptide processing or 
Figure 5. Distribution of N-terminal modifications in mature protein N-termini. 
Protein N-termini in N. meningitidis are assigned as retained initiator methionine, methionine cleavage 
and proteins with signal peptide cleavage (A). Frequency distribution of the position 2 (P2) amino acid for 
removed initiator methionine (open bars) and retained methionine (black bars) (B). Methionine removal 
is preferred for small and uncharged residues at the P2 position. For S. cerevisiae, protein N-termini were 
identified as naturally acetylated (45%) and free N-termini, which are dimethylated in the PTAG protocol 
(labeled N-termini, 55%). From the pool of acetylated proteins, 79% showed the methionine cleavage 
while 21% retained the methionine residue. Frequency distribution of naturally acetylated amino acids at 
the protein N-termini (D). Labeled N-termini are annotated as retained initiator methionine, methionine 
cleavage and proteins with signal/transit peptide cleavage (C). Methionine cleavage (open bars) is similar 
to prokaryotes preferred for small and uncharged residues at the P2 position (E).
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unspecific C-terminal cleavage specificity of trypsin. The remaining 222 N-terminal-dimethylated 
peptides are so-called neo-N-termini derived from internal cleavage sites throughout the protein. 
Neo-cleavage sites may originate from unknown proteolytic activity before (in vivo) or during 
harvesting (cell lysis), or from protein degradation during sample preparation [168]. The high 
labeling efficiency of the method is underlined by the identification of only 45 unmodified internal 
peptides (free a-amine). These peptides lack a PTAG affinity label as a result of incomplete 
derivatization chemistry, but are detected in dramatically reduced abundance compared to their 
PTAG-labeled analogues (Supplemental Figure 3). Cyclized N-termini are also enriched in the 
TiO2 flow-through fraction because these peptides lack a free a-amine for PTAG derivatization. 
Especially N-pyroglutamyl residues were frequently identified during method development 
(data not shown). Staes et al. [152] introduced a method to generate a free a-amine (for subsequent 
labeling) by enzymatic cyclization of N-terminal glutamine (Qcyclase) and subsequent cleavage 
(pGAPase) of the formed N-pyroglutamyl moiety. This method was successfully implemented 
Table 1. N-proteome analysis of tryptic N. meningitidis and tryptic S. cerevisiae using the PTAG 
strategy. 
The number of uniquea N-dimethyl- or N-acetyl-modified peptides are listed. Dimethylated N-terminal 
peptides include (true) protein N-terminal peptides and neo-N-terminal peptides with unknown cleavage 
specificity from e.g. (in vivo) proteolytic activity. Only N-dimethylated peptides which are assigned to 
as (true) protein N-termini indicated by retained initiator methionine, methionine cleavage and proteins 
with signal/transit peptide cleavage are used for further data evaluation. The TiO2 flow-through fraction 
was co-purified with N-unmodified (internal) peptides (lacking a PTAG due to incomplete derivatization), 
N-terminally cyclized peptides (N-pyroglutamate, N-pyrocarbamidomethyl cysteine and N-aspargine 
(P2)) and N-monomethylated peptides. 
N-dimethylated or N-acetylated peptide modifications N. meningitidis whole cells
N. meningitidis 
OMV fraction
S. cerevisiae 
whole cells
N-dimethylated peptides, incl. internal cleavages sites 645 897 776
N-dimethylated peptides assigned to protein N-termini 423 215 388
N-acetylated peptides assigned to protein N-termini – – 333
Number of proteins identified by N-terminal peptides 312 170 470
Co-purified peptide modifications N. meningitidis whole cells
N. meningitidis 
OMV fraction
S. cerevisiae 
whole cells
N-unmodified (internal) peptides 45 154 187
N-pyroglutamateb 14 (12) 6 (5) 18 (17)
N-pyrocarbamidomethyl cysteinec 35 23 130
N-aspargine (P2) cyclizedd 30 17 45
N-monometyle 56 164 95
aPeptide deamination and oxidation states are not considered unique.
b N-terminal glutamate was enzymatically cyclized by Qcyclase to N-pyroglutamate and subsequently 
cleaved by pGAPase generating an a-amine for PTAG and depletion. This enzymatic approach is 
especially inefficient for peptides with a peptidase inhibiting proline (P2) residue next to N-pyroglutamate 
(depicted between brackets).
c Cyclization of N-terminal carbamidomethylated (iodoacetamide) cysteine residues.
d N-terminal cyclization of the aspargine side chain is restricted for position 2 (P2) residues. 
e N-terminal monomethylation of internal peptides as a consequence of residual activity of the reagent 
formaldehyde during trypsin digestion.
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in the PTAG strategy because only 14 N-pyroglutamyl peptides were identified of which 12 
peptides had a pGAPase inhibiting proline residue following the pyroglutamyl cleavage site. 
Furthermore, 35 cyclized peptides with a N-terminal, iodoacetamine-alkylated cysteine residue 
(pyrocarbamidomethyl cysteine) [152] and 30 peptides where the position 2 aspargine side chain 
is N-terminally cyclized (X-Asn-X motif) [169] were recovered in the flow-through fraction. 
For proline starting proteins [170], the N-terminus (initiator methionine cleavage) is incorporated 
by a single methyl group by protective labeling with formaldehyde (N-monomethylation). 
Data evaluation revealed that 56 peptides were N-monomethylated. Several peptides could 
successfully be assigned as true proline starting protein N-termini, however the vast majority 
of peptides was identified as internal peptides. It appeared that, due to residual activity of the 
reagent formaldehyde, proteolytically generated internal peptides were (inefficiently) labeled at 
the N-terminus by a single methyl group, thereby blocking subsequent PTAG derivatization. 
The peptide identification results for tryptic OMV fractions from N. meningitidis and tryptic S. 
cerevisiae whole cells are in general similar as discussed above (Table 1). As expected, also quite a 
few N-acetylated termini (333) were detected in S. cerevisiae and none in N. meningitidis. Notably, 
a high number of neo-N-termini from internal cleavage sites were found for OMV in comparison 
to whole cell lysates. This high number may have been resulted from proteolytic activity upon 
cell lysis to stimulate OMV release or from protein degradation during OMV purification. 
N-proteome characterization 
The results of N-proteome enrichment of N. meningitidis and S. cerevisiae by the parallel use of 
trypsin, GluC and chymotrypsin are summarized in Figure 4. The results of the OMV fraction 
and the whole cell fraction of N. meningitidis largely overlap in terms of protein and peptide 
identifications (Supplemental Table 1). These data sets were combined to reduce the number of 
single peptide identifications (‘one hit wonders’) and hence reduce the chance of false positive 
peptide and protein identifications. In total, 753 unique N-terminal peptides were identified for 
N. meningitidis (428 proteins) predominantly by tryptic samples (Figure 4). The majority of the 
proteins (75%) were assigned by multiple MS/MS spectra of the same peptide at different charge 
states, deamidation or oxidation states or, more importantly, overlapping peptides with different 
lengths (Supplemental Table 1).
N-termini were assigned with retained initiator methionine, methionine cleavage sites and 
proteins with signal peptide cleavage (Figure 5A). Analysis of the native protein N-termini provide 
a profile for in vivo specificity of methionine removal (Figure 5B). This process depends on the 
amino acid at position 2 and is preferentially associated with the small and uncharged residues 
serine, alanine, proline, glycine and cysteine [170]. Furthermore, 123 neo-N-terminal peptides 
(43 proteins) were identified for proteins of which the signal peptide was removed (Figure 5A). 
The secretory signal peptide that targets a protein for translocation across membranes is typically 
14-30 amino acids long and is removed by a signal peptidase upon translocation. Signal peptide 
cleavage sites of 43 identified proteins could be accurately verified by prediction software because 
cleavage is governed by distinct zones (basic N-terminus, a hydrophobic region and a C-terminal 
region) with high sequence consistency around the cleavage site [162]. 
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N-proteome analysis of S. cerevisiae resulted in the identification of 928 unique N-terminal peptides 
that could be assigned to 572 proteins (Figure 4). Approximately 45% of the proteins were fully 
or partially N-acetylated, preferentially at alanine, serine, threonine and methionine (Figure 5C-
D). Methionine cleavage specificity is conserved in prokaryotes and eukaryotes and preferential 
for small, uncharged residues at position 2 (Figure 5E) [162]. In addition, 125 neo-N-terminal 
peptides (71 proteins) were identified for mitochondrial proteins of which the transit peptide was 
cleaved. Hallmarks for transit peptides cleavages are less well-described and predictable than 
those for signal peptides in prokaryotes [162]. The sequence consistency around the cleavage site 
is low, with arginine in position -3 or -2 relative to the cleavage site as the most common motif. 
For this purpose, accurate verification of peptidase cleavage site specificity was not performed by 
prediction [162], but instead a comparison was made with a recently published COFRADIC study. 
Vogtle et al. [163] characterized transit peptide cleavage specificity of an enriched mitochondrial 
protein fraction of S. cerevisiae. Identical cleavage sites were found for both positional proteomics 
strategies for the majority of the PTAG-identified mitochondrial proteins (46 out of 71 proteins).
Recent N-proteome enrichment procedures suffered from under-representation of histidine and 
arginine containing N-terminal peptides as a result of charge retention on SCX pre-enrichment 
or side reactivity of histidine residues with NHS-activated sepharose beads [151, 152]. To 
investigate possible undersampling, the frequency distribution of the amino acids (P2) following 
the N-terminal methionine was calculated for the experimental data as the theoretical proteome 
(protein-coding genes). The experimental data correlates reasonably well with the frequency 
distribution in the complete proteome set for both N. meningitidis as S. cerevisiae, demonstrating 
that the obtained data are representative for the global N-proteome (Figure 6). 
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Figure 6. 
N-proteome wide frequency distribution of the position 2 (P2) amino acid following the initiator 
methionine. The frequency distribution calculated for the complete set of proteins (protein-coding genes) 
is depicted in black bars and the frequency distribution for the experimentally identified protein N-termini 
is depicted in open bars. For both N. meningitidis (A) and S. cerevisiae (B), the experimental data correlates 
with theoretically data, indicating that the outcome the PTAG strategy is representative for the global 
N-proteome. 
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Discussion
In MS-based proteomics, complexity in protein samples greatly limits proteome coverage and 
identification of low abundant proteins [171]. Several advanced enrichment protocols have 
been introduced over the recent years to address this problem, including N-terminal positional 
proteomics strategies [140, 172]. Enrichment of N-terminal peptides by complete removal of 
internal peptides constitutes a major challenge [147]. PTAG was developed for specific labeling of 
free a-amines of internal peptides after proteolytic digestion. Subsequent, PTAG-labeled peptides 
were depleted by TiO2 affinity chromatography (Figure 1). High labeling efficiency was established, 
both at the protein level and at the peptide level, essential for minimizing the loss of N-terminal 
peptides. Dimethylation by formaldehyde was preferred because it is inexpensive, resistant 
to hydrolysis and full labeling of protein N-termini and lysine side chains was accomplished 
(Supplemental Figure 2). In addition, the availability of stable isotopically labeled analogues of 
formaldehyde and cyanoborohydride enables multiplexed relative quantification in combination 
with PTAG [144, 157]. Internal peptides were selectively modified by the commercially available 
PTAG reagent glyceraldehyde-3-phosphate (GAP3). This reagent is similar to formaldehyde, 
resistant to hydrolysis and showed a high conversion yield (> 99%), thereby reducing possible 
background contamination of internal peptides (Supplemental Figure 3.). Excellent compatibility 
to reversed phase C18 ensured easy removal of salts and excess reagents prior to either TiO2 
affinity chromatography or direct LC-MS/MS analysis. 
For the effective depletion of proteolytically generated internal peptides from a 100-µg proteome 
sample, a straightforward TiO2-based depletion strategy was developed using in-house slurry-
packed columns and including stringent washing conditions to minimize nonspecific adsorption 
[166] (Supplemental Table 2). The ability to efficiently reduce sample complexity and identify 
a large number of proteins (207 proteins) in the outer membrane vesicle (OMV) fraction of N. 
meningitidis, with dynamic range spanning several orders of magnitude, underlines the excellent 
recovery and selectivity of this strategy (Figure 3). It should be noted that the final enriched 
sample fraction of this complex OMV digest is slightly biased by breakthrough of poorly retained 
PTAG peptides (5%). These peptides were assigned by employing stable isotopically labeled 
variants of the PTAG reagent (Supplemental Figure 5 and 6). 
N-proteome analysis of N. meningitidis and S. cerevisiae by the PTAG strategy resulted in the 
identification of 753 (428 proteins) and 928 (572 proteins) unique N-terminal peptides, respectively. 
Characterization of native protein N-termini provided a profile for in vivo specificity of methionine 
removal. This process is conserved in prokaryotes and eukaryotes and preferentially associated 
to small and uncharged residues (Figure 5) [173]. Furthermore, in S. cerevisiae, about 45% of the 
proteins were fully or partially N-terminally acetylated on alanine, serine, threonine or methionine 
(Figure 5), which is a similar percentage as recently found by others [174]. N-proteome data also 
include neo-N-termini from subcellular-relocalized membrane (43 proteins, N. meningitidis) or 
mitochondrial proteins (71 proteins, S. cerevisiae). Accurate assignment of protease substrate 
cleavage sites could be problematic because these cleavage sites are typically not annotated in 
protein sequence databases [175]. Moreover, co-purification of neo-N-termini generated from 
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background proteolytic activity with unknown specificity could result in the false positive 
identification of cleavage sites [144]. For this purpose, signal peptide and transit peptide cleavage 
specificity of the reported proteins were confirmed by either prediction [162] or by experimental 
data from a recent COFRADIC study [150]. 
Confidence in protein assignment may be problematic in N-proteome analysis as the majority of 
proteins are identified by a single peptide. Similar to other positional proteomics strategies [135, 
176], pre-fractionation of the N-terminally enriched peptide fraction was performed to increase 
the number of MS/MS identifications per peptide and combined with strict database search 
criteria (FDR < 1%) to minimize the number false positive peptide identifications. Also, a number 
of proteases were used to generate N-terminal peptides with different lengths and hence not only 
enhance the confidence in protein assignment but also increase proteome coverage (Figure 3). It 
was estimated by in silico analysis that 50% of trypsin-generated N-terminal peptides could be 
analyzed by LC-MS/MS and parallel use of trypsin and GluC would increase coverage up to 80% 
[134, 147]. In practice, the increase in unique protein identifications for the use GluC in addition 
to trypsin is ~15% (Figure 3). This emphasizes one of the major challenges in N-proteomics: the 
identification of proteins by single N-terminal peptides with suitable LC-MS/MS characteristics, 
e.g. peptide length, hydrophobicity, ionization efficiencies and fragmentation properties. 
Alternative fragmentation techniques complementary to Collision Induced Fragmentation (CID) 
may be in particular beneficial in N-proteomics. A substantial fraction of the sample consists 
of long and highly charged N-terminal peptides with poor CID-fragmentation behavior. These 
long and highly charged peptides are generated by the ArgC digestion pattern of trypsin in 
combination with the remained ionic state of dimethylated lysine residues. Electron Transfer 
Dissociation (ETD) and Higher-energy Collisional Dissociation (HCD) have shown to be more 
effective for these highly charged peptides [177]. 
Recently, a number of large scale N-proteome studies for prokaryotes and S. cerevisiae were 
published. Timmer et al. [148, 149] characterized the N-proteome of E. coli by positive selection 
and identified 393 proteins, while Mc Donald et al. [134] identified more than 300 proteins in 
E. coli utilizing NHS-activated sepharose beads for depletion of internal peptides. N-proteome 
analysis of S. cerevisiae by COFRADIC in combination with SCX resulted in the identification of 
650 unique N-terminal peptides [178]. Helbig et al. [179] characterized protein N-acetylation in S. 
cerevisiae with SCX and detected 756 N-acetylated protein termini, including acetylated neo-N-
termini from internal cleavage sites. PTAG enabled the identification and characterization of 753 
unique N-terminal peptides (428 proteins) in N. meningitidis and 928 unique N-terminal peptides 
(572 proteins), thereby representing one of the largest N-proteome datasets for these organisms 
so far. More detailed evaluations of S. cerevisiae N-proteome data provided by Helsens et al. [178], 
Helbig et al. [179] and N-proteome analysis by PTAG, revealed relative small overlaps between 
the studies (Supplemental Figure 6). The small overlaps are most likely due to undersampling 
of the full proteome or differences associated with the used method. For example, the study of 
Helbig et al. [179] was restricted to N-acetylated peptides while Helsens et al. [178] used SCX 
pre-enrichment with known undersampling of histidine containing N-terminal peptides [151, 
152]. For N-proteome analysis by PTAG there is no indication of undersampling of certain amino 
acid sequences (Figure 6). However, a clear disadvantage of the PTAG strategy is the inability 
to recover N-termini of proteins of which the N-terminal domain is phosphorylated by nature. 
N-terminal phosphorylation has for example been demonstrated in the p53 tumor suppression 
protein [180] and several crucial proteins of the photosystem II (PSII) in A. thaliana [181]. 
In conclusion, the PTAG positional proteomics strategy greatly reduces sample complexity, 
while maintaining the N-proteome fingerprint of whole cell lysates. The use of commercially 
available and highly reactive PTAG reagents in combination with high performance TiO2 affinity 
chromatography provide a robust platform for global N-proteome analysis and MS-based 
profiling of proteolytic events. PTAG for unbiased selective isolation of protein N-termini is 
therefore a welcome alternative to well-established positional proteomics strategies. 
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Chapter 4
Quantitative proteomics reveals 
distinct differences in the protein 
content of outer membrane vesicle 
vaccines
56
Abstract
At present only vaccines containing outer membrane vesicles (OMV) have successfully stopped 
Neisseria meningitidis serogroup B epidemics. These vaccines however require detergent-extraction 
to remove endotoxin, which changes immunogenicity and causes production difficulties. To 
investigate this in more detail, the protein content of detergent-extracted OMV is compared 
with two detergent-free alternatives. A novel proteomics strategy has been developed, which 
allows quantitative analysis of many biological replicates despite inherent multiplex restrictions 
of dimethyl labeling. This enables robust statistical analysis of relative protein abundance. The 
comparison with detergent-extracted OMV reveals that detergent-free OMV are enriched with 
membrane (lipo)proteins and contain less cytoplasmic proteins due to a milder purification 
process. These distinct protein profiles are substantiated with serum blot proteomics, confirming 
enrichment with immunogenic proteins in both detergent-free alternatives. Therefore, the 
immunogenic protein content of OMV vaccines depends at least partially on the purification 
process. This study demonstrates that detergent-free OMV have a preferred composition.
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Introduction
The use of outer membrane vesicles (OMV) is a promising approach for vaccine development 
against Neisseria meningitidis serogroup B, which causes acute and severe meningitis [18, 50, 51, 
53, 182]. OMV consist of a phospholipid bilayer with outer membrane proteins, endotoxin and a 
lumen with periplasmic proteins [89, 183]. Outer membrane porin A protein (PorA) was identified 
as the dominant antigen in OMV, but is antigenically variable between circulating strains [57, 
58]. To obtain a broadly protective vaccine, recombinant strains with multiple PorA subtypes 
were developed [5, 7]. Recent studies demonstrated that conserved minor antigens, like factor 
H binding protein (fHbp, a lipoprotein) or iron-regulated membrane proteins, can complement 
PorA to further improve cross-protection [63, 64, 71]. In addition to well-described antigens 
the OMV proteome contains a considerable number of other proteins that may be relevant for 
immunogenicity [184]. 
The first OMV vaccines were prepared with detergent-extraction (dOMV) and have successfully 
stopped N. meningitidis serogroup B epidemics in several countries [49-54, 61]. The detergent-
extraction was required to remove endotoxin, but removed lipoproteins as well, and caused 
partially intact and aggregated vesicles [61, 185]. The lpxL1 mutation successfully attenuated 
meningococcal endotoxin and allowed a detergent-free process for vaccine development [6, 70]. A 
detergent-free process either uses extraction with a chelating agent to improve yield (native OMV; 
nOMV) [111, 186-189], or no extraction at all (spontaneous OMV; sOMV) [94, 97, 190]. It was found 
that detergent-free OMV retain lipoproteins like fHbp, which improved cross-protection and 
functional immunogenicity in mice [63, 104, 185, 191]. These immunological properties of OMV 
vaccines were measured with SBA (serum bactericidal activity), which is an established correlate 
of protection in humans but does not provide in-depth information at the protein level [46, 192]. 
Proteomics has been used to assess the protein content of OMV in more detail. Initial studies on 
dOMV from N. meningitidis serogroup B used gel electrophoresis combined with LC-MS/MS 
peptide identification [97, 193-195]. One study revealed that dOMV and sOMV vaccines have 
a different protein content [104]. More recently, quantitative 2D gel analysis with fluorescent 
labeling identified a limited number of differential proteins in dOMV after growth on two media 
[196]. Gel-based proteomics however is labor intensive and less compatible with hydrophobic 
membrane proteins from OMV than a gel-free approach [197]. It also has a strong bias toward 
highly abundant proteins [198]. To overcome these limitations, several gel-free quantitative 
proteomics methods have been developed [133, 157, 199]. Compared to other quantitative 
methods, multiplex dimethyl labeling of amino groups on N-termini and lysine residues is fast, 
robust and inexpensive [157, 200]. When dimethyl labeling is performed at the protein level, 
the N-terminal part of the protein (blocked a-amino group) can be selectively purified from the 
internal peptides after proteolytic cleavage (free a-amino groups). [134-136, 201]. Such a positional 
proteomics strategy strongly reduces sample complexity and uncovers low-abundant peptides, 
while preserving the original proteome fingerprint. 
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Positional proteomics successfully addressed sample complexity issues observed with complex 
proteomes that are dominated by a few proteins, like human plasma or OMV [202, 203]. Recently 
the PTAG strategy (phospho-tag) was developed for this purpose, using glyceraldehyde-3-
phosphate reagent to derivatize free amino groups of internal peptides after proteolytic cleavage 
[204]. PTAG-modified internal peptides were depleted with efficient titanium dioxide (TiO2) 
affinity chromatography, which purified protein N-terminal peptides for consecutive LC-MS/MS 
analysis. This PTAG strategy identified 572 unique proteins of S. cerevisiae and 428 unique proteins 
of N. meningitidis by their N-terminal peptides, representing one of largest N-proteome data 
sets available for these organisms. The study included 170 unique proteins from N. meningitidis 
nOMV vaccine, but dimethyl quantification was not implemented.
This work describes the first quantitative proteome comparison of detergent-extracted OMV 
vaccines with two detergent-free alternatives. A novel quantification method was developed, 
based on dimethylation with stable isotopes and selective purification of N-terminal peptides. 
Distinct differences in protein content were observed, including several immunogenic proteins. 
These findings demonstrate that purification processes can change the protein content of OMV 
vaccines and support previously observed differences in functional immunogenicity.
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Materials and methods
Strain, growth conditions and OMV purification
The N. meningitidis vaccine strain that was used is a recombinant variant of isolate H44/76 
(serogroup B) [109], combining one wild type and two recombinant PorA antigens (trivalent PorA; 
subtypes P1.7,16; P1.5-1,2-2 and P1.19,15-1) with a non-functional porB gene [7]. The cps locus 
was deleted, resulting in a non-encapsulated phenotype with galE-truncated LPS. Additional 
deletions in lpxL1 and rmpM genes were made to attenuate LPS toxicity and improve OMV yield, 
respectively [185]. Cultures were grown in chemically defined, iron-rich medium [4]. Erlenmeyer 
shake flasks with 150 mL medium were inoculated with 10 mL working seedlot (cells at OD590 
= 1.5 ± 0.1; stored at -135ºC with glycerol). Pre-culture shake flasks were incubated at 35ºC, 200 
rpm and 10 mL portions (OD590 of 1.5 ± 0.3) were used to inoculate secondary shake flasks. OD590 
of the secondary flasks was monitored and bacteria were harvested for OMV purification after 5 
hours of stationary growth. OMV vaccines were purified as described previously [185]. For OMV 
quality control, total protein concentration (>1.0 mg/mL; Lowry with Peterson’s modification), 
PorA content (>50% of total protein) and vesicle size distribution (average size 70-110 nm; 
polydispersity index <0.20) were performed [112, 186]. As reported before, detergent-extraction 
caused aggregation of dOMV samples which resulted in high polydispersity. nOMV and sOMV 
vaccines did pass all quality criteria [185]. 
Dimethyl labeling and N-proteome enrichment
Protein was extracted from OMV vaccines with Trizol reagent (Invitrogen, The Netherlands). 
An OMV amount corresponding to 500 µg of total protein was used for each extraction. OMV 
sample volume was first reduced to 20-50 µL with a vacuum dryer before adding 500 µL Trizol. 
Protein was extracted according to manufacturer’s protocol and the resulting pellets were stored 
at -80°C. Thawed pellets were dissolved in 50 µl buffer (100 mM KH2PO4, pH 7.5) containing 4M 
Guanidine-HCl. Total protein concentration was measured using the Lowry assay with Peterson’s 
modification (sample was diluted at least 100-fold to prevent interference of guanidine with the 
assay). SDS-PAGE analysis confirmed comparable protein compositions before and after Trizol 
extraction (data not shown). Protein labeling, digestion and purification protocols (including the 
PTAG strategy) were described previously[204]. The dimethyl labeling strategy was adapted 
for relative quantification purposes. The common reference (equal amounts of protein from all 
experimental protein samples) and the individual experimental samples were incubated with 
either light formaldehyde label (CH2O) or heavy label (CD2O; Sigma Aldrich), respectively, with 
addition of sodium cyanoborohydride (Sigma Aldrich) for 24 h at room temperature. Each heavy 
labeled sample was pooled individually with light labeled common reference in a 1:1 (w/w) 
ratio and digested by trypsin under previously described conditions[204]. A sample aliquot was 
diluted 100 times in formic acid/DMSO in water (5/5/90, v/v) and stored at -20°C until further 
analysis. Peptide mixtures after trypsin digestion were PTAG derivatized and the N-terminal 
peptides were recovered/enriched in flow-through fraction of TiO2 affinity chromatography. 
Samples were dried and reconstituted in formic acid/DMSO in water (5/5/90, v/v) and stored 
at -20°C until analysis.
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Peptide search list compilation using data-dependent LC-MS/MS
A search list containing entries with unique combinations of peptide sequence, accurate mass and 
retention time window was obtained by data-dependent LC-MS/MS analysis [205, 206]. Common 
reference sample aliquots were collected both before and after PTAG depletion and subsequently 
fractionated by strong cation exchange (SCX). The common reference samples were loaded onto 
a biphasic 200µm ID trapping column packed with 20 mm 5 µm C18 resin (Reprosil Pur C18-AQ 
(Dr. Maisch, Ammerbuch-Entringen, Germany) and 20 mm 5µm SCX resin (Polysulphoethyl A, 
PolyLC Inc, Colombia, USA) in 0.1M HOAc at 5µL/min. Following RP-to-SCX transfer using 50% 
acetonitrille in 0.1M HOAc, peptide fractions were recovered by flushing the SCX bed step-wise 
with 2 µL plugs of potassium chloride in 0.1 mM acetic acid containing acetonitrile. Seven different 
acetonitrile concentrations were used in the plugs, ranging from 10 to 500 mM. Fractions were 
dried and reconstituted in formic acid/DMSO in water (5/5/90, v/v) and analyzed by LC-MS/
MS. An LTQ-Orbitrap XL instrument (Thermo Fisher Scientific, The Netherlands) and Agilent 
1100 HPLC system (Agilent, The Netherlands) was modified for nanoflow LC separations as 
previously described [207]. The trap column was a 100-µm ID fritted microcapillary packed with 
20 mm, 5 µm particle size Reprosil Pur C18-AQ particles (Dr. Maisch, Germany). The analytical 
column was a 50-µm ID fritted microcapillary packed with 31 cm 3 µm particle size Reprosil 
Pur C18-AQ. The column effluent was directly electrosprayed into the MS using an in-house 
prepared, gold and conductive carbon coated fused silica tapered tip of ~2 µm (typically at 2.0 
kV) [207]. Solvent A consisted of 0.1 M acetic acid in deionized water and solvent B of 0.1 M 
acetic acid in acetonitrile. Gradients were as follows: 100% solvent A during sample loading (0-
10 min, flow rate 5 µL/min), 7% to 26% solvent B in 160 minutes followed by an increase to 60% 
solvent B in 20 minutes and reconditioning with solvent A for 10 min (total runtime 200 min). The 
mass spectrometer was set to acquire full MS spectra (m/z 350 to 1,500) for mass analysis in the 
Orbitrap at 60,000 resolution (FWHM) followed by data-dependent MS/MS analysis (LTQ) for 
the top 7 abundant precursor ions above a threshold value of 104 counts. The normalized collision 
energy was set to 35%, isolation width to 2.0 Da, activation Q to 0.250 and activation time to 30 
ms. The maximum ion time (dwell time) for MS scans was set to 200 ms and for MS/MS scans to 
2500 s. Charge state screening and preview mode were enabled. Precursor ions with unknown 
and +1 charge states were excluded for subsequent MS/MS analysis. Dynamic exclusion was 
enabled (exclusion size list with 500 entries) with repeat set to 1 and an exclusion duration of 180 
s. The background ion at m/z 391.284280 was used as lock mass for internal mass calibration. 
Analysis of LC-MS/MS raw data was carried out with Proteome Discoverer 1.2 software (Thermo 
Fisher Scientific, Bremen, Germany) applying standard settings unless otherwise noted. MS/MS 
scans were searched against the N. meningitidis serogroup B database (Uniprot Knowledgebase, 
July 18th 2012) using SEQUEST. Precursor ion and MS/MS tolerances were set to 10 ppm and 
0.8 Da, respectively. Decoy database searches were performed with False Discovery Rate (FDR) 
tolerances set to 5% and 1% for modest and high confidence filtering settings, respectively. The data 
were searched with full trypsin cleavage specificity, allowing 5 miss-cleavages (lysine cleavage is 
prevented by dimethyl modification). Cysteine carbamidomethyl and lysine dimethylation were 
set as fixed modifications, while aspargine deamidation and methionine oxidation were set as 
variable modifications. An additional search was performed using C-terminal trypsin cleavage 
specificity and implementation a fixed N-terminal dimethyl modification. High confidence 
peptide sequence identifications (Xcorr values >2.2, false discovery rate <1%, rank No.1) were 
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exported to an Excel data file (the peptide search list). Raw data files and protocols associated 
with this manuscript are available for the reader upon request.
High resolution peak quantification using LC-MS
Quantification experiments of light (common reference) and heavy (experimental sample) labeled 
peptide mixtures were performed on the full MS level, relying on the high mass accuracy of the 
Orbitrap (data-dependent MS/MS disabled). All analyses were performed with the same nano 
LC column and identical gradient conditions as described above for maximal chromatographic 
reproducibility. Light/heavy peptide mixtures prior to PTAG-labeling and TiO2 purification (15 
samples) and N-terminally enriched peptide mixtures after TiO2 purification (15 samples) were 
directly analyzed by LC-MS.
Data processing for analysis of relative protein abundance
Relative peptide abundances were determined by using the high resolution LC-MS data in 
combination with the precompiled peptide search list (accurate mass and retention time approach) 
[205, 206]. Raw LC-MS data files were deconvoluted to mono-isotopic masses to minimize isobaric 
interference of contaminants using Xcalibur software (Thermo Scientific; XtractAll plug-in; MH+ 
mode; S/N threshold = 2) [208]. The output was saved in NetCDF format (Thermo file converter) 
and imported in MS-Xelerator (MSMetrix, The Netherlands). The MSX-Quant plug-in of this 
software traced and extracted the peak areas of all peptide entries of the pre-compiled Excel 
search list using accurate mass ( ±0.01 Da) and retention time (±10 min) information. Light/heavy 
peak area ratios were calculated from extracted ion chromatograms. Further data processing was 
performed in R (http://www.R-project.org). Individual MSX-Quant result files were compiled 
and stringent quality criteria were applied. A peptide search list entry was positively identified 
when both light and heavy labeled chromatographic peaks were extracted for at least 3 out of 5 
independent biological replicates of at least 1 OMV vaccine type at an intensity threshold of >104 
counts (above background noise). In addition, all chromatographic peaks were required to have 
an accurate mass deviation of <10 ppm and retention time window ±10 min compared to the 
search list entry. Starting with entries that were positively identified in any OMV vaccine type, 
it was determined whether or not these entries were identified in each of the three OMV vaccine 
types, by using the same quality criteria. The resulting lists of positively identified entries were 
mapped to corresponding peptides and proteins. The overlap between the respective lists per 
OMV vaccine type was visualized as Venn diagrams. 
Statistical analysis of relative protein abundance
For quantification of relative protein abundance, the light/heavy ratio values of positively 
identified peptide search list entries were 2log transformed. For entries with a positive 
identification (found in ≥3 out of 5 replicates) for an OMV type, missing values (due to quality 
issues) were imputed as the mean of detected values. OMV types with a negative identification 
for a search list entry (found in ≤2 out 5 replicates) were imputed with background values. 
Background values were calculated from the mean of the minimal value for that entry across 
all experimental samples and the minimal value for that experimental sample across all search 
list entries. This ensured that both sample and entry-dependent background levels were taken 
into account. Next, log-transformed values of search list entries that belonged to the same 
peptide were averaged, followed by averaging of values from peptides that belonged to the 
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same protein. The resulting protein expression data were analyzed across all OMV types with 
one-way ANOVA. This identified proteins that were differentially expressed between any of the 
OMV types (maximal Fold ratio >2 and p<0.001). This corresponded to a False Discovery Rate 
(FDR) of <1%. The expression values of differentially expressed proteins were visualized as a 
heat map using Genemaths XT (Applied Maths, Belgium). Functional annotations and keywords 
of identified proteins were adopted from Uniprot Knowledgebase, N. meningitidis strain MC58 
(http://www.uniprot.org). A few entries were substituted with homologs from strain H44/76 or 
strain Alpha710, due to an outdated MC58 annotation. Predicted cellular locations were obtained 
with the PSORTb algorithm (http://www.psort.org/psortb) [209]. 
Serum blot proteomics 
Female BALB/c mice were immunized subcutaneously on day 0 and 28 with either dOMV, 
nOMV or sOMV vaccine and sera were collected on day 42, as previously described [185]. SDS gel 
electrophoresis was performed with 4 µg total protein of each OMV vaccine per lane[185]. Gels 
were either stained with Novex Colloidial Blue (Invitrogen, U.S.A.) or blotted to nitrocellulose 
membranes and blocked with buffer containing 0.5% Protifar (Nutricia, The Netherlands). Blot 
membranes were incubated with pooled mice sera after immunization with the corresponding 
OMV vaccine (200x diluted), with monoclonal antibody against fHbp (NIBSC, United Kingdom) 
or with PorA P1.19 monoclonal antibody (Intravacc, The Netherlands). Goat-anti-mouse 
antibody conjugated to alkaline phosphatase was used as a secondary antibody for staining. The 
protocol for direct surface digestion of blotted proteins was adapted from Luque-Garcia et al. 
[210]. Differential serum bands were excised and incubated in 100 mM KH2PO4 (pH 7.5), 10% 
acetonitrille with trypsin at an enzyme/protein ratio of 1/20 (w/w) at 37°C for 16 h. Peptide 
mixtures were purified with RP/SCX solid phase extraction as described above (peptide search 
list compilation paragraph). LC-MS/MS conditions and data analysis were also similar as above, 
however with 90 min. LC gradients (7%–40% solvent B in 80 min). Cleavage specificity was set to 
full trypsin allowing 2 miss-cleavages. Aspargine deamidation and methionine oxidation were set 
as variable modifications. At least 2 unique, high-confidence peptides were required for protein 
identification and large deviations between theoretical and observed protein molecular weight 
on the immunoblot were not tolerated. Protein identifications that matched the immunoblot 
pattern were verified manually, to confirm presence of the corresponding tryptic peptides in the 
raw chromatographic data.
63
Chapter 4
Results
Development of quantitative proteomics method
A novel quantitative proteomics method was developed based on duplex dimethyl labeling, 
combined with unbiased selection of N-terminal peptides (PTAG; phospho tagging)[204]. A 
detailed workflow is shown in Figure 1. Relative quantification was based on comparison of 
15 experimental samples (3 different OMV vaccines; 5 biological replicates per vaccine) against 
a common reference (CR). The CR contained equal amounts of protein from all experimental 
samples. Samples for high-throughput quantification were collected after proteolytic digestion 
(all dimethylated peptides) and after PTAG depletion (N-terminal peptides). Quantification was 
performed with a two-step approach, using stringent quality criteria (Figure 2) [205]. The CR 
allowed an unrestricted number of biological replicates despite inherent multiplex restrictions of 
the dimethyl labeling (either duplex or triplex [157, 200]). As a result, each experimental group 
(OMV vaccine) had 3–5 independent measurements per peptide, allowing robust statistical 
analysis. Prior to OMV proteome analysis, the quantification method was successfully validated 
with a standard protein mixture containing known ratios (Appendix 1). 
OMV protein identification and evaluation of PTAG procedure
The proteome analysis was performed on OMV vaccines from three different purification 
processes [185]. A total of 618 unique peptides were positively identified, 400 peptides in dOMV 
(detergent extraction), 509 peptides in nOMV (detergent-free extraction) and 497 peptides in 
sOMV (no extraction), with high reproducibility but moderate overlap between the three vaccines 
(282 peptides; Figure 3A). Merging of peptides with identical accession numbers yielded 185 
unique proteins, of which 76 proteins were shared between the three OMV vaccines (Figure 3B). 
These results were obtained after merging of datasets from internal peptides and N-terminal 
peptides (S-Table 2B, Supporting Information). Added value of the PTAG strategy was evaluated 
by comparing the contribution of each dataset to the total number of detected peptides (Figure 
3C) and proteins (Figure 3D). At the peptide level, the PTAG strategy resulted in detection of 86 
unique N-terminal peptides, of which 62% was not detected before this procedure (53 N-terminal 
peptides). These 53 additional N-terminal peptides accounted for 7 additional proteins, which 
indicates that most of the N-termini found with the PTAG strategy belonged to proteins that were 
already detected by their internal peptides (before PTAG). Cellular location prediction (PSORTb 
algoritm [209]) did not reveal enrichment in protein groups that were either detected before (143 
proteins) or after PTAG (7 proteins; Figure 3D). The 35 proteins that belonged to both groups 
were enriched with a membrane location (p<0.012). Since this group includes PorA, OpcA, PilQ 
and other major proteins of OMV, the observed enrichment is most likely related to protein 
abundance rather than a membrane location. A total of 42 proteins were identified by N-terminal 
peptides, of which 36 were positively verified. These N-termini were positioned at the first, 
second or SignalP predicted residue of the full protein sequence, or were cleaved after an AxA 
motif [297]. To account for unknown signal peptides, N-termini within the first 70 residues of the 
full protein sequence were also considered valid. The remaining 6 proteins were identified with 
degradation peptides from abundant proteins (e.g. PorA), which are also dimethylated during 
the PTAG procedure (neo N-termini). N-terminal peptides of lipoproteins were absent, due to 
a lipid modification that prevents dimethylation [74]. Details of the verification are provided in 
S-Table 2E (Supporting Information).
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The dOMV vaccines contain cytoplasmic proteins as a result of lysis
Relative protein abundance of all 185 detected proteins (Figure 3B) was quantified to identify 
differences between the OMV vaccines. A good overall correlation between biological replicates 
was observed (R = 0.96, 0.90 and 0.90 for dOMV, nOMV and sOMV, respectively). Proteins were 
Figure 1. Workflow for purification of dimethylated N-terminal peptides with PTAG.
(A) First, the common reference is mixed from equal amounts of protein from all experimental samples. 
Free N-terminal and lysine amino groups of the common reference are dimethylated at the protein level 
with formaldehyde (CH2O, light label). In parallel, experimental samples are dimethylated with heavy 
formaldehyde (CD2O isotope, heavy label). (B) Light and heavy labeled samples are mixed and washed 
with acetone precipitation. (C) Proteolytic digestion with trypsin generates internal peptides with free 
N-terminal amino groups. (D) Internal peptides are derivatized on the N-termini with PTAG reagent. 
(E) PTAG peptides are captured with TiO2 columns for selective purification of dimethylated N-terminal 
peptides. (F) Samples are collected after step C (all dimethylated peptides) and after step E (N-terminal 
peptides) for quantification of light/heavy peak ratios with nano LC-MS (Figure 2).
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clustered in 7 groups based on their expression profile (Figure 4). Group VII contained 39 proteins 
that were detected without significant differences in relative protein abundance (therefore not 
shown in Figure 4). This group included several well-known membrane proteins like PorA, OpcA 
and FetA [43, 48]. Groups I to VI each had a specific expression pattern (e.g. downregulated in 
dOMV). Functional annotation revealed interesting differences. The 146 differentially expressed 
proteins in group I to VI together had 33 ribonucleoprotein annotations (from Uniprot keywords) 
of which 17 were found in group II (upregulated in dOMV; enrichment p-value <0.05). Group II 
was also significantly enriched in RNA-binding (14/23 annotations), nucleotide binding (9/17), 
cytoplasm (9/16) and transferase functions (7/12). These proteins originate from the cytoplasm 
and may be present exclusively in dOMV as a result of lysis, an undesired side-effect of detergent 
Figure 2. Common reference-based peptide quantification using stringent quality criteria.
(A) High-throughput peptide identification was done with a two-step approach. First, the common 
reference (CR) was analyzed to compile a search list with accurate mass, retention time window and 
sequence ID of all detectable peptides (S-table 2B, Supporting Information) [205, 206]. Second, full LC-
MS chromatograms were acquired for all light/heavy mixtures. The light (CR) peptides were traced with 
the peptide search list. Corresponding heavy (experimental) peptides were matched based on calculated 
mass and retention time. Stringent criteria were required for a positive identification (see Material and 
Methods section). Search list entries that complied to these criteria nearly always provided a unique hit. 
(B) Peak areas were extracted for quantification of light/heavy ratios. The CR was used as an internal 
standard to calculate ratios between experimental samples, as illustrated for search list entry PEP0357, a 
peptide from factor H binding protein. After data processing, this protein had a low expression in dOMV 
compared to nOMV (2.5-fold higher) and sOMV (4.0-fold higher). Each detectable peptide in the search list 
was quantified with 3–5 independent biological replicates, allowing robust statistical analysis.
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extraction. Group III (upregulated in dOMV and nOMV) confirmed this hypothesis because it was 
also significantly enriched in ribonucleoprotein (12/33) and RNA-binding functions (7/23). This 
group however contained less proteins since nOMV purification (mild, detergent-free extraction) 
indeed caused less lysis than dOMV, but clearly more than sOMV (no extraction). 
Detergent-free OMV vaccines are significantly enriched with membrane (lipo)proteins 
The lysis-related results were further substantiated with cellular location predictions (PSORTb 
algorithm [209]), which confirmed that groups II and III indeed were enriched with cytoplasmic 
proteins. Group V (upregulated in detergent-free nOMV and sOMV vaccines) however was 
enriched with proteins that had a membrane location (21/40 annotations) or unknown location 
(21/34 annotations). Also, this group contained 6 out of 8 proteins with a lipoprotein annotation 
(all enrichment p-values <0.05). Proteins with such locations or functions are more likely to 
be relevant for the immunogenicity of OMV vaccines than lysis-derived cytoplasmic proteins. 
Notably, several oxidoreductases were found specifically in sOMV vaccines (group VI; 7/12 
annotations). In addition to these redox-related proteins, sOMV vaccines contained proteins 
with non-enriched functions that are involved in iron uptake (e.g. heme utilization protein and 
Figure 3. Venn diagrams of identified peptides and proteins.
(A) Peptide overlap between dOMV vaccine (detergent-extraction), nOMV vaccine (detergent-free 
extraction) and sOMV vaccine (no extraction). A moderate overlap of 282 out of 618 unique peptides was 
observed. (B) The peptides corresponded to 185 unique proteins, of which 76 were shared. (C) Assessment 
of the added value of PTAG depletion at the peptide level. A total of 53 N-terminal peptides out of 86 
(62%) were uncovered by the PTAG procedure. (D) The additional N-terminal peptides represented only 7 
additional proteins, since most proteins were already detected by their internal peptides. This indicates that 
OMV samples may not have sufficient complexity to challenge the PTAG procedure. S-Table 2 (Supporting 
Information) links the data in the Venn diagrams to corresponding peptides and proteins.
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bacterioferritin BfrA, which is regulated in response to iron availability [211, 212]). Since sOMV 
are spontaneously released and most similar to natural OMV, these virulence-related proteins 
may be relevant for the pathogenicity of N. meningitidis [213]. Detailed protein information with 
expression data and functional annotation is available online as Supporting Information. An 
overview of the PSORTb location distribution per OMV vaccine is shown in Appendix 2.
Serum blot proteomics supports the quantitative proteomics results for several 
immunogenic proteins
Serum blot proteomics was performed to identify immunogenic proteins in the different OMV 
vaccines. Figure 5A shows the overall protein composition of the OMV vaccines after 1D gel 
electrophoresis, visualizing the major contributions of PorA (41 kD), Omp85 (85 kD) and several 
proteins at 27 kD (e.g. OpcA protein). As discussed above, these proteins were found in all OMV 
types without significant expression differences. Next, mice sera after two vaccinations were used 
for immunoblotting against corresponding OMV vaccines. Despite a heavy immuno-dominance 
of PorA at 41 kD the serum blots revealed clear differences in immunogenicity, especially for 
dOMV compared to nOMV and sOMV (Figure 5B). This indicated that the different OMV 
processes retained or removed specific immunogenic proteins. These immunogenic proteins were 
not visible with 1D gel electrophoresis, therefore they represent a small but potentially important 
portion of the total protein content. 
Immunoblot bands with a differential pattern between OMV sera were excised and separately 
digested with trypsin, for qualitative LC-MS/MS analysis (serum blot proteomics). The analysis 
identified several proteins that matched the blot pattern (Figure 5C). At 41 kD, PorA was found 
abundantly on all blots. Lipoprotein E6MY46 (14 kD) was found on nOMV and sOMV blots, 
while LptD (LPS assembly protein; 85 kD) was unique for dOMV. In other sections no matching 
proteins were detected (100 kD, 50-70 kD and 15-20 kD) despite a differential serum blot pattern. 
Around 27 kD all serum blots had a visible band, but the bands for nOMV and sOMV were 
clearly more pronounced. Serum blot proteomics of this 27 kD band provided several interesting 
matches like PilQ, a protein involved in type IV pilus biogenesis and only found in nOMV and 
sOMV. Proteins Q7DDR0 (putative cell-binding factor) and Q9JYQ6 (uncharacterized protein) 
were found in nOMV and sOMV, and only in sOMV, respectively, but have not been described 
in literature. Two important identifications on the 27 kD blot section were fHbp and a C-terminal 
PorA fragment cleaved-off at the Pro268 position. These two immunogenic proteins were verified 
with monoclonal antibodies (Figure 5D). Detergent-extraction during dOMV purification is 
known to remove lipoproteins like fHbp[63, 94]. The anti-fHbp immunoblot confirmed that fHbp 
indeed was absent in dOMV. The blot with anti-PorA monoclonal confirmed an overall strong 
band at 41 kD and confirmed the C-terminal PorA fragment. This PorA fragment explains the 
weaker 27 kD band on the dOMV serum blot, while the presence of fHbp explains the stronger 
27 kD bands on nOMV and sOMV serum blots. Notably, the serum blot identifications were in 
full agreement with the quantitative proteomics results. Only LPS assembly protein LptD was 
somewhat ambiguous. LptD was 5-fold higher in dOMV, which may be induced by the detergent-
treatment and matches the serum blot results. The upregulation however was not significant 
(p-value just above threshold).
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Figure 4. Differentially expressed OMV proteins.
Quantitative proteome analysis was performed on OMV vaccines from 3 different purification processes, 
using 5 biological replicates per vaccine. Proteins were clustered in expression pattern groups, e.g. group 
V (downregulated in dOMV). The color scale covers 3.5-fold downregulation (green), via no regulation 
(black) to 3.5-fold upregulation (red). Functional annotation was based on Uniprot keywords and predicted 
cellular locations (PSORTb algorithm). Enriched protein functions are depicted for each expression group 
(p<0.05). The results demonstrate that OMV vaccines from biomass extraction processes (especially dOMV 
and to a lesser extent nOMV) are enriched with lysis-derived cytoplasmic proteins, including proteins with 
ribonucleoprotein, RNA-binding or nucleotide binding function. nOMV and sOMV vaccines (detergent-
free processes) are enriched with membrane proteins and proteins with unknown location, including 
lipoproteins like fHbp. Therefore detergent-free OMV vaccines, sOMV in particular, have a preferred 
protein composition. 
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Figure 5. Serum blot proteomics reveals differences in immunogenic protein content.
(A) Protein composition of OMV from three purification processes after SDS gel electrophoresis. (B) Sera 
of immunized mice were blotted against corresponding OMV vaccines. Despite a comparable SDS page 
pattern, the serum blots reveal differential immunogenicity (several variable bands at 50–85 kD and 14–27 
kD) and confirm immuno-dominance of PorA (41 kD). (C) Serum blot proteomics identified proteins that 
matched the differential pattern (circle: found in dOMV; triangle: nOMV; square: sOMV). This demonstrates 
that nOMV and sOMV vaccines (detergent-free process) are enriched with immunogenic proteins. (D) The 
results were verified with monoclonal antibodies against two protective antigens, PorA and fHbp. This 
confirms that PorA immunogenicity is not dependent on the purification process, while fHbp lipoprotein 
is largely removed after detergent-extraction (dOMV process).
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Discussion
To investigate previously observed changes in functional immunogenicity, the proteomes of 
OMV vaccines from different purification processes have been compared and quantified [185]. 
Dimethyl labeling of free amines at the protein level is followed by selective purification of 
N-terminal peptides with the PTAG strategy [204]. This novel protocol combines the analysis 
of internal peptides before PTAG and N-terminal peptides after the PTAG procedure, using a 
straightforward workflow (Figure 1). Dimethylated peptides are quantified relative to a common 
reference, which represents an internal standard between all experimental samples (Figure 2). 
Strong cation exchange (SCX) fractionation followed by LC-MS/MS analysis is only required to 
compile a peptide search list, linking accurate mass and retention time to peptide and protein 
identifications [205, 206, 214]. Once the search list is available, a single LC-MS run for each 
experimental sample is sufficient to identify and quantify all detectable peptides in the OMV 
proteome. This accurate mass and retention time approach reduces total acquisition time and 
allows a high number of independent biological replicates, resulting in robust statistical analysis 
of relative protein abundance. These advantages are not available with other quantitative 
proteomics methods, which mainly rely on weighed peptide fold-changes in a single biological 
sample for statistics [199]. 
The PTAG strategy effectively reduces sample complexity and uncovers the majority of N-terminal 
peptides in this study. The uncovered N-terminal peptides correspond to only 7 new proteins, 
since most proteins are already detected by their internal peptides. A limitation of positional 
proteomics approaches like PTAG is undersampling of the N-proteome, because these methods 
rely on detection of a single N-terminal peptide [204]. As a result, the N-termini of lipoproteins 
are absent due to a lipid modification that prevents dimethylation. To our knowledge PTAG does 
not introduce any other experimental bias. In addition, the strategy is likely to be beneficial for 
highly complex protein samples like cell lysates, because complexity reduction will improve 
specificity of the quantification. The present results comprise a dataset of 618 peptides from 
185 unique OMV proteins (Figure 3). Other studies identify between 25 and 166 OMV proteins 
with qualitative methods, like 1D or 2D gel electrophoresis and one gel-free approach [104, 193, 
194, 197]. A quantitative 2D electrophoresis study identifies 74 OMV proteins, of which 10 are 
differentially expressed [196]. Overlap of these studies with the current results is moderate to 
high (Appendix 3), therefore this study is representative and comprises the largest quantitative 
OMV dataset available to date.
Quantitative analysis of relative protein abundance reveals distinct differences between OMV 
vaccines (Figure 4). Several proteins are absent in one or two vaccine types, resulting in large 
fold ratios (>10). The dataset also contains a variety of subtle changes that remain unnoticed with 
a qualitative approach. Reproduciblity of biological replicates is sufficient for reliable protein 
quantification, but the use of less than five independent replicates may reduce the statistical power 
to detect subtle differences. dOMV vaccines contain substantially more cytoplasmic proteins than 
nOMV or sOMV vaccines. These proteins may be released during detergent-extraction, which 
removes endotoxin from dOMV but apparently causes lysis and contamination with cytoplasmic 
proteins. A much smaller but distinct set of cytoplasmic proteins is shared between dOMV and 
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nOMV vaccines, while sOMV remains largely free of cytoplasmic contamination. This supports 
the extraction hypothesis, since nOMV are purified with a milder, detergent-free extraction 
and sOMV purification does not require any extraction at all. Other studies have also found 
cytoplasmic proteins in dOMV, including one qualitative comparison of dOMV and sOMV from 
the New-Zealand vaccine strain [104, 194-197]. The present study adds an intermediate vaccine 
(nOMV) to the comparison, which demonstrates that cytoplasmic protein contamination of OMV 
is directly related to the purification process that is used. 
In addition to less cytoplasmic contamination, detergent-free OMV vaccines are significantly 
enriched with membrane proteins and proteins with an unknown cellular location. For sOMV 
vaccines, the difference is most pronounced (Appendix 2). Such proteins are more likely to 
be important for the immunogenicity of OMV vaccines than cytoplasmic proteins, which 
predominantly represent well-characterized aspects of microbial metabolism. The importance 
of unknown proteins is illustrated by the observation that 6 out of 9 lipoproteins in the dataset 
have an unknown predicted location rather than a membrane location. The data also shows that 
lipoproteins are selectively removed after detergent extraction. This includes factor H binding 
protein (fHbp), which contributes to functional immunogenicity and is currently investigated in 
clinical trials as a purified protein vaccine [67, 191, 215]. The sOMV vaccines contain an additional 
set of proteins with virulence-related functions. Therefore detergent-free OMV, in particular 
sOMV, have a preferred protein composition compared to dOMV.
The detergent-free OMV vaccines in this study previously had improved cross-protection 
and functional immunogenicity in mice [185], which was confirmed by others [63, 104, 191]. 
Functional immunogenicity is measured with SBA, which correlates to protection in humans 
but does not provide in-depth information on the protein content of vaccines. Therefore this 
study supplements SBA results with quantitative proteomics data. The results are refined with 
serum blot proteomics to visualize and assess differences in immunogenic protein content. 
Differential serum blot bands are excised, digested with trypsin and analyzed with qualitative 
LC-MS/MS. Several antigens match the immunogenicity pattern on the serum blot, including 
PorA (constant pattern) and proteins that are only found exclusively in detergent-free OMV like 
fHbp, type IV pilus assembly protein PilQ or putative cell-binding factor (Figure 5). Notably, 
the pattern of serum blot identifications is in full agreement with the quantitative proteomics 
results, indicating that both novel methods produced reproducible data. Serum blot proteomics 
demonstrates that detergent-free OMV are enriched with immunogenic proteins, but this does 
not necessarily translate to functional immunogenicity [92]. Differential endotoxin content of 
OMV vaccines should also be taken into account, since attenuated lpxL1 endotoxin in detergent-
free OMV vaccines adjuvates the immune response against proteins in the vaccine [6, 93]. Also 
the endotoxin itself contributes to functional immunogenicity [187]. Even though these aspects 
are not covered with proteomics, the current results provide valuable insight in the immunogenic 
protein content of different OMV vaccines. Such an approach can support functional assays like 
SBA.
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Conclusions
A novel proteomics method has been developed, providing a quantitative fingerprint of complex 
protein products. Quantification is based on a common reference sample, which enables a high 
number of independent biological replicates for robust statistics. The method has broad potential 
applications in the field of biotechnology, like time course analysis of relative protein abundance 
in whole-cells, or batch-to-batch comparison of product consistency This study compares the 
proteomes of OMV vaccines from different purification processes and reveals distinct protein 
profiles. Serum blot proteomics substantiates these results by identifying differential immunogenic 
proteins. The results indicate that the (immunogenic) protein content of OMV vaccines is at least 
partially determined by the purification process. This supports previously observed functional 
differences between OMV vaccines and illustrates that detergent-free OMV have a preferred 
protein composition.
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Appendix 1
Validation of quantitative proteomics method. 
The quantitative proteomics method was validated with a protein mixture containing known 
ratios. The mixture included carbonic anhydrase (1:1 ratio), lysozyme (1:1 ratio), insulin 
(1:2 ratio), alpha casein (1:5 ratio) and serum albumin (1:10 ratio) and was analyzed with 5 
independent replicates. Internal peptides before PTAG-labeling and TiO2 depletion allowed 
quantification of all proteins except carbonic anhydrase, because this protein has no lysine 
residues in its internal peptides (required for labeling). N-termini after depletion could be 
quantified for 3 out of 5 proteins. The N-terminus of lysozyme is too short for detection because 
trypsin cleaves off the N-terminus at the Asn2 residue. The serum albumin N-terminus was 
only detected for the light peptide, but not for the 10-fold less abundant heavy labeled peptide. 
The abundance was most likely below noise threshold, since several internal peptides of 
serum albumin had the same problem (data not shown). The noise threshold is determined 
by the detection sensitivity, but also by the accuracy of mono-isotopic mass deconvolution. 
Deconvolution errors are most likely to occur for isotope pairs with a greatly downregulated 
heavy labeled peptide (like serum albumin), due to overlapping isotope envelopes from the 
light labeled peptide. Other serum albumin peptides that were correctly detected had a variable 
ratio (25 ± 18). The large standard deviation indicates that the 1:10 ratio of serum albumin 
represents the outer limit of the dynamic range. Therefore, larger ratios are scored as >10 in the 
remainder of this study. Proteins with ratios between 1:1 and 1:5 were quantified with good to 
high accuracy, indicating that the method can be used to measure unknown ratios.
*Labeling not possible (no lysine residues).
**N-terminal peptide too short for detection.
***Heavy labeled peptide below noise threshold.
Protein Uniprot ID Internal peptides N-terminus
Fold ratio
Expected Observed
Carbonic anhydrase P00921 not quantified* quantified 1.0 1.0 ± 0.0
Lysozyme P00698 quantified not detectable** 1.0 1.3 ± 0.4
Insulin P013017 quantified quantified 2.0 2.1 ± 0.2
Alpha casein P02662 quantified quantified 5.0 5.1 ± 1.1
Serum albumin P02769 quantified not quantified*** 10.0 25 ± 18
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Appendix 2
Distribution of predicted protein locations.
The different OMV vaccines in this study had a process-dependent protein location distribution. Detergent-
extraction of dOMV vaccines resulted in enrichment with cytoplasmic proteins (51% of all proteins) due 
to bacterial lysis, while sOMV (no extraction) contained 35% cytoplasmic proteins. The mild, detergent-
free extraction of nOMV resulted in an intermediate amount (40% cytoplasmic proteins). Due to the low 
amount of cytoplasmic proteins, detergent-free OMV vaccines (nOMV and sOMV) were enriched with 
membrane and unknown proteins, which are more likely to be relevant for immunogenicity. Cellular 
locations were predicted using the PSORTb algorithm (http://www.psort.org/psortb).
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Appendix 3
Overlap of this study with available literature. 
Available studies on OMV vaccines identified 25–166 proteins with several different proteomics methods 
(gel-free processing versus 1D or 2D gel electrophoresis, combined with qualitative or quantitative LC-
MS/MS). Overlap of these studies with the current results was moderate to high, 43–61% of all detected 
proteins. Therefore the results of this study are likely to be representative and comprise the largest OMV 
dataset available to date.
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Chapter 5
Identification and optimization of 
critical process parameters for the 
production of nOMV vaccine against 
Neisseria meningitidis
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Abstract
Outer membrane vesicles (OMV) are used as a vaccine against Neisseria meningitidis serogroup 
B and traditionally produced with detergent-extraction to remove toxic lipoploysaccharide. 
Engineered strains with attenuated lipopolysaccharide allow the use of native vesicles (nOMV) 
with improved stability and immunogenicity. In the nOMV production process detergents are 
omitted and vesicle release is stimulated with EDTA extraction (a chelating agent) to enable 
a higher yield. Many process parameters may affect the EDTA extraction efficiency, but it is 
unknown what the optimal ranges for these parameters are in terms of quality. The present study 
systematically optimizes EDTA extraction and is representative for production at large-scale. 
Two critical process parameters have been identified, harvest point of the cultivation (harvest) 
and pH of the extraction buffer (pH), which significantly affects yield (7-fold) and bacterial 
lysis (35-fold). The other quality attributes remain unchanged. Optimization of harvest and pH 
reveals that the desired low bacterial lysis coincides with intermediate but sufficient yield. High 
functional immunogenicity and low toxicity of the optimized vaccine are also confirmed. The 
EDTA extraction is therefore a robust process step which produces high quality OMV if harvest 
and pH are controlled accurately.
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Introduction
The use of outer membrane vesicles (OMV) is an established strategy for development of a 
vaccine against N. meningitidis serogroup B, which causes acute and severe meningitis [3, 18, 
182, 216]. OMV are released from growing N. meningitidis bacteria and consist of a phospholipid 
bilayer with outer membrane protein, lipopolysaccharide (LPS) and a lumen with periplasmic 
constituents [89]. PorA outer membrane protein was identified as the major protective antigen [57, 
90]. OMV vaccines that have successfully stopped outbreaks in Norway, Cuba and New Zealand 
were made with a process that used detergent extraction (dOMV, detergent OMV) to decrease 
the amount of toxic LPS in the vesicles [49, 51, 53, 88]. It was established that deletion of specific 
lipid A biosynthesis genes, like lpxL1, resulted in attenuated LPS toxicity [6]. OMV from strains 
with attenuated LPS did not require detergent-extraction, which enabled further development 
of detergent-free approaches. Detergent-free OMV with attenuated LPS were intrinsically better 
than dOMV, because they had equally low toxicity and improved stability [72, 94, 185, 187]. In 
addition, detergent-free OMV contained lipoproteins that contributed to a protective immune 
response [73, 74, 94]. 
There are two types of detergent-free OMV. The first type, sOMV (spontaneous OMV), is produced 
by the bacterium itself. The sOMV are purified from the cultivation supernatant without any 
treatment to enhance OMV release [97, 99]. Even though up to 11% of total biomass can be present 
as sOMV further yield improvement is required for economically feasible vaccine production [98]. 
This may be established by deletion of the rmpM gene, which anchors the outer membrane to the 
peptidoglycan layer [108, 121, 185], or through the deletion of gna33, which has been associated 
with increased sOMV release through an unknown mechanism [104]. The second detergent-free 
OMV type uses extraction with a chelating agent (EDTA; ethylenediaminetetraacetic acid) to 
further increase yield [185]. EDTA destabilizes the outer membrane by chelating calcium and 
magnesium ions, which stimulates the release of nOMV (native OMV) [111, 189, 217]. Despite the 
use of an extraction step, nOMV have a native composition with biochemical and immunological 
properties that are more similar to sOMV than to dOMV [40, 185]. Vaccines based on nOMV 
were successfully tested in preclinical and clinical phase I/II studies, but clinical phase III studies 
have not been reported [94, 100, 101, 103, 187, 218, 219]. For such studies, a robust and fully 
scalable production process is an important requirement. The central step in such a process for 
the production of nOMV is the EDTA extraction, which actively releases nOMV from the bacteria 
before purification. 
Many process parameters may influence the outcome of detergent-free extraction during nOMV 
production. These include physiological parameters like the pH of the extraction buffer, the 
amount of EDTA in the extraction buffer and duration or temperature of the extraction step. 
Process parameters that affect the concentrated biomass, which is the input material for the 
extraction, may also have an effect. These are the condition of the cells at harvest point or the 
method for concentrating the biomass that was chosen [220]. Setpoint estimates for these process 
parameters can be obtained from literature [2, 40], but it is currently unknown whether they 
are optimal or how they interact to affect nOMV quality. Quality is herein defined as a set of 
quality attributes whose values must be within predefined targets to obtain an effective vaccine. 
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High quality nOMV must be biochemically stable, non-toxic and able to induce functional 
immunogenicity. Furthermore the production process should provide sufficient yield and low 
bacterial lysis (low DNA release). Lysis is an issue because genomic DNA is an undesirable 
component of the final nOMV vaccine, especially when the bacteria have recombinant 
genes in their genome [69]. The viscosity of DNA also complicates nOMV purification when 
(ultra)filtration or gelfiltration equipment is used.
The present study describes the optimization of EDTA extraction during large-scale production of 
nOMV from N. meningitidis. Five potentially critical process parameters have been assessed with 
an approach that was aiming at Quality by Design (QbD) [221-223]. First, the quality attributes of 
the vaccine were defined, then the process parameters that affect these attributes were explored 
and finally the process was optimized. 
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Materials and methods
Experimental design and data analysis
Modde 9.0 Design of Experiments software (Umetrics, Umea, Sweden) was used to create a 
fractional factorial resolution V experimental design containing 5 factors (process parameters), 
with the goal to identify critical process parameters. This resulted in 19 extraction experiments, 
including 3 centre points (Appendix 1). A partial least squares (PLS) model was fitted for each 
nOMV quality attribute, describing the mathematical relation between process parameters 
and quality attribute for the entire preliminary design space. Quality attribute models were 
individually refined by excluding process parameters with non-significant effects. Model validity 
was verified by performing ANOVA and lack of fit statistical analyses and by calculating R2 and 
Q2 values. Quality attribute models were considered valid, if ANOVA p-value was <0.05, lack of fit 
p-value was >0.05, R2 (correlation) was >0.7 and Q2 (explained variation) was >0.7 (Appendix 2). 
Since a valid model not necessarily represents large variation, biological significance of observed 
quality attribute variation was also assessed. Aggregation percentages above 10% and a >2.0 fold 
change in nOMV size, yield or ratio of biochemical components were considered biologically 
significant (Table 2). Quality attribute predictions (Figures 2 and 3) were calculated with Modde, 
using the model coefficients (Appendix 2) for a range of process parameter setpoints.
Quality attributes of nOMV
Previous work indicated that PorA content in OMV may be dependent on growth rate, while 
phospholipid content did not show significant changes [112]. Therefore phospholipid yield 
was used to estimate nOMV yield, thus allowing detection of relative changes in PorA, total 
protein and LPS content. This approach required stable nOMV with invariable size (confirmed, 
see results section) and invariable fatty acid composition of the phospholipid (confirmed; data 
not shown). Yield of nOMV (phospholipid yield), total protein yield, PorA yield and LPS yield 
were measured in the final nOMV sample. DNA release was measured in the supernatant of 
the first ultracentrifugation cycle. Yield was expressed as the amount of biochemical component 
(µg) obtained after purification of 60 mL (maximum volume of the ultracentrifugation tubes) 
crude nOMV extract, which originated from 0.62 gram of dry cells. Ratios were calculated by 
dividing the yield of one biochemical component (e.g. PorA yield) with the yield of another 
biochemical component (e.g. nOMV yield), followed by 2log transformation to obtain a linear 
scale. For optimization purposes, the amount of LPS per OMV (LPS/OMV ratio) was used to 
assess potential toxicity effects. Potential immunogenicity effects were assessed with the amount 
of PorA and total protein per OMV (PorA/OMV and total protein/OMV ratios). After the 
optimization, toxicity and functional immunogenicity were verified with established correlates 
(IL-6 monocyte activation [125] and serum bactericidal activity (SBA) [46, 192], respectively).
Bacterial strain and growth conditions
The N. meningitidis strain that was used is a recombinant variant of serogroup B isolate H44/76 
[109], combining one wild type and two recombinant PorA subtypes (trivalent PorA; subtypes 
P1.7,16; P1.5-1,2-2 and P1.19,15-1) with a non-functional porB gene [7]. The cps locus containing 
siaA, siaD and galE genes was deleted, resulting in a non-encapsulated phenotype with galE-
truncated LPS. Additional deletions in lpxL1 and rmpM genes were made to attenuate LPS 
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toxicity and improve yield (2-4 fold higher) [185]. All cultures were grown in chemically defined 
growth medium, containing glucose, amino acids, salts, iron and trace elements [4]. A primary, 
150 mL pre-culture was inoculated with 10 mL working seedlot (cells at OD590 = 1.5 ± 0.1; stored 
at -135°C with glycerol) and incubated in disposable 500 mL erlenmeyer shake flasks with 
vented closure (Nalgene, Rochester NY, U.S.A.) at 35°C, 200 rpm. The pre-culture was used to 
inoculate a secondary pre-culture, grown in a 5 L bioreactor with 3 L working volume (Applikon, 
Schiedam, The Netherlands). At OD590 values between 1.5 and 4.5, a fixed amount of bacteria was 
transferred to the 60L production bioreactor with 40 L working volume (Applikon, Schiedam, 
The Netherlands). Bioreactors were operated as described previously [4]. Harvest point samples 
were taken for OMV extraction and subsequent purification at 1, 5 and 9 hours after onset of the 
stationary growth phase (10 L, 5 L and 10 L of cultivation, respectively).
nOMV purification process
At each harvest point, biomass was concentrated approximately 5-fold using hollow fiber 
microfiltration units with 0.22 µm pore size and 0.37 m2 surface area (Spectrum Laboratories, 
Rancho Dominguez CA, U.S.A). Circulation was constant at 0.9 L/min and feed pressure was 
monitored at-line. The concentrated biomass sample was diafiltrated with the microfiltration 
unit using 2 volumes of buffer (100 mM Tris-HCl, pH 8.6). Final volume of the diafiltrated 
biomass was normalized between harvest points based on the OD590 before microfiltration, to 
assure equal amounts of bacteria per mL. For OMV extraction, subportions of 280 mL diafiltrated 
biomass were used to allow parallel handling of multiple experiments. The pH was adjusted 
and 10x concentrated EDTA solution was added to a final concentration of 5-15 mM according 
to the experimental design (Appendix 1). Subsequent OMV extractions were performed 
accordingly. After extraction, bacteria were removed from the crude OMV extract by subsequent 
centrifugation (75 min., 12500x g, 4ºC) and filtration (SuporMach V system with 0.22 µm PES 
membrane; Nalgene, Rochester NY, U.S.A.). The nOMV were purified with ultracentrifugation 
(65 min., 125000x g, 4ºC) and resuspension in storage buffer (10 mM Tris-HCl pH7.4, 3% (w/v) 
sucrose). PorA concentration was measured and nOMV samples were diluted with storage buffer 
to a final concentration of 1 mg/mL PorA and stored at 4ºC. Thiomersal (0.01% (w/v)) was added 
as a preservative. 
Analytical procedures
Fatty acid composition was analyzed to characterize phospholipid composition (OMV) and 
quantify LPS concentration, using a modified gas chromatography method as described 
previously [185]. Total protein concentration of nOMV was measured using the Lowry protein 
assay with Peterson’s modification, according to manufacturer’s protocol (Sigma-Aldrich, 
Zwijndrecht, The Netherlands) [112]. PorA concentration was measured with quantitative SDS 
gel electrophoresis under denaturing conditions [112, 113]. Per lane, 4 µg total protein from nOMV 
was loaded. Gels were stained with Novex Colloidal Blue (Invitrogen, Breda, The Netherlands) 
and PorA was quantified as a percentage of total protein using TL100 1D gel analysis software 
(Totallab, Newcastle upon Tyne, U.K.). DNA in the ultracentrifugation supernatant was 
quantified with fluorescence spectroscopy using Quant-it Picogreen dsDNA reagent (Invitrogen, 
Breda, The Netherlands), according to manufacturer’s protocol. The nOMV size and aggregation 
were measured after 3 months storage at 4ºC as described previously [185], by using dynamic 
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light scattering (nOMV size) and by measuring total protein content of nOMV before and after 
centrifugation at low speed (aggregation percentage). Serum bactericidal activity and IL-6 
monocyte activation were measured as described previously [185]. 
potentially critical process parameter setpoints experimental design
abbreviation description units lower limit centre point upper limit
pH pH extraction buffer – 7.4 8.6 9.0
EDTA EDTA concentration extraction buffer mmol 5 10 15
harvest harvest point of cultivation hours stat. growth 1 5 9
temp extraction temperature ºC 4 20 35
time extraction length minutes 5 30 55
reduc volume reduction method for biomass – not included (microfiltration)
stir extraction stirrer speed rpm not included (100 rpm)
Table 1. Potentially critical process parameters for OMV extraction.
Parameters were selected by a project team. Reduc and stir were excluded based on risk assessment and 
historical data. The remaining process parameters were used in an experimental design (Appendix 1) 
which systematically explored the preliminary design space, defined by the combined setpoint limits.
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Results
Experimental strategy
Potentially critical process parameters were selected in a project team, resulting in 7 candidates 
(Table 1). Risk assessment and historical data review allowed exclusion of ‘volume reduction 
method for biomass’ (reduc) and ‘extraction stirrer speed’ (stir). Fixed setpoints were chosen for 
these process parameters based on historical data (microfiltration (qualitative) and 100 rpm, 
respectively). Broad setpoint ranges were assigned to the remaining process parameters, based 
on historical data and further refined with preliminary experiments. The pH upper limit value 
was initially set at 9.8 but lowered to 9.0 because the preliminary experiments revealed major 
processing difficulties above pH 9.0, caused by fast lysis of the bacterial suspension (data not 
shown). The pH centre point value was chosen asymmetrically (at pH 8.6) based on historical 
data. The setpoint ranges together defined a preliminary design space that was explored with 
fractional factorial experimental design. Triplicate centre point experiments were added to 
measure reproducibility, giving a total of 19 extraction experiments (Appendix 1). For each 
extraction experiment, the quality attributes listed in Table 2 were measured and their values 
were used as input for modeling and optimization of a preliminary design space.
Process parameter effects
The nOMV extractions were performed on samples from a 40 L cultivation. Growth characteristics 
of the experimental batch (batch 1) were compared with 5 replicate batches (Figure 1). Regression 
analysis confirmed that growth curves were reproducible (R2 = 0.993) and that batch 1 was 
representative, since the OD590 measurements of this batch fall within the 95% prediction limits 
shown in Figure 1. Controller and sensor output profiles of the cultivations (e.g. gas flows, 
temperature and oxygen uptake rate) were equally comparable (data not shown). The results 
showed that process parameters time, EDTA and temp did not affect any of the quality attributes, 
indicating that they are not critical within the tested ranges (Table 2). Harvest and pH did have 
significant effects on many quality attributes, confirming that they are critical process parameters 
for OMV extraction. Previous work indicated that PorA content in OMV may be dependent on 
growth rate, while phospholipid content remained constant [112]. Therefore phospholipid yield 
was used to estimate nOMV yield, which allowed detection of potential changes in relative PorA, 
total protein and LPS content. The yields of nOMV (phospholipid), PorA, total protein and LPS 
increased at higher harvest setpoints, as did the DNA release (bacterial lysis). The pH setpoint also 
affected quality attributes, however to a smaller extent than harvest. For some quality attributes, 
harvest*harvest effects were observed, indicating an exponential change of a quality attribute value 
towards specific harvest setpoints. In addition, a harvest*pH effect was observed which results in 
either amplification or levelling of a quality attribute value, caused by interactions between both 
process parameters. A comprehensive overview of process parameter effects is given in Table 2. 
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Figure 1. Bacterial growth of replicate cultivations at 40 L scale.
OMV extraction experiments were performed on cultivation samples from batch 1, at the depicted harvest 
points (vertical lines at T=1, 5 and 9 hours of stationary growth), which correspond to the values used for 
harvest in the experimental design. T=0 indicates onset of stationary growth. A sigmoid growth curve was 
fitted through the data using regression (black line; R2 = 0.993) with 95% prediction limits (grey lines), 
showing that batch 1 had a representative cultivation profile.
Figure 2. Relation between critical process parameters and quality attributes of the nOMV vaccine.
Critical process parameters harvest and pH are depicted on the x- and y-axes, nOMV quality attributes 
on the z-axis. The nOMV yield increased 7-fold towards late harvest and high pH (panel A). Bacterial 
lysis (DNA release) increased even more, 35-fold, which had implications for the manufacturing process 
(panel B). Quality attribute surfaces are scaled identically from low (black) to high (white) values. Z-axes 
represent yield units (in µg/60 mL crude extract; obtained from 0.62 gram of dry cells).
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Quality attribute variation
PLS models were fitted which mathematically described the entire preliminary design space 
for each quality attribute and validity was assessed. Since a valid PLS model not necessarily 
represents large quality attribute variation, biological significance of the variation was also 
estimated. The results are summarized in Table 2 and complemented with a list of all PLS 
model coefficients (Appendix 2). Constant quality attribute values and invalid PLS models 
were obtained for aggregation (2.8 ± 2.2%), nOMV size (78 ± 5 nm) and PorA/total protein ratio 
(79 ± 3%), indicating that the entire preliminary design space provided stable nOMV with high 
PorA purity. Valid quality attribute models were obtained for ratios of LPS/OMV, PorA/OMV 
and total protein/OMV, but the observed variation was small and biologically insignificant 
(<2-fold change). Constant ratios are favorable, because these quality attributes were used to 
screen for potential effects on toxicity (LPS/OMV ratio) and immunogenicity (ratios of PorA/
OMV and total protein/OMV) of the vaccine. The yields did change significantly for all measured 
biochemical components. The observed variation was between 5.0-fold (PorA yield) and 34.7-fold 
(DNA release).
Setpoint optimization of harvest and pH
For optimization of harvest and pH setpoints, relevant quality attributes were first selected. Figure 
2A shows the nOMV yield response surface defined by both critical process parameters, revealing 
a 7-fold change within the preliminary design space. Response patterns of PorA, total protein 
and LPS yield resembled nOMV yield closely (data not shown) and had therefore no added value 
for the optimization. The DNA release surface (Figure 2B) had a different pattern, revealing that 
bacterial lysis increased exponentially compared to nOMV yield when setpoints were adjusted 
towards late harvest and high pH. This suggested that both nOMV yield and DNA release may be 
relevant for the optimization. Variation in the ratios of LPS, PorA, and total protein per OMV was 
biologically insignificant. Observed variation was <2-fold, indicating that there was no need to 
include these quality attributes in the optimization. After selection of relevant quality attributes, 
harvest and pH setpoints were optimized for nOMV yield and DNA release. When nOMV yield 
was maximized without DNA release restriction, 13646 ± 1029 µg nOMV and 4820 ± 531 µg DNA 
was obtained (harvest = 9.0 and pH = 9.0). This corresponds to 27.8 ± 2.1 mg PorA per gram of 
dry cells and represented the highest possible yield, however requires a large-scale purification 
process with high DNA removal capacity (>4820 µg/60 mL crude extract) to compensate bacterial 
lysis. Not removing the DNA would result in major processing difficulties caused by viscosity. 
For regulatory approval, genomic (recombinant) DNA is considered an undesirable component 
of the final vaccine. Therefore, yield was maximized while maintaining minimized DNA release 
(Figure 3; DNA target = 0 µg). An nOMV yield of 5965 ± 641 µg (corresponding to 13.9 ± 1.3 mg 
PorA per gram of dry cells) and DNA release of 0 ± 617 µg was obtained for harvest = 3.3 and 
pH = 8.4 setpoints. These values represent the true optimum, in which sub-maximal but feasible 
nOMV yield was allowed to ensure the benefits of a crude nOMV extract with low DNA content. 
This optimum was visualized in Figure 3 and was situated in the centre of the preliminary design 
space. It also revealed that the margins which guarantee an optimal result are narrower towards 
lower pH values.
87
Chapter 5
Verification of functional immunogenicity and toxicity
For optimization purposes, potential toxicity and immunogenicity effects were monitored with 
fast biochemical assays for all 19 nOMV samples from batch 1 (Figure 1). The optimal harvest and 
pH setpoints were then applied during the production of a new vaccine batch (batch 2, Figure 1) 
and functional immunogenicity and toxicity were verified with established correlates (SBA and 
IL-6 monocyte activation, respectively [46, 125, 192]). Table 3 shows that the optimized vaccine 
induced high bactericidal titers against all 3 PorA subtypes in mice sera after 2 immunizations. 
Mean 2log titers of responders were 11.8 ± 1.1 (PorA P1.7,16), 12.1 ± 1.1 (PorA P1.5-1,2-2) and 
9.1 ± 1.6 (PorA P1.19,15-1). For PorA subtypes P1.7,16 and P1.5-1,2-2 all 10 mice responded to 
vaccination. P1.19,15-1 had only 5 responders but this PorA was expected to be less immunogenic 
in mice [5, 126]. Next, IL-6 monocyte activation of the optimized vaccine was compared to a 
reference vaccine with low toxicity. The reference vaccine consisted of detergent-extracted OMV 
with reduced amounts of toxic galE-LPS and was well tolerated by toddlers and children [60]. An 
experimental reference vaccine with high toxicity was also included to provide a context for the 
results (spontaneously released OMV with high amounts of toxic galE-LPS (ΔR-sOMV) [185]). 
The results showed that the optimized vaccine and the low toxicity reference induced comparable 
amounts of IL-6 in monocytes (0.44 and 2.36 ng IL-6 per µg PorA, respectively). As expected, the 
high toxicity reference induced substantially more pro-inflammatory cytokine (2.3x104 ng IL-6 
per µg PorA). These results indicate that the optimized vaccine was non-toxic and induced high 
functional immunogenicity.
Figure 3. Optimization of critical process parameters harvest and pH.
Relevant quality attributes for optimization (nOMV yield and DNA release) were selected as described in 
the results section. The targets were chosen to combine high nOMV yield with low DNA release. Grey areas 
indicate which quality attributes meet the target (see legend). The optimum (white circle) is depicted at 
the intersection of harvest = 3.3 and pH = 8.4 and the black area corresponds to the model error around this 
optimum. Within the black, optimal area the nOMV yield was feasible but below maximum, however the 
benefits of a crude extract with low viscosity (low DNA) were ensured. Towards lower pH values, a more 
accurate control of harvest is required to guarantee an optimal result.
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Discussion
Production of nOMV vaccine against N. meningitidis serogroup B requires extraction with a 
chelating agent (EDTA) to destabilize the bacterial outer membrane [63, 73, 94, 100-103]. This 
study systematically explores the impact of changing extraction conditions on nOMV quality, with 
the goal to identify and optimize critical process parameters (Table 1; Appendix 1). Experiments 
have been performed on samples from a 40 L cultivation which is representative for vaccine 
production at large-scale (Figure 1) and the experimental strategy is aiming at Quality by Design 
(QbD) guidelines [4, 221-223]. The combined process parameter ranges define a preliminary 
design space in which the effect on nOMV quality attributes has been measured (Table 2). The 
results have been used to build PLS models that accurately predict quality attribute values for 
any given setpoint combination in the preliminary design space (Figure 2; Appendix 2). 
The temperature, duration and EDTA concentration of the extraction have been assessed as 
potentially critical process parameters (Table 1), but have no effect on nOMV quality within broad 
setpoint ranges (Table 2). This indicates that the extraction step is robust for these important 
physiological parameters. Harvest point of the cultivation (harvest) and pH of the extraction 
buffer (pH) are critical and able to cause significant change in quality attributes nOMV yield 
and bacterial lysis (Figure 2). The 7-fold nOMV yield increase towards late harvest suggests an 
increased sensitivity for the EDTA extraction, higher spontaneous OMV release by the bacteria, or 
both. The setpoints for harvest are all within the stationary phase, in which the bacteria encounter 
nutrient limitations that result in growth arrest. Exposure to nutrient limitation, high temperature 
or toxic agents is known to increase OMV release in other gram-negative bacteria [79-81, 224, 
225], but these observations have not been described for N. meningitidis. The present results 
indicate that N. meningitidis has a similar response to stress as these other gram-negative bacteria. 
Nutrient limitation is the most likely cause, but the current study is not designed to substantiate 
such a hypothesis.
The preliminary design space provides unaggregated nOMV with a highly homogeneous vesicle 
size and high PorA purity for any combination of process parameter setpoints. These important 
findings reconfirm that detergent-free nOMV are an improvement compared to detergent-
extracted dOMV, which are more heterogeneous and tend to aggregate [61, 185, 226] even 
though this does not affect immunogenicity [107]. Towards late harvest, DNA release increases 
exponentially compared to nOMV yield (Figure 2). This is caused by bacterial lysis, as reflected 
in the growth curve (Figure 1). The late harvest point has a lower OD590, indicating that the 
stationary phase is approaching death phase. This confirms that the latest possible harvest point 
has been included in this study. Setpoint optimization of harvest and pH for minimized bacterial 
lysis resulted in an nOMV yield that is economically feasible but below maximum (Figure 3). 
For regulatory approval genomic DNA is an undesirable component of the final vaccine [69]. 
Therefore, large-scale processing of crude nOMV extract should include sufficient DNA removal 
capacity to allow further nOMV yield improvement. Combined nuclease treatment and gel 
filtration chromatography may be a suitable approach because they are fully scalable, remove 
DNA effectively and decrease viscosity for simplified and faster processing [227, 228]. 
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The optimization is based on biochemical properties like nOMV size, aggregation and yield or 
ratios of vesicle components. The assays that are used do not require animal experiments or cell 
culture and have been performed in parallel for many samples with high technical reproducibility, 
which is a prerequisite for optimization experiments. Functional properties like serum bactericidal 
activity (functional immunogenicity) [46, 192], or IL-6 monocyte activation (toxicity) [125] have 
been verified after the optimization, on a representative nOMV vaccine that has been produced 
with the optimal setpoints for harvest and pH (Figure 1; batch 2). The optimized vaccine induces 
high bactericidal titers in mice against all three PorA subtypes, as shown in Table 3. One PorA 
antigen (P1.19,15-1) has 5 responders out of 10 mice, but this has been observed before and is not 
caused by the optimization [5, 126]. IL-6 induction in monocytes is comparable to a reference 
dOMV vaccine with low toxicity [60]. Therefore the optimization of harvest and pH is unlikely 
to change functional properties of the vaccine. The optimal setpoints have been obtained for a 
process that is representative for production at large-scale, which is an important requirement for 
clinical studies. The previously optimized growth medium [4] and previously selected production 
strain with specific genetic modifications [185] have not been included as variables. Therefore the 
optimum may not be valid for all N. meningitidis serogroup B strains or for other growth media. 
Especially strains that do not have the rmpM deletion to increase yield may behave differently. 
Despite these limitations, the current results illustrate that process parameters harvest and pH can 
be of major importance for the production of nOMV vaccine against N. meningitidis. 
This study shows that large-scale EDTA extraction yields high quality nOMV within broad process 
parameter ranges. Only two process parameters, pH and harvest, are critical and have a significant 
effect on yield and bacterial lysis. The impact of harvest is related to biological processes that 
occur during the stationary growth phase, but detailed understanding of its effect on yield is 
serum bactericidal activity
strain mean 2log titre responders number of responders
H44/76 P1.7,16 11.8 ± 1.1 10/10
H44/76 P1.5-1,2-2 12.1 ± 1.1 10/10
H44/76 P1.19.15-1 9.1 ± 1.6 5/10
monocyte activation
vaccine IL-6 induction (ng/µg PorA)
optimized vaccine 0.44
low toxicity reference 2.36
high toxicity reference 2.3x104
Table 3. Functional immunogenicity and toxicity of the optimized vaccine.
Optimal setpoints for harvest and pH were used to produce a representative batch of nOMV vaccine (Figure 
1; batch 2). The optimized vaccine induced high bactericidal titres in mice against all three PorA subtypes, 
including P1.19,15-1 which is known to be less immunogenic in mice (less reponders) [5, 126]. In addition, 
monocyte activation was comparable to a reference vaccine with low toxicity [60]. An experimental reference 
vaccine with high toxicity [185] induced substantially more IL-6. Therefore the setpoint optimization did 
not affect functional properties of the vaccine.
91
Chapter 5
currently not available. Setpoint optimization has revealed that low bacterial lysis coincides with 
intermediate but sufficient yield and it has been confirmed that these optimal setpoints do not 
change functional properties of the vaccine. The EDTA extraction is therefore a robust process 
step which produces high quality nOMV if harvest and pH are controlled accurately. 
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Chapter 6
Cysteine depletion causes oxidative 
stress and triggers outer membrane 
vesicle release by Neisseria 
meningitidis; implications for 
vaccine development
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Abstract
Outer membrane vesicles (OMV) contain immunogenic proteins and contribute to in vivo survival 
and virulence of bacterial pathogens. The first OMV vaccines successfully stopped Neisseria 
meningitidis serogroup B outbreaks but required detergent-extraction for endotoxin removal. 
Current vaccines use attenuated endotoxin, to preserve immunological properties and allow a 
detergent-free process. The preferred process is based on spontaneously released OMV (sOMV), 
which are most similar to in vivo vesicles and easier to purify. The release mechanism however is 
poorly understood resulting in low yield. This study with N. meningitidis demonstrates that an 
external stimulus, cysteine depletion, can trigger growth arrest and sOMV release in sufficient 
quantities for vaccine production (±1500 human doses per liter cultivation). Transcriptome 
analysis suggests that cysteine depletion impairs iron-sulfur protein assembly and causes 
oxidative stress. Involvement of oxidative stress has been confirmed by showing that addition of 
reactive oxygen species during cysteine-rich growth also triggers vesiculation. The sOMV in this 
study are similar to vesicles from natural infection, therefore cysteine-dependent vesiculation is 
likely to be relevant for the in vivo pathogenesis of N. meningitidis.
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Introduction
The release of outer membrane vesicles (OMV) is observed among many bacterial species 
including gram-negative pathogens like Escherichia coli, Vibrio cholerae, Salmonella typhimurium or 
Neisseria meningitidis [183]. Pathogens produce OMV for in vivo survival, virulence or interactions 
with the host immune system [76, 229, 230]. The vesicles are spherical particles with a diameter of 
50-200 nm, containing a phospholipid bilayer with outer membrane proteins, lipopolysaccharide 
(LPS or endotoxin) and a lumen with periplasmic constituents [76, 213]. N. meningitidis serogroup 
B epidemics in Norway, Cuba and New-Zealand were successfully controlled with outer 
membrane vesicle vaccines, which was a milestone for the application of OMV in vaccinology 
[3, 50, 51, 53]. These vaccines however required extraction with a detergent (deoxycholate), to 
decrease the amount of toxic LPS. The detergent-extraction was effective but resulted in partially 
intact and aggregated vesicles with an altered composition [61, 104, 185]. Discovery of the lpxL1 
mutation successfully attenuated the LPS of N. meningitidis and allowed the use of detergent-free 
OMV [6]. This provided vaccine concepts with equally low toxicity but improved immunological 
and biochemical properties [94, 104, 185, 187]. Detergent-free OMV are more similar to in vivo 
produced vesicles [213] and are now used for the development of several next-generation vaccines 
against serogroup B meningococcal disease [63, 70, 71, 73, 231].
There are two types of detergent-free OMV. The first type, sOMV (spontaneously released OMV), 
is as similar to in vivo vesicles as possible with a production system for human vaccines [213]. The 
sOMV are released by the bacterium during in vitro growth, without any treatments to enhance 
vesiculation [97, 99]. The second type, nOMV (native OMV) [63, 186, 187]), uses detergent-free 
extraction with ethylenediaminetetraacetic acid (EDTA) to chelate calcium and magnesium ions. 
This destabilizes the outer membrane which enhances nOMV release and preserves the desired 
biochemical and immunological properties, even though nOMV are not fully identical to sOMV 
[40, 111, 185, 189, 217]. The properties do change significantly when detergents are added to the 
extraction buffer. The purification of nOMV is less straightforward than sOMV purification due 
to more complicated handling (i.e. the extraction step; Appendix 1). New approaches that release 
sOMV in sufficient quantities to compensate the EDTA extraction step are therefore relevant for 
vaccine development. 
Even though the existence of sOMV is known for decades, the mechanism that triggers their 
release is not fully understood [42, 232]. A model was proposed for S. typhimurium in which 
the density of associations between inner membrane, outer membrane and peptidoglycan layer 
regulates vesicle release [76]. This model was in agreement with observations that disruption of 
transmembrane anchor genes increased vesiculation (i.e. tol, pal and ompA in E. coli or rmpM in 
N. meningitidis) [185, 233]. Not only physical changes to the outer membrane but also external 
stimuli can trigger sOMV release. For E. coli these stimuli include heat shock, activitation of the 
envelope stress response pathway or lysine depletion [41, 79-81]. Such external triggers have 
not been identified for N. meningitidis but recent work indicated that vesicle yield increased 
significantly during stationary growth [186].
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This study demonstrates that a novel external stimulus, depletion of cysteine, can trigger the 
onset of stationary growth and sOMV release by N. meningitidis. It is substantiated that cysteine 
depletion causes oxidative stress as the intracellular signal for increased vesiculation. The results 
also demonstrate that this approach is applicable for vaccine production.
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Materials and methods
Bacterial strain and shake flask cultivations
The N. meningitidis vaccine strain that was used is a recombinant variant of serogroup B isolate 
H44/76 [109], combining one wild-type and two recombinant PorA antigens (trivalent PorA; 
subtypes P1.7,16; P1.5-1,2-2 and P1.19,15-1) with a non-functional porB gene [7]. The cps locus 
was deleted, resulting in a non-encapsulated phenotype with galE-truncated LPS. Additional 
deletions in lpxL1 and rmpM genes attenuate LPS toxicity and improve yield [185]. All cultures 
were grown in chemically defined growth medium [4]. For shake flask cultivations, 150 mL pre-
culture was inoculated with 10 mL working seedlot (cells at OD590 = 1.5 ± 0.1; stored at -135°C 
with glycerol) and incubated in 500 mL erlenmeyer shake flasks (Nalgene, Rochester NY, U.S.A.) 
at 35°C, 200 rpm. At an OD590 of 1.5 ± 0.3, 10 mL portions from the pre-culture shake flask were 
used to inoculate several secondary shake flasks, containing media with different arginine 
and cysteine concentrations (for Figure 1). Alternatively, secondary shake flasks with normal 
medium were grown to an OD590 of 2.5 ± 0.3 for repletion experiments (for Figure 3). Shake flasks 
for Figure 3 were pooled and centrifuged in 150 mL portions (20 min.; 3000x g; 4ºC). Pellets 
were resuspended, washed in 75 mL medium (with/without cysteine) and re-centrifuged. The 
depletion/repletion experiments started after resuspending the pellets in 150 mL medium with/
without cysteine. To induce oxidative stress, 150 µM peroxide was added to each shake flask 
(triplicates) directly after depletion/repletion (t=0). Growth was then monitored with hourly 
OD590 measurements. If the average optical density increased >10% between 2 measurements, 
50 µM peroxide was added to repress growth. This was necessary at t=2.5 and 5.5 hours after 
depletion/repletion (arrows in Figure 3).
Bioreactor cultivations
Transcriptome analysis (Figure 2) and OMV production (Figure 4) was performed on samples 
from a fully instrumented, 5 L bench top bioreactor (Applikon, Schiedam, The Netherlands) with 
6-blade Rushton impeller for mixing and gas dispersion and initial working volume of 3.5 L. 
Controller set points were 35.0 ± 0.5 ºC (temperature), 30 ± 5% (dissolved oxygen concentration), 
7.2 ± 0.1 (pH), 300-750 rpm (stirrer speed). The bioreactor was inoculated with 150 mL pre-culture 
at OD590 = 1.5 ± 0.3. The bioreactor was connected to an ADI-1040 control system (Applikon), 
operated with BCSV software (Compex, Gent, Belgium). After inoculation, dissolved oxygen 
concentration was first controlled by gradually increasing stirrer speed to 750 rpm. Then the 
fraction of oxygen in the headspace increased gradually while maintaining a constant total gas 
flow of 1.0 L/min. Samples for nutrient analysis were sterile filtered (0.22 µm) and stored at 4ºC.
Transcriptome analysis
Microarray analysis was performed as described previously [234, 235]. RNA samples were 
analyzed with a full-genome N. meningitidis MC58 microarray [236], which covered 93% 
of predicted ORFs (Operon, Köln, Germany). Oligonucleotides were spotted in triplicate 
on UltraGAPS II coated slides (Corning, Corning NY, USA). The transcriptome profile was 
preserved by mixing 1 volume of bacterial culture (corresponding to 2.5 mL at OD590 = 1) with 
2 volumes of RNA-later solution (Ambion, Paisley, United Kingdom), then concentrated with 
centrifugation (20 min.; 3000x g; 4ºC) and stored at -80ºC until RNA extraction. Bacterial pellets 
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were thawed and pre-treated in Tris-EDTA buffer with 0.5 mg/mL lysozyme (Sigma–Aldrich, 
Zwijndrecht, The Netherlands) prior to RNA extraction according to manufacturer’s protocol (SV 
Total RNA isolation kit; Promega, Fitchburg WI, USA). Nucleic acid concentration was adjusted 
with ethanol precipitation and spectral analysis was used to determine purity and concentration. 
RNA integrity was measured with the Bioanalyzer RNA6000 Nano assay (Agilent Technologies, 
Santa Clara CA, USA), according to the manufacturers’ protocol. RNA integrity number (RIN) 
scores were used to assess RNA integrity (score >8.0 required for inclusion) [237]. Total RNA 
from triplicate samples at each time point were reverse transcribed to cDNA and labeled with 
Cy3 dye using the Chipshot Indirect Labeling and Clean-Up kit (Promega), according to the 
manufacturer’s protocol. Common reference samples, containing equal amounts of total RNA 
from all experimental samples, were labeled with Cy5. The labeled and purified cDNA samples 
were pooled in Cy3/Cy5 pairs. Hybridization buffer was added to a final concentration of 25% 
formamide, 56 SSC and 0.1% SDS. Samples were applied to the microarray slides and incubated 
in a hybridization chamber (16-20 h; 42ºC; dark). Differential gene expression was calculated 
through comparison with the common reference. Microarrays were scanned with a ScanArray 
Express microarray scanner (Perkin Elmer, Waltham MA, USA) and median fluorescence 
intensities were quantified for each spot using ArrayVision software (Imaging Research). The 
data were natural-log transformed, quantile normalized and values of replicate spots were 
averaged. These data processing steps were done with the statistical software R, using an in-
house developed script. P-values were calculated with one-way ANOVA statistical analysis. 
Significantly regulated genes were selected with a False Discovery Rate (FDR) of <10% to adjust 
p-values for multiple testing. Fold ratio (FR) values were expressed as the natural log of the 
normalized signal difference between the two groups. To further select for biologically relevant 
effects, a FR threshold of >2.0 (untransformed value) was applied to obtain the final results. Gene 
annotations were obtained from Uniprot Knowledge Base (www.uniprot.org; N. meningitidis 
MC58; version July 2011). Principal component analysis (PCA) and clustering of differentially 
expressed genes in expression groups was performed with Genemaths XT software (Applied 
Maths, Sint-Martens-Latem, Belgium). Overall gene expression differences between samples 
were assessed by calculating the Euclidian distance between gene expression values over the 
entire set of genes (this corresponds to the distance in a PCA plot). Functional annotations of 
cysteine regulated genes were retrieved from the Gene Ontology database, using corresponding 
Uniprot protein IDs (www.geneontology.org; version February 2012). Enrichment for a specific 
Gene Ontology was assessed by comparing the number of hits in the cysteine dataset with the 
number of hits in the MC58 genome. Enrichment p-values were obtained by calculating the 
binomial distribution probability. The binomial distribution probability was also used to calculate 
a p-value for the overlap between gene lists, allowing comparison of the cysteine dataset with 
relevant literature.
OMV purification and characterization
This study used small-scale, detergent-free OMV purifications as described previously [185]. 
Cultivation samples (250-400 mL) were taken from the bioreactor and purified. The samples were 
split in supernatant (for sOMV) and pellet (for nOMV) with centrifugation (20 min.; 3000x g; 4ºC). 
To purify sOMV, supernatant was sterile filtered (0.22 µm) and concentrated with ultrafiltration 
(UF), using centrifugal units with 100 kD cutoff (Centricon 70-plus Ultracell, Millipore, Billerica 
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MA, USA). UF units were washed with saline, filled with 70 mL supernatant and concentrated 
to 10-15 mL by centrifugation. The retentate was re-diluted to 70 mL with fresh supernatant and 
the cycle was repeated until the full sample was processed (centrifugation at 1500x g; 4ºC). Final 
retentate was diluted to 70 mL with storage buffer and concentrated to 10 mL (first wash step). 
The sOMV in the retentate were then pelleted with ultracentrifugation (120 min.; 125000x g; 4ºC) 
and resuspended in a suitable volume of storage buffer (second wash step). To purify nOMV, the 
bacterial pellet was resuspended in 7.5 volumes (mL/g wet weight) of EDTA buffer (100 mM 
Tris-HCl pH8.6 with 10 mM EDTA) and incubated (30 min. ambient temperature). Cells were 
discarded by semi high-speed centrifugation (75 min.; 20000x g; 4ºC). Ultracentrifugation was 
used to pellet nOMV in the supernatant (120 min.; 125000x g; 4 ºC) and the pellet was resuspended 
in a suitable volume of storage buffer. Final total protein concentration was 1.0 ± 0.5 mg/mL for 
all OMV samples. Total protein concentration, PorA quantity and vesicle size distribution of OMV 
samples were performed as described previously [112, 185]. Briefly, total protein concentration 
was measured with the Lowry protein assay. Peterson’s modification was used to reduce the 
effect of interfering substances. PorA antigen content was determined by SDS gel electrophoresis, 
followed by total protein staining and quantification of the 40-44 kD bands (PorA). Gels were 
stained with Novex Colloidal Blue (Invitrogen, Breda, The Netherlands) and PorA was quantified 
as a percentage of total protein using TL100 1D gel analysis software (Totallab, Newcastle upon 
Tyne, U.K.). Vesicle size distribution was measured with dynamic light scattering (DLS) at 25ºC 
with a Malvern 4700 system. Homogeneity of the vesicle size distribution was reflected in the 
polydispersity index (PdI), which ranges between 0.0 (fully homogeneous size distribution) and 
1.0 (random size distribution).
Quantification of nutrients and sOMV release
Cysteine (after reaction with bromoacetic acid and reduction using tris(2-ethylcarboxy)phosphine 
(TCEP)) and arginine were quantified by HPLC after derivatization with orthophtalic anhydride 
(OPA). Release of sOMV in the culture supernatant was monitored by using the fluorescent signal 
of a phospholipid-specific probe (SynaptoRed C2, Biotium, Hayward, CA, USA; ex500, em650). 
An aqueous solution of SynaptoRed C2 (0.05 mM, 50 µL) was mixed with 50 µL of sterile filtered 
culture supernatant or OMV standard with a known concentration. Fluorescence of the resulting 
mixture was recorded in black microtiter plates using a fluorometer (Synergy MX microplate 
reader; Biotek, Bad Friedrichshall, Germany). A calibration curve was constructed from the 
responses of the standards (dilutions of purified nOMV standard corresponding to 0-10 mg/L 
PorA antigen). Concentration of sOMV in culture supernatant samples was calculated from this 
calibration curve.
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Results
Cysteine is the growth-limiting medium component
Previous work showed that vesicle release by N. meningitidis increased during the stationary 
growth phase [186]. To identify the growth-limiting medium component of these experimental 
conditions, nutrient consumption was monitored. Arginine and cysteine were depleted upon 
onset of stationary growth, while the growth medium still contained sufficient amounts of all 
other components (data not shown). Therefore, concentrations of arginine and cysteine were 
lowered systematically to identify the growth-limiting component (Figure 1). Control medium 
with normal amounts of cysteine and arginine produced regular growth curves in shake flasks 
(exponential growth; dry biomass yield 3.9 ± 0.1 gdw/L). Medium with normal cysteine but 
half the normal amount of arginine gave identical growth (exponential; 4.2 ± 0.3 gdw/L), 
indicating that less arginine did not have an effect on growth. Media with half the amount of 
cysteine however produced half the amount of biomass, regardless the amount of arginine (1.9 
± 0.1 gdw/L and 2.1 ± 0.1 gdw/L for normal and low arginine, respectively). Nutrient analysis 
confirmed that cysteine was indeed depleted upon onset of stationary growth for all 4 media, 
while arginine depletion occurred at a different time point (Appendix 2). These results indicate 
that cysteine, not arginine, is the growth-limiting component of the medium. 
Figure 1. Cysteine is the growth-limiting medium component.
Previous work demonstrated that vesicle release by N. meningitidis increased during the stationary 
growth phase [186]. Nutrient analysis of the chemically defined medium indicated that only arginine and 
cysteine were depleted during early stationary growth. Therefore, concentrations of both components 
were systematically lowered to identify the growth-limiting nutrient. Black lines and black intersected 
lines represent growth curves on media with normal and low arginine concentration, respectively. Normal 
and low cysteine concentrations are marked with circles and triangles. Cultivation time t=0 represents the 
expected onset of stationary growth on reference medium with normal amounts of cysteine and arginine. 
The results indicate that cysteine, not arginine is the growth-limiting component. See Appendix 2 for 
corresponding nutrient data.
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Transcriptome analysis identifies 149 cysteine regulated genes
Transcriptome analysis was performed with DNA microarrays to identify genes that are regulated 
after cysteine depletion. Growth and cysteine availability of triplicate cultivations on normal 
growth medium were monitored. Transcriptome analysis was performed on samples at -2.5, -1.4 
and -0.4 hours (before cysteine depletion) and at +1.4 and +3.5 hours (after cysteine depletion). 
Principal component analysis on the full transcriptome confirmed high reproducibility of 
replicates (Appendix 3A). The experimental treatment (cysteine depletion) accounted for 70% of 
total gene expression variation and resulted in 2 distinct groups on the first principal component 
axis (PC1; corresponding to ‘before’ and ‘after’ cysteine depletion). PC2 explained 7% of all 
variation and the other principal components <5%, indicating that additional effects had only a 
minor impact on overall gene expression. Subsequent statistical analysis selected 149 significantly 
regulated genes (Fold Ratio >2.0 and False Discovery Rate <0.10). Upon cysteine depletion, 90 
genes were upregulated and 48 were downregulated. A variable expression pattern was observed 
for 11 genes (Appendix 3B).
The gene expression profile of cysteine depletion resembles (oxidative) stress and 
virulence
Cysteine regulated genes were compared with available literature. Genes from a heat shock 
study [238] had significant overlap with peroxide stress [239] (p<0.0001; binomial distribution 
probability). Since both studies investigated stress stimuli they were compiled into a single group 
(‘stress’) for the comparison with cysteine depletion. In addition, studies on iron depletion [212] 
and two host interaction studies [240, 241] were compiled to ‘virulence’ based on significant 
overlap (p<0.0001). Studies on restrictive oxygen conditions [242] and putative pathogenicity 
genes [236] were not used due to insufficient overlap with cysteine regulated genes and/or 
available literature. The compiled gene sets ‘stress’ and ‘virulence’ were then compared with the 
cysteine depletion genes, revealing a significant overlap between the 3 groups (p<0.0001). The 
overlap indicates that similar mechanisms may be involved in these biological events (Figure 
2A). Functional annotation of 149 cysteine regulated genes revealed 36 enriched Gene Ontologies 
(p<0.05), related to 11 functional groups (Figure 2B). Functional groups with distinct expression 
patterns were sulfur metabolism (9/9 genes upregulated), iron-sulfur cluster (6/6 upregulated), 
translation (13/16 downregulated), metal ion uptake (11/16 upregulated), cell wall (3/3 
downregulated) and stress (2/2 upregulated). Non-distinct patterns were observed for redox (27 
genes), membrane transport (23 genes), amino acid biosynthesis (10 genes), energy metabolism 
(4 genes) and other functions (19 genes). Some functional groups were directly related to the 
experimental context, like sulfur metabolism and amino acid biosynthesis (cysteine depletion), 
downregulated translation machinery (stationary growth) or membrane transport (upregulated 
sulfate uptake genes). The remaining functional groups were primarily related to oxidative 
stress (redox, iron-sulfur cluster, metal ion uptake and stress). Details are available online as 
Supplemental Information.
Cysteine depletion triggers increased sOMV release
Based on the transcriptome results it was hypothesized that in addition to growth arrest, cysteine 
depletion causes oxidative stress as an intracellular signal for sOMV release. The hypothesis was 
verified with a medium repletion experiment in shake flasks (Figure 3). Precultures on control 
104
medium with the normal amount of cysteine were pooled and repleted with control medium or 
medium without cysteine (two groups). A third group was repleted with control medium but 
growth was repressed with peroxide to induce oxidative stress. Repleted cultures were monitored 
for growth and sOMV release. The sOMV were measured in small culture supernatant samples 
(sterile filtered; <3 mL) with a fluorescent probe that specifically binds phospholipid bilayer 
structures. Biomass concentration of the pooled preculture (0.78 gdw/L) was comparable to the 
biomass density directly after repletion (0.76 ± 0.05 gdw/L), indicating that no biomass losses 
occurred during the repletion procedure. Shake flasks that were repleted with control medium 
continued growth to a final dry biomass concentration of 3.75 ± 0.02 gdw/L. Cysteine depleted 
and oxidative stress shake flasks did not grow, resulting in final biomass concentrations of 0.64 
± 0.01 and 1.28 ± 0.20 gdw/L, respectively (Figure 3A). The sOMV results however revealed 
opposite effects. Control shake flasks grew normally but had a low specific sOMV yield of 1.1 ± 0.2 
mg PorA antigen/gdw, while the cysteine depleted shake flasks yielded 13.7 ± 1.3 mg PorA/gdw 
(with a constant sOMV release rate). Oxidative stress shake flasks temporarily released sOMV 
after each peroxide addition (variable sOMV release rate) resulting in an intermediate yield 
(7.7 ± 0.8 mg PorA/gdw; Figure 3B). Shake flasks were harvested before cysteine in the control 
medium was exhausted, to prevent unintended sOMV release. Integrity of sOMV in the culture 
supernatant was confirmed with dynamic light scattering (DLS), which measured a distinct peak 
around 100 nm indicating that the bacteria were not disintegrating while releasing the OMV 
(data not shown). The above results demonstrate that cysteine depletion triggers increased sOMV 
release. Other stress stimuli like growth repression with peroxide can mimic this effect.
Figure 2. The gene expression profile of cysteine depletion resembles (oxidative) stress and virulence.
Intracellular effects of cysteine depletion were explored with transcriptome analysis, resulting in 149 
significantly regulated genes. (A) Significant overlap is found (p<0.0001) between cysteine regulated genes 
and relevant literature (compiled gene sets ‘stress’ [238, 239] and ‘virulence’ [212, 240, 241]), indicating that 
similar mechanisms are involved in these different stimuli. (B) Functional annotation of cysteine regulated 
genes identified 36 enriched Gene Ontologies (p<0.05) from 11 functional groups. In addition to expected 
groups like sulfur metabolism or translation, several functional groups are related to oxidative stress (e.g. 
redox or iron-sulfur cluster). Therefore it is hypothesized that cysteine depletion impairs the sulfur supply 
for iron-sulfur protein biogenesis, ultimately resulting in oxidative stress. Details of the transcriptome 
analysis are provided in Appendix 3 (principal component analysis and gene clustering) and Appendix 4 
(expression data with functional annotation).
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Cysteine depletion approach is feasible for sOMV vaccine production
The shake flask repletion experiment measured sOMV yield directly in the supernatant without 
taking purification losses or vaccine quality into account. To assess whether the cysteine 
depletion approach was feasible for vaccine production, larger samples (250-400 mL) were taken 
from a bioreactor system to purify nOMV (reference vaccine) and sOMV (experimental vaccine) 
in parallel, according to the protocol in Appendix 1. Purifications were done at several time 
points before and after cysteine depletion. The cultivations were monitored to measure biomass 
concentration and cysteine (time points A to N). As observed in shake flasks, biomass growth 
during the exponential phase was reproducible for all 6 replicate bioreactor cultivations (R2 = 
0.975) and growth arrest occurred upon cysteine depletion (time point G; Figure 4A). 
Purification of nOMV and sOMV vaccines was performed at time points D, F (before) and I, 
K, M (after cysteine depletion). Yield of purified nOMV (reference) correlated to the amount 
of biomass that was used, resulting in a constant amount of 6.3 ± 0.3 mg PorA antigen/gdw 
regardless nutrient availability (Figure 4B). Yield of purified sOMV however depended on 
cysteine availability. Before depletion the yield was just above detection limit (0.2 ± 0.1 and 0.3 
± 0.1 mg PorA/gdw, respectively). Cysteine depletion then triggered sOMV release resulting in 
a cumulative increase during time point I (0.9 ± 0.4 mg PorA/gdw), time point K (2.0 ± 0.4 mg/
gdw) and time point M (4.3 ± 1.4 mg/gdw). The reference yield (nOMV) was significantly higher 
Figure 3. Cysteine depletion triggers sOMV release.
The effect of cysteine depletion on sOMV release is demonstrated with a repletion experiment in shake 
flasks. (A) Pre-cultures are grown on control medium with cysteine (circles). Harvested cells are repleted 
with control medium (circles) or medium without cysteine (triangles). Shake flasks without cysteine enter 
the stationary phase, while cysteine repleted flasks continue growth normally. A third group (squares) is 
repleted with control medium, but growth is repressed with peroxide to mimic oxidative stress and verify 
the transcriptome data (arrows indicate peroxide additions). Y-axis represents dry biomass concentration 
(g dry weight per L). (B) Vesicle release in the cultivation supernatant is monitored with a fluorescent probe 
up to 6 hours after repletion. Shake flasks with control medium grow normally but do not release sOMV, 
while cysteine depletion triggers a sustained release of vesicles. Oxidative stress has a similar but transient 
effect, since sOMV are released temporarily after each peroxide addition. Cysteine depletion is therefore 
an external stimulus for sOMV release, which induces oxidative stress as the intracellular signal. Y-axis 
represents specific sOMV yield (mg PorA antigen per g dry weight).
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than sOMV at most time points (D, F, I and K; p<0.001) but no significant difference was found at 
time point M, indicating that the cysteine depletion approach can generate sufficient sOMV for 
feasible vaccine production. Protein composition and vesicle size distribution were measured to 
assess vaccine quality. Purified nOMV had a comparable overall protein composition at all time 
points, with a high PorA antigen content (64 ± 3% of total protein; Figure 5A). Purified sOMV were 
comparable to nOMV at time points F, I, K and M (PorA content 61 ± 5%), but time point D had 
a low and variable purity (43 ± 23%) caused by a yield that was below the threshold for reliable 
Figure 4. Implications for vaccine development.
A novel approach for the production of sOMV vaccine against N. meningitidis serogroup B is explored 
by utilizing the effect of cysteine depletion. (A) Biomass concentration (closed circles) is monitored in 
bioreactor cultivations (time points A to N). Time point G marks onset of stationary growth, caused by 
depletion of cysteine (open circles). (B) Yield of purified sOMV vaccine (black bars) is compared with nOMV 
reference vaccine, which uses detergent-free biomass extraction to improve yield (white bars). Several time 
points before (D, F) and after (I, K, M) cysteine depletion are included. After cysteine depletion, sOMV 
yield increases steadily to quantities that are comparable to the nOMV reference (no significant difference 
at time point M). Significant yield differences are indicated with asterikses (p<0.05). ‘NS’ indicates a non-
significant difference.
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analysis. Vesicle size averages of nOMV (reference) and sOMV samples were comparable (83 ± 5 
and 97 ± 9 nm respectively). The sOMV samples however had a slightly broader size distribution 
and contained minor particle peaks at ~5 µm, indicating that the purification procedure may 
require improvements (Figure 5B). 
Figure 5. Quality of sOMV and nOMV vaccines.
In addition to yield, quality of the sOMV and nOMV vaccines is compared. It was previously demonstrated 
that both vaccine types provide low toxicity and high functional immunogenicity in mice [185]. (A) Protein 
composition of nOMV reference vaccines is comparable to sOMV vaccines after cysteine depletion (time 
points I, K, M). Each lane contains 4 µg total protein, except sOMV at time points D and F (low protein 
concentration due to a low yield; maximal sample volume is loaded). PorA antigen (~41 kD) has a major 
contribution to total protein content (>60%) in all vaccines. (B) Dynamic light scattering analysis reveals 
that sOMV vaccines have a slightly broader size distribution and minor aggregation compared to the 
nOMV references, indicating that the purification procedure is not yet fully consistent. X-axis represents 
vesicle size distribution (nm).
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Discussion
This study with Neisseria meningitidis demonstrates that cysteine depletion can trigger growth 
arrest and the release of outer membrane vesicles (OMV) in sufficient quantities for vaccine 
production. The vesicles are released spontaneously (sOMV) and are as similar to in vivo vesicles 
as possible with a production system for human vaccines [213]. Therefore the obtained results 
may be relevant for the in vivo vesiculation and pathogenesis of N. meningitidis. To our knowledge, 
external stimuli that trigger sOMV release were not previously described for N. meningitidis or 
for cysteine as the limiting nutrient. Cysteine was found to be the growth-limiting component of 
human serum when supplemented to a chemically defined medium [243]. In serum-free media, 
some strains had an absolute cysteine requirement but others were able to grow on a variety of 
sulfur sources after adaptation [244, 245]. The vaccine production strain in this study is unable 
to adapt its sulfur metabolism after cysteine depletion, resulting in stationary growth despite a 
genetic ability to use alternate sulfur sources from the medium (Figure 1). The strain has specific 
mutations to express multiple protective PorA antigens, attenuate LPS toxicity and improve 
OMV yield, which are required for detergent-free vaccine production [185]. These mutations 
however may cause an inability to adapt to cysteine depleted conditions, since previous work 
with a strain that resembled the H44/76 parent strain more closely did not reveal an absolute 
cysteine requirement for growth [246]. 
Nutrient depletion was not previously associated with increased sOMV release by N. meningitidis, 
but specific genetic modifications are known to have a comparable outcome. The strain 
in this study has a disrupted rmpM gene to prevent anchoring of the outer membrane to the 
peptidoglycan layer with an OmpA-like domain [108, 121, 185]. The gna33 mutation increases 
vesiculation through an unknown mechanism [104]. External stimuli for vesiculation have been 
identified in E. coli, including heat shock, lysine depletion or conditions that activate the σE 
envelope stress response pathway [41, 79-81]. In agreement with these observations, this study 
identified an external stress stimulus for N. meningitidis vesiculation. It remains unknown to what 
extent the current results are restricted to cysteine as the depleted nutrient or to this specific N. 
meningitidis strain.
Transcriptome analysis was performed to elucidate the intracellular effects of cysteine depletion 
in more detail. The transcriptome profile resembles studies with N. meningitidis that investigated 
stress [238, 239] and virulence stimuli [212, 240, 241] (Figure 2). Functional annotation revealed 
several pathways that are directly related to cysteine depletion or a decreased growth rate. The 
remaining pathways are related to oxidative stress, with a central role for iron-sulfur protein 
biogenesis. Iron-sulfur proteins are highly conserved in prokaryotes and eukaryotes. Mutants 
with an impaired biogenesis accumulate free intracellular iron and produce reactive oxygen 
species (ROS), which causes oxidative stress [247, 248]. In addition, iron-sulfur protein biogenesis 
requires sulfur acquisition and storage protein for free iron [249, 250]. These aspects are all 
represented by genes that are upregulated after cysteine depletion, including iron-sulfur cluster 
assembly (erpA, nifU), cysteine synthase/desulfurase (cysK, iscS), storage of Fe2+ ions (bfrA), ROS 
scavenging (sodB, sodC) and several reductases. Therefore it is hypothesized that impaired iron-
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sulfur protein biogenesis also occurs in N. meningitidis after cysteine depletion, causing increased 
intracellular iron levels and oxidative stress.
Recent work by our group showed that sOMV release by N. meningitidis increased significantly 
during the stationary growth phase, but the mechanism was not fully understood [186]. By 
comparing cysteine repleted with depleted conditions, this study demonstrates that cysteine 
depletion is the trigger for onset of stationary growth and increased sOMV release (Figure 3). It 
also shows that growth repression with oxidative stress, the hypothesized outcome of cysteine 
depletion, mimics this effect temporarily. Release of sOMV increases directly after each peroxide 
addition but then stabilizes, while cysteine depletion results in sustained vesicle release. Also, 
the peroxide dose range is narrow and critical for bacterial viability (data not shown). Despite 
these limitations, the results confirm involvement of oxidative stress as an intracellular signal for 
sOMV release and support the transcriptome data. N. meningitidis encounters oxidative stress in 
vivo, when phagocytes use ‘oxidative burst’ to eliminate the invading pathogen [251, 252]. In such 
conditions vesiculation may provide decoys for phagocytosis and enhance bacterial survival.
This study provides a novel approach for the production of sOMV vaccine against N. meningitidis 
serogroup B, in which onset of stationary growth and vesiculation is determined by the cysteine 
concentration of the growth medium. The use of a synthetic medium with a single growth-
limiting component greatly improves process control. Other media for N. meningitidis have 
unidentified limiting nutrients and contain undefined components like casamino acids, resulting 
in less predictable growth [49, 61, 63, 253]. Purification of sOMV does not require concentration, 
resuspension or extraction of the bacterial biomass (Appendix 1). These steps are labor intensive 
and complicate processing, especially when translated to large-scale processes. Therefore sOMV 
purification is the preferred approach for process development. To assess feasibility, yield and 
quality of sOMV vaccines were compared with nOMV references at several time points before 
and after cysteine depletion. In agreement with the initial observations (Figure 3), sOMV release 
is triggered after cysteine depletion and then increases over time. Final yield is comparable to the 
nOMV reference, indicating that cysteine depletion can also provide a feasible yield (Figure 4; 
±1500 human doses sOMV vaccine per L cultivation). The sOMV have a slightly broader size 
distribution, indicating that the purification procedure is not yet fully consistent. This procedure 
may improve by replacing the centrifugal ultrafiltration units with more robust and scalable 
equipment like tangential flow ultrafiltration [254].
In conclusion, this study shows that cysteine depletion can trigger growth arrest and outer 
membrane vesicle release by N. meningitidis. Transcriptome data suggests a relation between 
cysteine depletion and impaired iron-sulfur protein assembly, resulting in oxidative stress. This 
hypothesis is substantiated by showing that induced oxidative stress during cysteine-rich growth 
also triggers vesiculation. Cysteine depletion improves the production of a vaccine against 
serogroup B meningococcal disease, resulting in substantial amounts of sOMV. Since the sOMV 
are more similar to vesicles from natural infection, cysteine-dependent vesiculation is likely to be 
relevant for the in vivo pathogenesis of N. meningitidis.
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Appendix 1
Detergent-free OMV purification.
There are two different detergent-free OMV purification types; sOMV (spontaneously released OMV) 
are purified from the culture supernatant without additional treatments to enhance vesicle release, 
while nOMV (native OMV) are obtained after detergent-free extraction of the bacterial biomass with a 
chelating agent (EDTA). Therefore both OMV types can be purified in parallel from a single cultivation. 
This study uses nOMV as a reference for high yield and quality [186]. Cultivation harvest was split in 
supernatant and bacterial pellet with low speed centrifugation. The supernatant was sterilized with 
filtration, then sOMV were concentrated with ultrafiltration and pelleted with ultracentrifugation. Purified 
sOMV were resuspended in a suitable volume of storage buffer. The bacterial pellet was resuspended 
in EDTA extraction buffer to release nOMV. Cells were incubated and discarded with semi high-speed 
centrifugation. Ultracentrifugation was used to concentrate nOMV and the pellet was resuspended in 
a suitable volume of storage buffer. Purification of nOMV requires several complicated steps in terms 
of handling (concentration, resuspension and extraction of the bacterial biomass). Therefore sOMV 
purification is the preferred approach for process development.
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Appendix 3
Details of the transcriptome analysis are available online as Supporting Information (Figure S3): 
http://dx.plos.org/10.1371/journal.pone.0054314
Appendix 4
Details of the functional annotation are available online as Supporting Information (Table S1): 
http://dx.plos.org/10.1371/journal.pone.0054314
Nutrient monitoring identifies the growth-limiting medium component.
Media with different combinations of cysteine (cys) and arginine (arg) are tested to determine the growth-
limiting component. Upper plots represent nutrient concentrations in media with normal cys, while the 
lower plots represent media with low cys. Media with normal or low arg are indicated with circles or 
triangles, respectively. Y-axes represent cys concentration (plots on the left) or arg concentration (plots 
on the right), The X-axis represents cultivation time, with t=0 as the expected time point of growth arrest 
(confirmed for control medium with normal amounts of cys and arg; upper left plot, circles). Grey vertical 
lines indicate the observed growth arrest time point (obtained from Figure 1). The results demonstrate that 
growth arrest depends on cys availability and is independent of arg.
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Chapter 7
Improved production process 
for native outer membrane 
vesicle vaccine against Neisseria 
meningitidis
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Abstract
An improved detergent-free process has been developed to produce vaccine based on native 
outer membrane vesicles (nOMV) against Neisseria meningitidis serogroup B. Performance was 
evaluated with the NonaMen vaccine concept, which provides broad coverage based on nine 
distinct PorA antigens. Scalable aseptic equipment was implemented, replacing undesirable steps 
like ultracentrifugation, inactivation with phenol, and the use of preservatives. The resulting 
process is more consistent and gives a higher yield than published reference processes, enabling 
nOMV production at commercial scale. Product quality met preliminary specifications for 9 
consecutive batches, and an ongoing study confirmed real-time stability up to 12 months after 
production. As the nOMV had low endotoxic activity and induced high bactericidal titers in mice, 
they are expected to be safe and effective in humans. The production process is not limited to 
NonaMen and may be applicable for other N. meningitidis serogroups and other gram-negative 
pathogens. The current results therefore facilitate the late-stage development and clinical 
evaluation of nOMV vaccines.
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Introduction
Neisseria meningitidis is a human pathogen that causes acute meningitis and septicemia with high 
fatality rates [18]. Outbreaks of serogroup B meningococcal disease in Norway, New Zealand, 
and Cuba were successfully controlled with outer membrane vesicle (OMV) vaccines, which was 
a milestone for the application of OMV in vaccinology [3, 50, 51, 53]. The outer membrane porin A 
protein (PorA) is the dominant protective antigen but varies among strains [57, 90]. Recombinant 
strains with multiple PorA subtypes were developed to increase vaccine coverage, resulting in 
a nonavalent OMV vaccine (NonaMen concept) with potential coverage of 80% [5, 7, 62, 255]. 
Coverage has also been increased by complementing multiple Pores with conserved antigens, 
like fHbp or FetA [63, 64]. In addition OMV improved the immunogenicity of a vaccine with 
purified fHbp, NadA and NHBA protein, which has been submitted for regulatory review in 
Europe [66-68]. The use of OMV-based vaccines therefore remains a promising approach for the 
control of serogroup B meningococcal disease [71]. 
The vaccine strains used in Norway, New Zealand, and Cuba contained lipopolysaccharide 
(LPS) with strong endotoxic activity. To remove most of the LPS, the production process 
required extraction by deoxycholate, a detergent of animal origin [2, 49, 61]. The resulting 
detergent-extracted OMV (dOMV) tended to aggregate, and the deoxycholate was not fully 
removed during purification [49, 61, 185]. These issues, together with a high strain specificity of 
the immune response, have delayed the late-phase development of broadly protective dOMV 
vaccines. Van der Ley et al. attenuated LPS by introducing the lpxL1 mutation rather than 
physically removing it with detergent [6]. As lpxL1-LPS has low endotoxic activity, it enables the 
development vaccines based on native OMV (nOMV) for use in humans [70]. nOMV are very 
similar to the natural vesicles released during infection [213]. Vaccines based on nOMV therefore 
have several advantages over those based on dOMV, including absence of aggregation and a 
broader immunogenicity provided by protective lipoproteins like fHbp [72-74, 185].
nOMV vaccines against N. meningitidis gave promising results in preclinical and clinical studies, 
but were either produced at small-scale or required process steps that are undesirable at 
commercial scale [82, 185, 187, 188, 190, 253]. These steps include the use of growth medium with 
undefined components of animal origin (casamino acids), inactivation of bacteria with hazardous 
chemicals like phenol, or the use of excessive mechanical force to release or homogenize nOMV 
(e.g., blender, micro fluidizer). Other problems involve use of preservatives with toxic components 
(like thiomersal) and use of ultracentrifugation, which limits production scale and complicates 
handling. nOMV production for phase III clinical trials and commercial use demands an efficient 
and reliable process that fully meets present-day regulatory requirements. As such a process was 
unavailable for nOMV vaccines, a novel process was developed. Performance was assessed with 
the NonaMen concept, a vaccine with broad coverage based on nonavalent PorA. Our results 
show that this new process provides a robust production platform for the late-stage development 
and clinical evaluation of nOMV vaccines.
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Trivalent strains and seedlots
The nOMV vaccines in this study were produced with RL strains 1, 2 and 3 (Appendix 1). Deletion 
of rmpM (R) and lpxL1 (L) genes improved yield and attenuated LPS toxicity [185]. The RL strains 
are non-encapsulated variants of the N. meningitidis serogroup B isolate H44/76 [109] derived by 
deletion of the cps-locus (siaA, siaD and galE genes). Each RL production strain has 3 cloning sites 
for recombinant antigens, which were used to express unique PorA subtype variants (NonaMen 
concept; nonavalent PorA). For each strain, the research seedlot was adapted to the production 
medium in Erlenmeyer shake flasks to obtain frozen master seedlots (Figure 1, phase A). One 
master seedlot was used to generate approximately 50 frozen working seedlots through two 
additional expansions in shake flasks (two-tiered seedlot system). Master and working seedlots 
(cells at OD590 = 1.5 ± 0.3; stored at -135°C with 17% (v/v) glycerol) were produced according to 
GMP guidelines.
Production of nOMV
Bulk nOMV were produced according to standard operating procedures in a non-GMP pilot 
facility, but future use of the process in a GMP facility was anticipated. Evaluation of deviations, 
batch review, and batch release were performed by QA/QP officers according to GMP standards. 
All cultures were grown in chemically defined production medium free of animal components 
and containing glucose, amino acids, salts, iron, and trace elements [4]. A primary 150 mL pre-
culture was inoculated with 10 mL working seedlot and incubated in disposable 500 mL shake 
flasks with vented closure (Nalgene, Rochester NY, U.S.A.) at 35°C, 200 rpm. The pre-culture 
was used to inoculate a secondary pre-culture, grown in a 5 L bioreactor with 3 L working 
volume (Applikon, Schiedam, The Netherlands). At OD590 values between 1.5 and 4.5, a fixed 
amount of bacteria (corresponding to 1 L at OD590 = 3) was transferred to the 60L production 
bioreactor with 40 L working volume (Applikon, Schiedam, The Netherlands). Bioreactors were 
operated as described previously [4]. Antifoam was omitted, and a mechanical foam breaker 
was used to control foaming at 40 L scale (the 5 L reactor did not require a foam breaker) [4]. The 
production culture was harvested 3 hours after onset of the stationary phase (Figure 1, phase 
B), as observed with online monitoring of the oxygen consumption. Biomass was concentrated 
5-fold using hollow-fiber microfiltration units with 0.2 µm pore size and 1.8 m2 surface area 
(Spectrum Laboratories, Rancho Dominguez CA, U.S.A). Circulation was constant at 6.5 L/min, 
and feed pressure was monitored (phase C). Concentrated biomass was then diafiltrated with the 
microfiltration unit, using 2 volumes of buffer (100 mM Tris-HCl, pH 8.6). Concentrated EDTA 
solution was added to a final concentration of 10 mM to stimulate nOMV release (30 min at 
ambient temperature with continuous stirring). Bacteria were separated from the crude OMV by 
centrifugation (6 buckets with a content of max. 1 L; 75 min., 12500x g, 4ºC), and the supernatant 
was depth-filtered (0.5-0.2 µm) to remove any residual pathogens (phase D). In phase E, the 
crude OMV extract was concentrated 12-fold and washed with ultra(dia)filtration (100 kD cut-
off; 100 mM Tris-HCl pH 8.6). In phase F, any DNA that might be present was digested with 
1000 U/L Benzonase (Merck; Schiphol-Rijk; The Netherlands). To remove impurities (bacterial 
host proteins, salts, small DNA), the nOMV were loaded onto a gel filtration chromatography 
column packed with Sepharose 6 Fast Flow size exclusion matrix (GE Healthcare, Hoevelaken, 
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The Netherlands). During gel filtration (phase G), the buffer was changed to storage buffer 
containing10 mM Tris-HCl pH 7.4 with 3% (w/v) sucrose [107]. Bulk nOMV were sterilized with 
filtration (0.22 µm; Pall, Mijdrecht, The Netherlands), diluted to storage concentration (1 mg 
PorA/mL), and safely stored in the dark at 2-8 ºC until further use (phase H). Stability of the bulk 
NOMV under these conditions is at least one year (ongoing real-time stability study). To prepare 
nonavalent vaccines for preclinical evaluation purposes (phase I), aseptic fill and finish were 
performed according to GMP guidelines. First, bulk nOMV from three trivalent RL strains were 
mixed to achieve nonavalent vaccine, then diluted to dose concentration with storage buffer, 
based on PorA concentration. Vials with 0.6 mL extractable volume were filled with vaccine and 
labeled. Each vaccine dose (0.5 mL) contained 15 µg of each PorA with a total of nine different 
PorA subtypes (Appendix 1). 
Quality Control
QC tests were performed according to GMP and European Pharmacopoeia guidelines. PorA 
identity was verified with qualitative ELISA, using specific antibodies for each PorA subtype 
[61]. OMV from monovalent PorA strains and a ΔporA strain were used as controls. Total 
protein concentration (Ph. Eur. 2.5.33) was measured with the Lowry protein assay. Peterson’s 
modification was used to reduce the effect of interfering substances [112]. The assay was 
performed according to manufacturer’s protocol (Sigma-Aldrich, Zwijndrecht, the Netherlands). 
PorA content was determined by SDS gel electrophoresis (Ph. Eur. 2.2.31) followed by total 
protein staining and quantification of the 40-44 kD PorA bands. Gels were stained with Novex 
Colloidal Blue (Invitrogen, Breda, The Netherlands), and PorA was quantified as a percentage of 
total protein using TL100 1D gel analysis software (Totallab, Newcastle upon Tyne, U.K.) [112, 
113]. Total nucleic acid concentration was used to estimate residual genomic DNA. Samples were 
incubated with ethidium bromide solution (MP Biochemicals, Illkirch, France), and fluorescence 
intensity was measured to quantify DNA concentration based on a salmon sperm DNA standard 
(Invitrogen, Breda, The Netherlands) [4, 114]. For bulk nOMV and nonavalent vaccines, there 
was no need to discriminate between RNA and DNA with an RNAse pre-treatment, because 
total nucleic acid concentration was low (<0.06 mg/mL). RNAse pre-treatment was used for in-
process controls on intermediate products (before phase F). Fatty acid composition was analyzed 
to quantify LPS concentration with a modified gas chromatography method [115, 116] (Ph. Eur. 
2.2.28). LPS was isolated with hot phenol-water extraction [117] and quantified using the peak 
height of C14:0-3OH, with C12:0-2OH as the internal standard (two C14:0-3OH residues per 
LPS). The molecular weight of galE-lpxL1-LPS in the RL strains was previously estimated at 2848 
g/mol [185], but recent mass spectrometry work provided a more reliable estimation of 3191 g/
mol, which was used for this study (Pupo Escalona et al., manuscript in preparation). Identity 
of galE-lpxL1-LPS was verified with mass spectrometry [119]. An aliquot of 200 µL isolated 
LPS (see above; 50 nmol/ml) was freeze-dried and taken up in 0.1 ml of 2% acetic acid (pH 
2.8). The mixture was heated to hydrolyze the LPS and release the lipid A moiety. Chloroform-
methanol (2:1 v/v) was used to extract the lipid A and, after phase separation, the upper phase 
was used for analysis with mass spectroscopy (nano electrospray tandem MS on a Finnigan 
LCQ instrument in the negative-ion mode) [256]. Vesicle size distribution was measured with 
dynamic light scattering (DLS) at 25ºC with a Malvern 4700 system [185] (Ph. Eur. 2.9.31). The 
vesicle size distribution was reflected in the polydispersity index (PdI), which ranges between 
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0.0 (fully homogeneous size distribution) and 1.0 (random size distribution). Aggregation was 
quantified by comparing the protein content of the nOMV starting material with the protein 
content of the supernatant after centrifugation at low speed (10 min. at 5000 xg) [185], using the 
total protein assay described above. Aggregation was calculated by expressing the difference 
between the total protein content of supernatant and starting material as a percentage of the 
starting material. Sterility was determined by filtration (Ph. Eur. 2.6.1). Aliquots of 30 mL were 
filtered through a membrane (<0.45 µm pore size) to retain any contaminating organisms and 
remove constituents that might inhibit growth. The membrane was incubated in shake flasks 
with 180 mL tryptic soy broth (TSB) for 14 days at 30-35ºC, with continuous aeration. The shake 
flask was inspected for visible growth and, if negative or sterile, it was inoculated with 10-100 cfu 
of Bacillus subtilis and re-incubated as a positive control for medium quality. Endotoxic activity 
of bulk nOMV was measured as described previously by stimulating IL-6 production in human 
macrophage cell line MM6 [120] (Ph. Eur. 2.6.30) [185]. Macrophages were seeded in 96-well 
plates (3.75x104 cells/well) in 125 µL IMDM medium supplemented with penicillin, streptomycin, 
L-glutamine, and fetal calf serum (Invitrogen, Breda, The Netherlands). Two-fold dilution series 
were made for all bulk nOMV samples in the supplemented IMDM medium, and cells were 
stimulated by adding 125 µL to each well. DOMV vaccine with known low toxicity (containing 
reduced amounts of non-attenuated galE-LPS) [257] and DTP-IPV vaccine (RIVM Bilthoven, The 
Netherlands) were included as references. A human dose of DTP-IPV vaccine contained 4 IU 
whole-cell pertussis, 30 IU diphtheria toxoid, 60 IU tetanus toxoid, and 40, 4 and 7.5 D-antigen 
units of inactivated poliovirus (type 1, 2 and 3, respectively). A human dose of OMV vaccine 
corresponded to 15 µg of each PorA subtype. Cells were stimulated for 16-18 hours at 37ºC with 
5% CO2, and IL-6 was quantified in the supernatant using ELISA, according to manufacturer’s 
protocol (PeliKine Compact, Amsterdam, The Netherlands). Endotoxic activity was expressed in 
ng/mL IL-6 per human dose. Serum bactericidal activity of trivalent bulk nOMV was measured 
in sera of NIH mice (19-25 grams; <8 weeks old) after two subcutaneous immunizations on day 
0 and 14 with 22.5 µg PorA (7.5 µg of each PorA subtype), with 10 mice per group. Sera were 
collected at day 28 and stored at -20ºC. Bactericidal titers were measured as described before 
[118]. PorA epitope concentrations were quantified in bulk nOMV using biosensor analysis on a 
Biacore T100 (GE Healthcare Benelux, Diegem, Belgium). One representative PorA subtype was 
chosen for each RL production strain: P1.7,16 for strain 1; P1.22,14 for strain 2, and P1.12,13 for 
strain 3. Quantification was based on titration of free antibody after incubation with bulk nOMV. 
Recombinant PorA protein of a specific subtype was diluted in the presence of 0.05% (w/v) 
Zwittergent 3.14 and subsequently coupled to a CM5 sensor chip using an amine coupling kit 
according to manufacturer’s protocol (GE Healthcare), with immobilization levels between 10.000 
and 12.000 response units (RU). Dilution series of bulk nOMV in HBS-P buffer (GE Healthcare) 
were made, and samples were incubated overnight with PorA-specific monoclonal antibody in 
a suitable dilution. An OMV reference with known epitope concentration was also included. 
After incubation, the mixtures were centrifuged (5 min. at 3000x g) to remove any aggregates. 
The antibody excess was quantified by injecting samples on the sensor chip (10 µl/min for two 
minutes). Assay data were analyzed by fitting a four-parameter logistic curve with Biacore T100 
evaluation software. PorA epitope concentrations of bulk nOMV were calculated relative to the 
reference OMV.
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Strain stability
Genetic stability of the RL production strains was assessed by continuing bacterial growth several 
generations beyond the normal harvest point of the production culture, using shake flasks. The 
age of the master seedlot was set at N=0 generations, and experimental seedlots were stored at 
N=30 generations of growth (regular production harvest), N=45 generations (post-production 
A), and N=60 generations (post-production B). The total number of generations at each time-
point was calculated by taking the cumulative result of all previous passages in shake flasks 
and bioreactors. The number of generations from an individual passage was calculated with 
the formula: ln(ΔOD590) / ln(2), in which ΔOD590 was the difference between the initial and final 
OD590 of a passage. At each time-point, relevant genetic modifications of the RL production 
strains (Appendix 1) were verified: PorA identity, identity of galE-lpxL1-LPS, rmpM and porB gene 
disruptions. Resistance against erythromycin, kanamycin, and chloramphenicol was tested by 
plating on GC agar with these antibiotics. 
nOMV stability
Stability of bulk nOMV was monitored in an ongoing three-year stability study. The results up to 
12 months after production are currently available. Bulk nOMV (n=3; one bulk product from each 
RL strain) were stored at a total PorA concentration of 1 mg/mL, at 4ºC in the dark. At t=0, 3, 6 
and 12 months, PorA epitope concentration (one representative epitope for each bulk product), 
PorA content, OMV size, aggregation, and pH were tested as described above. Sterility was tested 
at t = 0 and 12 months after production. Results were assessed with trend analysis. Data from 
replicates and time-points were merged for each stability parameter and analyzed for normality 
and sufficient sample size (D’Agostino’s K2 test; prerequisite for further analysis). A trend line 
was fitted with linear regression, and trends were tested for significant deviations from a non-
zero slope (F test).
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Results
Process outline and specifications
The improved NOMV production process is outlined in Figure 1. Product phases A to H 
describe the production of trivalent bulk nOMV. The upstream process starts with thawing of 
a working seedlot (phase A). After multiple passages of growth, the 40 L production culture 
is harvested (phase B), and biomass is concentrated with microfiltration (phase C). After a 
detergent-free treatment using the chelating agent EDTA (ethylenediaminetetraacetic acid), 
biomass is removed with consecutive centrifugation and filtration steps to obtain the pathogen-
free, crude nOMV (phase D), which are the input material for downstream processing. Crude 
nOMV are concentrated and washed with ultra(dia)filtration (phase E), and DNA is digested 
with nuclease (phase F). The resulting nOMV are purified with gel filtration to remove salts and 
digested DNA fragments and also to enable a buffer change to storage buffer (phase G). After 
sterile filtration (phase H), the bulk nOMV from strains with trivalent PorA can be stored until 
they are combined as a nonavalent vaccine and diluted to the appropriate dose concentration 
Figure 1. Flow-chart for improved nOMV production. 
Process performance was evaluated with the NonaMen concept, a nonavalent PorA vaccine comprised of 
three trivalent RL production strains (ΔrmpM-ΔlpxL1 mutant strains; Appendix 1). Production of trivalent 
bulk nOMV is depicted in phases A to H. The transition from one phase to the next requires a specific unit 
operation (1 to 10). The seedlot (A) is first expanded in shake flask and bioreactor pre-cultures, then used 
to inoculate the production bioreactor. Harvested cells (B) are concentrated with microfiltration (C), and 
vesicle release is stimulated with a detergent-free buffer containing the chelating agent EDTA (D). Cells are 
discarded, and the crude nOMV are concentrated with ultrafiltration (E). Any residual DNA is digested 
with nuclease (F), and the extract is purified with gel filtration chromatography. The non-sterile bulk (G) 
is then sterilized by filtration to obtain the bulk nOMV (H). The trivalent product can be stored for at least 
one year before mixing as nonavalent vaccine and diluting to dose concentration (I).
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(phase I). The bulk nOMV vaccines in this study were produced for use in preclinical evaluation. 
As a starting point for process development, specifications were defined for processing aspects 
based on analysis of three reference processes: one large-scale nOMV process [253] and two large-
scale dOMV processes [49, 61]. Appendix 2 compares these references with the current process. 
Table 1 summarizes the solutions designed to meet the specifications and their current status of 
implementation.
Bacterial strains
The three RL production strains (ΔrmpM-ΔlpxL1 mutant strains; Appendix 1) with different 
combinations of PorA antigens were adapted to the production medium and stored as frozen 
master and working seedlots. Quality Control testing confirmed microbiological identity (N. 
meningitidis), bacterial monoculture (no contaminating organisms), cell viability (>105 cfu/
mL), and PorA identity (trivalent). Seedlots were produced, released, and stored according to 
GMP guidelines and may therefore be used to produce vaccines for clinical evaluation. Genetic 
stability of the RL production strains was constant at all four time-points that were assessed: 
master seedlot (N=0 generations of growth), production harvest (N=29 ± 1 generations), and two 
post-production time-points (N=43 ± 2 and N=61 ± 1 generations of growth, respectively). PorA 
identity results matched the subtypes in Appendix 1, as did the LPS identity (galE-lpxL1-LPS). 
Gene disruptions of rmpM and porB were confirmed with PCR (data not shown). Disruption of the 
cps locus (siaA, siaD and galE genes) was confirmed at all time-points by testing functionality of the 
erythromycin resistance gene (eryR) used for disruption. Comparable tests confirmed kanamycin 
Table 1. Specifications for improved nOMV production. 
An outline with 7 consecutive unit operations (corresponding to Figure 1) was used as a starting point 
for process development and optimization. One large-scale nOMV process [253] and two large-scale 
dOMV processes [49, 61] were used as references to define desired specifications for each unit operation 
(Appendix 2). Solutions that are expected to provide these specifications are summarized, together with 
their implementation status in the current production process.
unit operation specification solution/result current status
1. produce biomass
reproducible growth chemically defined growth medium optimized
scalable >500 L 40 L bioreactor, scalable to 800 L optimized [4]
no antifoam Low-shear foam breaker optimized [4]
on-line harvest point decision oxygen consumption monitoring optimized
2. concentrate biomass replace centrifugation hollow fiber microfiltration functional [186]
3. increase OMV release
mild, low-shear blender omitted functional
high extraction efficiency critical process parameters identified optimized [186]
aseptic biomass removal continuous centrifugation not functional
inactivation without phenol depth filtration 0.5-0.2 µm optimized
4. increase concentration replace ultracentrifugation ultrafiltration 100 kD cutoff functional
5. remove DNA replace ultracentrifugation nuclease treatment functional
6. remove impurities replace ultracentrifugation gel filtration chromatography optimized
7. sterilize
replace thiomersal sterile filtration 0.2 µm optimized
high efficiency detergent-free (prevents aggregation) optimized [186]
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and chloramphenicol resistance at all time-points, providing supplementary confirmation of 
lpxL1 and rmpM disruption. These results indicate that the RL production strains are genetically 
stable for at least 30 generations of growth beyond the usual production harvest, in the absence 
of selective antibiotics. 
Upstream production process
The primary pre-culture was inoculated with a thawed working seedlot, grown in a shake-flask 
to an OD590 of 1.4 ± 0.2 and used to inoculate the secondary pre-culture, which was grown in 
bioreactors to an OD590 of 2.9 ± 0.9. Inoculants were transferred during the exponential growth 
phase. All cultures were grown on chemically defined growth medium, without antifoam, and a 
mechanical foam breaker was implemented for the production bioreactor [4]. Production cultures 
started at an OD590 of 0.12 ± 0.02, at 40 L cultivation volume. Biomass growth was monitored by 
measuring OD590 and expressed as dry biomass concentration (1 OD590 unit corresponds to 0.32 
g/L dry biomass or 2.47 g/L wet biomass). In addition, oxygen consumption was monitored on-
line to determine the harvest point. The resulting characteristics are shown in Figure 2. Biomass 
Figure 2. Upstream process characteristics. 
(A) The upstream process was performed at 40 L scale, which was representative for large-scale (800 L 
[4]). Biomass growth (black line) on chemically defined production medium was highly reproducible 
(regression R2 = 0.977). Cultivations from RL production strain 1, 2, and 3 were are indicated by squares, 
circles, and triangles (respectively). Duplicates for each strain are indicated with open and closed symbols, 
giving a total of 6 cultivations. (B) Oxygen consumption was monitored continuously. Cultivations were 
aligned at the time-point of maximal oxygen consumption (t=0), which represented onset of the stationary 
phase. Harvest point of the cultivations was previously optimized at t=3 hours [186].
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growth was highly reproducible for all cultivations (n=6; duplicates for each strain; R2 = 0.977). 
Cultivation profiles were aligned at the time-point of maximal oxygen consumption, which 
represented the onset of the stationary phase (t=0). The production cultures were harvested for 
further processing at 3.1 ± 0.3 hours after onset of the stationary phase, with a wet biomass yield 
of 23.8 ± 2.2 g/L. Harvest was concentrated 5-8 fold with microfiltration (scalable, aseptic) and 
washed with 2.1 ± 0.2 volumes Tris-HCl pH 8.6 buffer to adjust pH. This ensured a pH of 8.3–8.6. 
The EDTA treatment was performed with optimal setpoints for ‘harvest’ and ‘pH’, which were 
previously identified as critical process parameters [186]. 
Downstream production process
In the NonaMen vaccine concept, PorA is the primary protective antigen, and therefore a high 
PorA content is desired. When nOMV from the trivalent RL strains are properly purified, PorA 
content comprises more than 55% of total protein present in the vesicles [185, 186]. Figure 3A shows 
how PorA content evolves through the phases of the downstream process. During phases D, E 
and F, it was relatively low at an average of 26 ± 5% of total protein. Gel filtration chromatography 
removed impurities effectively and reproducibly, resulting in a final PorA content of 71 ± 7% at 
phases G and H. This was significantly higher than at the previous phases (p<0.0001). Figure 
3A also shows the PorA recovery at various production phases. Initial PorA yield after EDTA 
treatment of cells (phase D) was set at 100%, and recovery at downstream phases (E to H) was 
Figure 3. Downstream process characteristics. 
(A) PorA content and recovery are shown for the consecutive product phases of the downstream process, 
from crude nOMV to bulk nOMV (Figure 1, phase D to H). PorA content (black bars) reaches final values 
from phase G onwards, indicating that the gel filtration chromatography effectively removed impurities. 
PorA recovery relative to phase D (grey bars) showed that losses were spread equally across the process, but 
notably not during sterile filtration (phase G to H), resulting in a reproducible and good overall recovery. 
Error bars indicate standard deviation of combined data from the three RL production strains (n=9). (B) 
Total protein and PorA yield of RL bulk nOMV (phase H) and large-scale reference processes. Reference 1 
[253] is most comparable the current process since both are detergent-free (nOMV product). References 2 
[49] and 3 [61] use detergent-extraction (dOMV product). All RL strains have a higher PorA yield than the 
references. RL strain 3 has a lower yield than the other two RL strains, resulting in a total protein yield that 
is comparable to reference 2 but still higher than the other references. The results of individual RL strains 
are reproducible, therefore this yield difference is not caused by the process. Error bars indicate standard 
deviation of replicate batches (n=3). 
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expressed as percentages of the initial yield. Losses were distributed evenly across phases E, F 
and G (22 ± 8%, 22 ± 7%, and 25 ± 7% yield loss, respectively), resulting in a good overall PorA 
recovery of 31 ± 10%. PorA recovery for RL strain 3 was lower than for the other strains, resulting 
in slightly elevated standard deviations. Notably, sterile filtration (phase G to H) was performed 
with a recovery of 96 ± 6%, indicating that the OMV passed the 0.2 µm filter without detectable 
losses.
Process yield
Mean yield of the novel process was substantially higher than the yield of large-scale reference 
processes, as illustrated in Figure 3B. Reference 1 [253] is most comparable to the current process, 
since they are both detergent-free, whereas references 2 [49] and 3 [61] use detergent-extraction 
(Appendix 2). The mean yield of three RL production strains was 40 ± 17 mg total protein per L 
reactor volume, which was 15-fold higher than reference 1 (2.7 mg/L), 2-fold higher than reference 
2 (21.7 mg/L), and 9-fold higher than reference 3 (1.9–7.4 mg/L). However, the individual RL 
strains varied: RL strain 3 had a yield of 19 ± 2 mg/L, which was considerably less than RL strains 
1 and 2 (54 ± 6 and 48 ± 7 mg/L, respectively). Figure 3B therefore shows the individual RL yields 
rather than their average. In addition, Figure 3B confirms a substantially higher PorA yield for all 
RL strains (2–30 fold). According to the literature, yield of reference 1 was based on 270 L reactor 
volume, 450 mL product with 0.8 mg/mL total protein and PorA content of 50% (our estimation); 
yield was multiplied by 2.03, because 49.3% (not 100%) of total biomass was processed. Reference 
2 yield was based on 15 L reactor volume; 13000 doses (25 µg total protein with 33% PorA). 
Reference 3 yield was based on 135 L reactor volume; 250 to 1000 mg total protein with 89% PorA.
Quality Control
The most important aspect of process performance is the resulting product quality, in this 
case the quality of bulk nOMV with trivalent PorA. Therefore, batches of bulk nOMV (n=9; 
three for each RL production strain) were characterized with Quality Control tests according 
to GMP and European Pharmacopoeia (EP) guidelines. The analyses confirmed that quality 
was within preliminary specifications for all batches (Table 2A). The nOMV were sterile, had 
the expected PorA identity (trivalent), high total protein content (1.4 ± 0.2 mg/mL), high total 
PorA content (0.98 ± 0.09 mg/mL), and low residual DNA (0.007 ± 0.002 mg/mL). They also had 
native amounts of galE-lpxL1-LPS (0.23 ± 0.06 mg/mL), homogeneous OMV size (81 ± 7 nm), 
and absence of aggregation (3 ± 3%). Three batches of bulk nOMV (one for each trivalent RL 
strain) were assessed for endotoxic activity, functional immunogenicity, stability, and appearance 
(see paragraphs below). In addition, bulk nOMV were mixed to produce nonavalent vaccine, 
for evaluation in mice and rabbits. This separate study confirmed that the nonavalent vaccine 
induces broad immunogenicity and is well-tolerated [258].
The endotoxic activity of bulk nOMV (n=3) was measured with IL-6 monocyte activation (Table 
2B). Used as references were a dOMV vaccine with low toxicity, as proven in a phase I clinical 
study [257], and a DTP-IPV vaccine (containing diphtheria and tetanus toxoid, whole-cell 
pertussis, and inactivated polio virus). The bulk nOMV induced 27 ± 2 ng/mL of IL-6 per human 
dose (26, 27 and 29 ng/mL for RL strains 1, 2 and 3, respectively; one human dose corresponded 
to 15 µg PorA of each PorA subtype). This was approximately 25-fold lower than both reference 
vaccines. The dOMV vaccine induced 700 ng/mL of IL-6 per human dose, and the DTP-IPV 
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vaccine induced 778 ng/mL of IL-6 per human dose. Therefore the nOMV are expected to be safe 
for parenteral use in humans. 
Functional immunogenicity was assessed by measuring serum bactericidal activity in mice sera 
after two immunizations with trivalent bulk nOMV, one for each RL strain (Table 2C). High 
bactericidal titers (>4 fold increase in mean 2log titer of responders) were observed for 8 of 9 tested 
PorA subtypes. PorA subtype P1.18-1,3,6 had a low titer, with only 1 mouse of 10 responding to 
vaccination. Of the 8 PorA subtypes with high titers, P1.19,15-1 was just above threshold, and 
P1.7-1,1 had a lower number of responders (5 out of 10 mice). These results indicate that the bulk 
nOMV induced high functional immunogenicity in mice for most PorA antigens. In addition to 
the Quality Control tests, we assessed protein composition and appearance of the nOMV. Total 
protein composition (determined by SDS gel electrophoresis) is shown in Figure 4A, illustrating the 
major contribution of PorA protein (42 kD; 71 ± 7% of total protein). Overall protein composition 
of bulk nOMV was comparable among the three trivalent RL production strains, resulting in 
nonavalent vaccine with an equally comparable composition. Dynamic light scattering (DLS) was 
used to visualize nOMV appearance (Figure 4B) and found non-aggregation; homogeneous size 
distribution with averages of 86.2 nm (RL strain 1), 86.7 nm (RL strain 2), and 73.8 nm (RL strain 
3); and low polydispersity indices of 0.12, 0.08, and 0.11, respectively. A representative electron 
micrograph of non-adjuvated nonavalent vaccine after dilution to dose concentration (Figure 4C) 
showed fully intact, non-aggregated vesicles with a size between 40 and 100 nm.
Figure 4. Protein composition and appearance of nOMV.
(A) Protein composition of trivalent bulk nOMV is shown in lanes 1 to 3 for RL strains 1, 2 and 3, respectively 
(phase H), and composition of the nonavalent vaccine (phase I) in lane 4. Bulk nOMV from the three RL 
production strains were comparable, therefore the nonavalent vaccine had an equally comparable protein 
composition. (B) Vesicle size of trivalent bulk nOMV was similar for RL strain 1 (black line), RL strain 
2 (grey line), and RL strain 3 (dashed line). All bulk nOMV were non-aggregated and had comparable, 
homogeneous size distributions, with averages between 74 and 87 nm. (C) Electron micrograph of 
nonavalent vaccine (non-adjuvated) after dilution to dose concentration shows that vaccine contained 
fully intact, non-aggregated OMV, an important benefit of the detergent-free production process. 
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nOMV stability
The production dates of three batches of bulk nOMV (one for each RL strain) were used as 
starting points for an ongoing real-time stability study. The nOMV were stored at a total PorA 
concentration of 1 mg/mL, at 4°C in the dark. Quality Control tests focused on biochemical 
aspects (PorA content, OMV size, aggregation, and pH), sterility, and epitope concentration 
(determined by quantitative Biacore assay with specific antibodies against a PorA subtype, using 
Table 2. Quality Control testing of bulk nOMV. 
(A) General characteristics include biochemical composition, PorA identity, and sterility for which 
preliminary specifications were set. (B) Endotoxic activity of the bulk nOMV was approximately 25-fold 
lower than in dOMV and DTP-IPV reference vaccines. (C) In addition, high bactericidal titers were induced 
in mice (2log titers >4 for 8 out of 9 PorA subtypes), with few non-responders. These results indicate that 
the bulk nOMV have a consistent product quality and are likely to be safe and immunogenic in humans. 
2A – general characteristics
QC parameter preliminary specification result (n=9)
sterility no growth no growth
PorA identity trivalent trivalent
total protein >1.0 mg/mL* 1.4 ± 0.2 mg/mL
total PorA 1.00 ± 0.25 mg/mL* 0.98 ± 0.09 mg/mL
PorA content >55% of total protein 71 ± 7%
galE-lpxL1-LPS 0.25 ± 0.15 mg/mL 0.23 ± 0.06 mg/mL
OMV size <220 nm 81 ± 7 nm
aggregation no specification 3 ± 3%
DNA <0.050 mg/mL 0.007 ± 0.002 mg/mL
2B – endotoxic activity
vaccine preliminary specification result (ng/mL IL-6 per human dose)
bulk nOMV (n=3) <DTP-IPV reference 27 ± 2
dOMV low toxicity – 700
DTP-IPV reference – 778
2C – serum bactericidal activity
vaccine PorA subtype 2log titer** responders
bulk nOMV strain 1 
(n=1)
P1.7,16 10.3 (>4) 9/10
P1.5-1,2-2 12.0 (>4) 10/10
P1.19,15-1 4.6 (>4) 9/10
bulk nOMV strain 2 
(n=1)
P1.22,14 8.7 (>4) 10/10
P1.7-1,1 6.2 (>4) 5/10
P1.18-1,3,6 3.0 (<4) 1/10
bulk nOMV strain 3 (n=1)
P1.5-2,10 10.2 (>4) 10/10
P1.12-1,13 7.7 (>4) 10/10
P1.7-2,4 6.4 (>4) 7/10
*During processing PorA concentration of bulk nOMV is set at 1 mg/mL for storage purposes. 
**Mean titers of responders.
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one representative PorA selected for each RL strain). Stability data at 0, 3, 6 and 12 months after 
production are presented in Appendix 3. The data did not contain trends with significant non-
zero slopes, indicating that the nOMV were sterile and had a stable PorA content, vesicle size, 
and pH. Aggregation was low at all time points (<5%), but trend analysis could not be performed 
due to skewed distribution. Epitope concentrations seemed constant, but sample size at t=12 was 
still too small for reliable trend analysis. The table shows results for all time-points up to t=12, 
indicating that the bulk nOMV were stable for at least one year after production. Trivalent bulk 
nOMV were also mixed to produce nonavalent vaccine [258]. Functional immunogenicity of this 
vaccine in mice will be monitored up to 36 months after production in a second, real-time stability 
study (data not yet available).
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Discussion
An efficient and consistent process for the detergent-free production of nOMV vaccine against 
N. meningitidis has been developed (Figure 1). Compared to previously described processes, 
this process offers important improvements that are likely to enable production at commercial 
scale (Table 1; Appendix 2) [49, 61, 253]. Process performance was evaluated with the NonaMen 
vaccine concept, which provides broad protection against serogroup B meningococcal disease 
based on nine different PorA antigens [5, 60, 62]. 
The upstream process uses production strains with multiple recombinant antigens that are 
genetically stable in the absence of selective antibiotics. The strains also have mutations in lpxL1 
and rmpM genes to attenuate LPS toxicity and improve yield [6, 185] (Appendix 1). Without 
these genetic modifications, the detergent-free approach would not be feasible. To prevent 
hydrophobic interactions with the outer membrane, antifoam is omitted from the growth 
medium. Instead, a mechanical foam breaker was implemented that does not impose significant 
shear force or lysis [4]. The resulting growth curves are highly reproducible (Figure 2A) and 
with a higher biomass yield than large-scale references [49, 253]. Biomass yield can be further 
improved by implementing a feed strategy, since onset of the stationary phase is triggered by 
nutrient depletion rather than limitations in the oxygen supply (data not shown). The production 
culture is harvested after three hours of the stationary phase, and the harvest point is detected 
online with oxygen consumption monitoring (Figure 2B). Biomass density is constant during 
this period, but the oxygen consumption does not stabilize. It is therefore uncertain whether the 
stationary phase is a temporary transition from exponential growth to death phase, or a truly 
stationary phase in which growth remains at maintenance levels for a prolonged period. 
Harvested biomass is concentrated with scalable, aseptic equipment, and nOMV release is 
stimulated with a detergent-free EDTA buffer under optimized conditions [186]. The EDTA 
treatment does not require a blender, which is likely to increase lysis. Spent biomass is then 
separated from the crude nOMV with consecutive centrifugation and depth-filtration. These steps 
remove all pathogenic activity from the crude nOMV without the need for hazardous chemicals 
like phenol. However, the centrifugation still requires handling in a biohazard cabinet, with 
risk of contamination, and limits the process scale to approximately 100 L cultivation volume. 
Therefore future improvements will include the implementation of alternatives, like continuous 
flow centrifugation for initial biomass removal, as demonstrated for Bordetella pertussis and fragile 
mammalian cells [259, 260]. 
During downstream processing (Figure 3A), the crude nOMV are concentrated with ultrafiltration, 
and nuclease is added for digestion of any DNA. Subsequent gel filtration chromatography 
removes impurities and ensures a high final PorA content. These steps replace ultracentrifugation, 
which is commonly used and effective but limits the production scale. Ultracentrifugation also 
requires manual homogenization of multiple nOMV pellets. This is performed in a flow cabinet, 
with risk of contamination, and followed by a micro fluidizer treatment that imposes excessive 
shear force. The current process uses scalable, aseptic equipment and allows the nOMV to 
remain a stable colloid suspension during all production stages. Overall PorA recovery is good, 
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approximately one third of the initial crude nOMV yield. The ultrafiltration and nuclease steps 
give reproducible results but are not yet optimized, resulting in higher losses and offering room for 
future improvement. Importantly, sterile filtration of bulk nOMV is performed without detectable 
losses and obviates the need for preservatives like thiomersal. This is an notable benefit of the 
detergent-free approach, ensuring that the nOMV are non-aggregated and smaller than the filter 
cut-off (<220 nm). Detergent-extracted OMV are prone to aggregation and more heterogeneous in 
size, resulting in significant losses during sterile filtration [61, 185, 226]. Even though these issues 
do not affect immunogenicity, it is clearly beneficial to prevent them by omitting the detergent-
extraction [107].
Overall PorA yield of the new production process is substantially higher than the yield of 
published reference processes with or without detergent-extraction (Figure 3B) [49, 61, 253]. This 
is a cumulative benefit of production strains with rmpM mutation [185], a higher biomass yield, 
and a generally more efficient process. RL strain 3 had a lower yield than the other strains but 
not as a result of the process, which gave reproducible results for all three strains. The lower 
yield may originate from a less effective assembly of recombinant PorA antigens in strain 3, but 
this remains speculative. One of the reference processes [49] was commercialized to control a 
meningitis epidemic in New Zealand. Compared to that reference, the current process shows a 
higher PorA yield for all RL strains, avoids components of animal origin (deoxycholate), and is 
scalable to at least 800 L cultivation volume [4]. Therefore it is likely to be feasible at commercial 
scale. 
Quality Control testing showed that product quality is within preset criteria for all 9 bulk nOMV 
batches, an important indicator for process performance (Table 2A). The product quality has been 
constant for at least the first year of an ongoing real-time stability study (Appendix 3). This study 
seeks to show stability for up to three years. Endotoxic activity of the bulk nOMV is approximately 
25-fold lower than a low-toxicity vaccine based on detergent-extracted OMV [257] or the DTP-
IPV vaccine with whole-cell pertussis component. Long used in the Dutch national vaccination 
program, that DTP-IPV vaccine had a relatively high rate of adverse events and was replaced 
in 2005 with one containing acellular pertussis [261, 262]. It thus represents the upper range of 
low endotoxic activity, providing a useful context for our results. Functional immunogenicity 
of the trivalent bulk nOMV in mice is high, and comparable to detergent-extracted HexaMen 
and NonaMen vaccine [5, 61]. The improved production process therefore generates high quality 
nOMV that are likely to be well-tolerated and induce a functional immune response in humans 
(Table 2B-C). The contribution of individual PorA antigens needs to be assessed in more detail, 
since subtypes P1.7-1,1 and P1.18-1,3,6 gave low titers or few responders. Other studies with 
multivalent PorA vaccine confirm this observation [5, 258]. Priming with monovalent OMV from 
less immunogenic PorA subtypes before immunization with the multivalent vaccine may solve 
this issue [126]. A recent study with mice and rabbits confirmed that NonaMen vaccine from the 
improved process induced broad immunogenicity without related toxicity or pathology. These 
results encourage clinical evaluation [258].
The scope of the novel production process is not restricted to the NonaMen concept and may 
be applicable for the late-stage development of other nOMV vaccines. These include promising 
serogroup B concepts with a different antigen composition or vaccines against other N. meningitidis 
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serogroups [63, 64, 82, 187, 188, 190, 231]. The outer membrane vesicles from gram-negative 
pathogens in general, like Escherichia coli, Vibrio cholera, or Bordetella pertussis, are also within the 
scope if the upstream process is adjusted to meet the nutritional requirements of these pathogens 
[83, 84, 263-267]. Even recombinant antigens derived from other pathogens may benefit from an 
OMV presentation form [70, 268-270]. This work thus provides a robust production platform to 
facilitate the late-stage development and clinical evaluation of nOMV vaccines.
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Appendix 1
Genetic modifications of the trivalent RL production strains. 
The RL strains are non-encapsulated variants of strain H44/76, in which rmpM (R) and lpxL1 (L) genes 
have been disrupted to improve yield and attenuate LPS toxicity (galE truncated lpxL1-LPS). Each RL 
strain has 3 cloning sites for recombinant antigens. The NonaMen vaccine concept (nonavalent PorA) was 
used to evaluate performance of the new production process. Therefore all cloning sites of the trivalent 
RL strains contained PorA subtype variants. The RL strains are genetically stable for at least 30 genera-
tions of growth beyond the regular production harvest, in the absence of selective antibiotics.
Strain Cloning site 1 Cloning site 2 Cloning site 3 LPS type Other mutations Genetic stability
RL strain 1 porA P1.7,16 porA P1.5-1,2-2 porA P1.19,15-1
ΔgalE
ΔlpxL1
Δcps
ΔrmpM
ΔporB
ery-R
kan-R
cam-R
confirmed
RL strain 2 porA P1.22,14 porA P1.7-1,1 porA P1.18-1,3,6 confirmed
RL strain 3 porA P1.5-2,10 porA P12-1,13 porA P1.7-2,4 confirmed
Appendix 2
Comparison of large-scale OMV production processes. 
The table shows how important OMV processing aspects are addressed in the current production process 
and in large-scale reference processes. Reference 1 [253] is most comparable to the current process, since 
both are detergent-free. References 2 [49] and 3 [61] use detergent-extraction. 
process aspect current process reference process 1 reference process 2 reference process 3
reduce LPS toxicity ΔlpxL1 ΔlpxL1 deoxycholate extraction
deoxycholate 
extraction
components of animal 
origin none casamino acids
casamino acids, 
deoxycholate deoxycholate
working volume 
bioreactor 40 L* 270 L 15 L 135 L
undefined medium 
components none casamino acids
casamino acids, 
yeast extract yeast extract
reduce foam foam breaker antifoam not described not described
concentrate biomass microfiltration continuous centrifugation centrifugation
cont. centrifugation, 
centrifugation
increase OMV release ΔrmpM, detergent-free extraction
blender, detergent-
free extraction
deoxycholate 
extraction
deoxycholate 
extraction
inactivate biomass depth filtration phenol, heat deoxycholate deoxycholate
remove biomass centrifugation** centrifugation centrifugation centrifugation
increase OMV 
concentration ultrafiltration ultrafiltration ultracentrifugation ultracentrifugation
remove impurities nuclease, gel filtration
nuclease, 
ultracentrifugation ultracentrifugation ultracentrifugation
sterilize filtration micro fluidizer, filtration thiomersal thiomersal
*The 40 L bioreactor has been successfully scaled to 800 L [4]. **Will be replaced with continuous 
centrifugation if scale-up to >100 L cultivation volume is required. 
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Appendix 3
Real-time stability of bulk nOMV. 
Results of an ongoing stability study are shown at 0, 3, 6 and 12 months after production. They are pre-
sented as (A) Quality Control tests for general stability aspects and (B) Stability of selected PorA epitopes. 
Results were highly reproducible throughout the study, as confirmed by trend analysis, indicating that 
the bulk nOMV were stable for at least one year after production. 
3A – general characteristics (n=3)
QC parameter unit t = 0 t = 3 t = 6 t = 12 trend p-value*
sterility – sterile not available not available sterile not applicable
PorA content % total protein 72 ± 8 77 ± 3 72 ± 4 73 ± 5 >0.05 (0.91)
OMV size nm 82 ± 7 82 ± 7 82 ± 7 81 ± 7 >0.05 (0.86)
aggregation % 3 ± 4 1 ± 2 2 ± 2 0 ± 1 not available**
pH – 7.4 ± 0.1 7.3 ± 0.2 7.4 ± 0.1 7.3 ± 0.2 >0.05 (0.61)
3B – epitope concentration (n=1)
bulk NOMV unit t = 0 t = 3 t = 6 t = 12 trend p-value*
RL strain 1 (P1.7,16) mg/mL 0.39 0.41 0.53 0.55 not available**
RL strain 2 (P1.22,14) mg/mL 0.50 0.47 NA*** 0.47 not available**
RL strain 3 (P1.12,13) mg/mL 0.63 0.54 0.57 0.50 not available**
*P-value >0.05 indicates that the time trend does not deviate significantly from a non-zero slope (confirms 
stability). **Skewed distribution and/or sample size too small. ***Missing data point.
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Chapter 8
Preclinical safety and 
immunogenicity evaluation of 
a nonavalent PorA native outer 
membrane vesicle vaccine against 
serogroup B meningococcal disease
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Abstract
Background. An improved nonavalent PorA native outer membrane vesicle vaccine 
was developed with intrinsic adjuvating activity due to presence of less-toxic (lpxL1) 
LPS. In the present study, the safety and immunogenicity of this next-generation 
NonaMen vaccine were evaluated following repeated vaccination in rabbits and mice. 
Methods. A repeated–dose toxicology study was performed in rabbits. Immunogenicity 
of next-generation NonaMen was evaluated by determining the serum bactericidal 
antibody (SBA) titers against meningococcal serogroup B strains containing several 
PorA subtypes. Release of the pro-inflammatory cytokine, interleukin-6 (IL-6), by 
the human monocyte cell line (MM6) was measured to estimate pyrogenic activity. 
Results. No toxicologically relevant findings were noted in vaccinated rabbits receiving 
plain next-generation NonaMen. In agreement, next-generation NonaMen induced reduced 
amounts of the pro-inflammatory cytokine, IL-6, released by human monocyte cell line. 
In both rabbits and mice, next-generation NonaMen induced high SBA titers against all 
tested MenB strains regardless of whether or not aluminum phosphate adjuvant is used. 
Conclusions. The data suggests that next-generation NonaMen is a safe vaccine with the potential 
to develop a broadly protective immune response and encourage the start of the first clinical 
studies.
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Introduction
At present, no broadly protective vaccine against MenB strain infections is available. So far, 
only MenB vaccines based on OMV have been proven successful in controlling prevailing MenB 
epidemics [3, 50-54]. OMV vaccines have been traditionally prepared with detergent extraction 
to remove reactogenic lipopolysaccharides (LPS) and to increase vesicle release. The LPS of N. 
meningitidis is highly toxic, but residual amounts are needed to maintain the outer membrane 
vesicle structure and to potentiate the immune response by its adjuvating activity [93]. The use 
of a detergent has major disadvantages. Along with LPS, detergents remove phospholipids and 
membrane lipoproteins that may contribute to immunogenicity [72, 94]. In addition, the vesicle 
integrity can be affected by treatment with detergent resulting in aggregation of the OMV vaccine 
product [61, 185]. A detergent-free OMV purification process retains all LPS, which results not only 
in a preserved native vesicle structure, but also in an OMV vaccine product that is too toxic for 
parenteral immunization [3]. Discovery of lpxL1 mutant strains, at the Institute for Translational 
Vaccinology (Intravacc) in the Netherlands, provides a solution for the undesired toxic effect of 
LPS [6, 70]. Inactivation of the lpxL1 gene attenuates LPS toxicity, while preserving the adjuvant 
activity needed to potentiate the immune response [6, 94]. Human monocytes, macrophages 
or peripheral blood mononuclear cells exposed to lpxL1-LPS induced less pro-inflammatory 
cytokines compared to exposure to wild-type LPS, indicating that the reactogenicity of lpxL1-LPS 
in human is expected to be far less than that of wild-type LPS [72, 94, 185, 271, 272]. Furthermore, 
it was found that the poor immunogenicity of OMV from LPS-deficient strains could be restored 
by adding external lpxL1-LPS [105, 106]. 
PorA protein (class 1 protein) has been identified as major protective antigen of N. meningitidis. 
However, many PorA protein variants exist among circulating strains which complicates 
development of a broadly protective vaccine. To circumvent this, three meningococcal serogroup 
B vaccine strains obtained from the H44/76 parental strain were genetically engineered to express 
three different PorA subtypes [5, 273]. OMV from these three recombinant strains were pooled 
to obtain the nonavalent PorA vaccine (NonaMen). NonaMen has the potential to prevent the 
majority of serogroup B infections in Europe, i.e. 80% of cases [5, 7, 62]. Based on the most recent 
national surveillance data available, our NonaMen vaccine formulation is expected to protect 
in 2007, 2008, 2009, 2010 and 2011 against respectively 89.0%, 89.3%, 94.0%, 91.7% and 85.5% of 
the occurring MenB sero-subtypes in the Netherlands. Previously, detergent-extracted NonaMen 
was shown to be safe and immunogenic in rabbits and mice and well-tolerated in healthy adults 
[5, 273]. Unfortunately, the need of a detergent for removal of toxic LPS in the production process 
of this NonaMen resulted in an OMV product with lower quality, i.e. partially disintegrated and 
aggregated vesicles [61]. Inactivation of the lpxL1 gene has solved this problem and facilitated a 
stable OMV vaccine product without the need for detergent extraction to remove toxic LPS. To 
address the safety and immunogenicity of this next-generation NonaMen vaccine, a repeated 
dose study was conducted in both rabbits and mice. 
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Material and methods
Vaccine preparations
Three trivalent PorA vaccine strains, which were genetically modified by inactivation of the 
lpxL1 gene, were developed from a rmpM deletion mutant of the H44/76 MenB parental strain 
(Figure 1). [6, 185]. The subsequent three trivalent bulk OMV products were pooled to generate 
the next-generation nonavalent vaccine (NonaMen). Vaccine doses were based on total PorA 
concentration. Plain NonaMen 7.5 or 15 (contained respectively 7.5 μg or 15 μg PorA per subtype 
per dose of 0.5 mL) were formulated in Tris-sucrose buffer. Adjuvated NonaMen 15 (15 μg PorA 
per subtype per dose of 0.5 mL) was formulated in Tris-sucrose buffer containing aluminum 
phosphate (3 mg/mL). A dose of 15 μg/PorA type in 0.5 mL represents the highest intended 
human dose. Placebo consisted of Tris-sucrose buffer containing aluminum phosphate (3 mg/
mL) without MenB component. 
GLP toxicology study in rabbits
A fully GLP compliant repeated-dose toxicology study (including local tolerance) was performed 
by an external contract research laboratory. Four groups of New Zealand White rabbits (2-3 kg), 
each consisting of 5 main animals per sex, and 3 recovery animals per sex, were immunized by 5 
intramuscular injections, on days 1, 15, 29, 43 and 57, in alternating hind limbs. At day 60, main 
animals were bled under anesthesia. Recovery of initial pathological effects was investigated in 
the remaining recovery animals that were sacrificed and bled at day 71. The four groups received 
respectively, placebo, plain NonaMen 7.5, plain NonaMen 15 or adjuvated NonaMen 15. Rectal 
body temperature was measured 4 hours after vaccination based on results of a previous study 
in which body temperature was measured continuously by using implanted temperature data 
showing a peak temperature 4 hours after vaccination with NonaMen [274]. At the end of the 
study, macroscopic examination of organs, including organ weights, and histopathology on 
selected tissues were performed by a veterinary pathologist. Blood samples were taken at days 4, 
57, 60, and 71 to determine relevant hematology and biochemical safety parameters. 
Figure 1.
Schematic design of the three trivalent vaccine strains derived from the H44/76 parental (PorB deficient) 
strain that were used for preparing next-generation NonaMen.
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Monocyte activation test
The pyrogenicity of the next-generation NonaMen was assessed by an in vitro monocyte 
activation test (MAT) as previously described [185]. Apart from the adjuvated and plain next-
generation NonaMen 15, a Diphtheria toxoid (30 IU), Tetanus toxoid (60 IU), whole cell Pertussis 
(4 IU), Inactivated Poliomyelitis Virus (type 1 (40 D-antigen units (DU)); type 2 (4 DU); type 
3 (7.5 IU)) (DTwcP-IPV) vaccine (supplied by Netherlands Vaccine Institute) and a previously 
clinically tested deoxycholate-extracted OMV (dOMV) NonaMen (lot005; containing galE-LPS; 
15 μg PorA per subtype per human dose of 0.5 mL) [273], were included in MAT. Briefly, human 
monocytic MM6 cells [120] were incubated for 20 hours at 37 °C in a humid atmosphere with 5% 
CO2 with various dilutions of the vaccine samples. Release of human interleukin-6 (IL-6) by MM6 
cells was determined with a commercially available enzyme immunoassay (ELISA) according 
to the manufacturers’ instructions (Sanquin, Amsterdam, The Netherlands). Dilution series of 
supernatants and IL-6 standard were tested in quadruplicates. 
Biochemical analysis of vaccine
Total protein concentration, total PorA concentration and LPS concentration of the vaccine 
samples were determined for plotting IL-6 release from MAT against these parameters (Figure 2) 
Total protein concentration was measured as described previously [112]. Total PorA concentration 
was determined with quantitative SDS gel electrophoresis PorA under denaturing conditions 
[275]. LPS concentration was determined with a modified gas chromatography method as 
described previously [185]. Amount of LPS per vaccine sample was calculated based on the mass 
of the corresponding LPS molecules. The molecular weight of the galE-lpxL1-LPS present in next-
generation NonaMen vaccine and the galE-LPS present in dOMV NonaMen were estimated at 
respectively 3191 g/mol and 3374 g/mol based on mass spectrometry data. The molecular mass 
of LPS present in DTwcP-IPV was estimated at 3728 g/mol, which was calculated based on the 
published LPS structure of Bordetella pertussis [276].
Immunogenicity in rabbits and mice by serum bactericidal activity assay
NIH female mice aged between 6-8 weeks were obtained from own breeding facilities. A total of 
10 mice were immunized four times subcutaneously in the groin area at days 1, 22, 43 and 64 with 
either plain NonaMen 1.5 (1.5 μg per PorA), plain NonaMen 0.75 (0.75 μg per PorA) or adjuvated 
NonaMen 1.5 (1.5 µg per PorA). Blood samples from mice were taken two weeks after the fourth 
immunization, since a 4-dose vaccination schedule is intended for humans. Animals were bled 
under anesthesia. In addition, blood samples from rabbits of the GLP toxicology study were 
used that were taken two weeks after the fourth immunization. Collected sera were stored until 
analysis at -20 °C. The serum bactericidal antibody (SBA) assay was performed as previously 
described [5, 118]. In this assay, the lytic activity of sera from the immunized animals was 
determined against nine monovalent isogenic MenB test strains derived from H44/76 parental 
strain, each representing PorA present in the NonaMen vaccine strains, i.e. P1.5-1,2-2; P1.7,16; 
P1.19,15-1; P1.5-2,10; P1.12-1,13; P1.7-2,4; P1.22,14; P1.7-1,1; P1.18-1,3,6. Briefly, sera were thawed 
and heat-inactivated for 30 minutes at 56°C. Two-fold serial dilutions of serum with 105 bacteria 
CFU/mL were allowed to incubate for 15 minutes at room temperature in 96-well plates. Baby 
rabbit complement was added at a final concentration of 20% (Invitrogen), zero-time samples 
were taken, and the 96-well plates were incubated at 37°C for 60 minutes. The serum bactericidal 
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titer was reported as the reciprocal of the lowest serum dilution yielding ≥ 90% bacterial killing. A 
SBA titer of < 8, the lowest serum dilution determined in the assay, was considered negative, i.e. 
non-responder. All animal experiments were performed according to the current animal welfare 
regulations in the Netherlands. According to Dutch legislation, the institutional Animal Ethical 
Review Committee evaluated and approved all experiments. 
Statistical analysis
Dunnett-test based on pooled variance significance was performed to compare body temperature 
of NonaMen-treated animals with placebo treated animals in the GLP toxicology study (Table 1). 
SBA titers were statistically analyzed with the non-parametric Mann-Whitney test to compare 
differences between the various treatment groups. P-values below 0.05 were considered to be 
significant.
Figure 2.
IL-6 release by MM6 cells after incubation of various dilutions of human dose of plain next-generation 
NonaMen (15 µg per PorA/human dose; > 60% PorA of protein content, with 10-20% (lpxL1-)LPS of 
protein content) (circles), aluminum phosphate adjuvated next-generation NonaMen (15 µg per PorA/
human dose; squares), deoxycholate-extracted OMV NonaMen (15 µg per PorA/human dose; > 60% PorA 
of protein content, with 2-8 % LPS of protein content; upright triangle) and a human dose of diphtheria, 
tetanus, whole cell pertussis, inactivated poliomyelitis combination vaccine (DTwcP-IPV) vaccine 
(standing down triangle). IL-6 release was plotted against dilution factor, LPS concentration and PorA 
protein concentration of the vaccine samples.
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Results
GLP toxicology study in rabbits
No relevant findings regarding local and systemic toxicology were macroscopically noted in the 
vaccinated rabbits. A slight increase in rectal temperature (0.1°C–0.9°C) was found in NonaMen-
treated animals compared to placebo at 4 hours after each dosing. However, 24 hours after 
vaccination, no difference in body temperature was observed in any animal (Table 1). Treatment-
related changes in hematology and clinical biochemistry parameters were generally minor and 
transient. An independent expert rated the observed changes as expected effects of vaccination 
in general rather than vaccine-specific signs of toxicity. Histopathological findings were limited 
to injection sites, regional iliac lymph nodes and bone marrow. In both plain NonaMen treatment 
groups, an inflammatory reaction at the injection site was characterized by infiltration of 
lymphocytes, which is inherent to the generation of an immune response to vaccination, whereas 
in the placebo treatment groups more often macrophages were present. In animals receiving 
adjuvated NonaMen 15 occasionally granulomatous inflammation areas were observed at the 
injection site. In conclusion, next-generation NonaMen was well-tolerated in rabbits receiving 
five injections. 
Monocyte activation test
IL-6 release by MM6 cells was considerably lower after incubation with next-generation NonaMen 
compared to the reference vaccine samples, DTwcP-IPV vaccine and dOMV NonaMen, with 
established safety profile in humans [273, 277] (Figure 2). Adjuvated next-generation NonaMen, 
however, induced release of IL-6 levels that was comparable to DTwcP-IPV vaccine and dOMV 
NonaMen. MM6 cells incubated with aluminum phosphate alone, in similar concentrations as 
present in adjuvated vaccine samples, did not release any IL-6 above background levels. 
Immunogenicity in rabbits and mice
In rabbits, NonaMen induced high SBA titers against all nine monovalent MenB strains that 
expressed the different PorA’s present in NonaMen, i.e., P1.7,16; P1.5-1,2-2; P1.19,15-1; P1.5-2,10; 
P1.12-1,13; P1.7-2,4; P1.22,14; P1.7-1,1 and P1.18-1,3,6 (Figure 3A). High SBA titers were also found 
in mice, but were more variable between the different PorA subtypes (Figure 3B). Considering 
both geometric mean SBA titers and number of responders of the mice, high SBA responses 
were measured against P1.7,16, P1.5-1,2-2, P1.5-2,10 and P1.12-1,13, intermediate responses were 
observed to P1.7-2,4 and P1.22,14 and lower responses to P1.19,15-1, P1.18-1,3,6, and P1.7-1,1. 
Rabbits receiving 4 doses of plain NonaMen 15 (15 μg per PorA) had a SBA titer that was slightly, 
but statistically significant, higher compared to rabbits receiving the lower vaccine dose (7.5 µg 
per PorA) against 5 out of the 9 PorA subtypes, i.e. P1.7,16; P1.19,15-1; P1.7-2,4; P1.22,14 and 
P1.7-1,1 (Figure 3A). In mice, only for the P1.5-1,2-2 PorA subtype a slightly, but statistically 
significant, higher SBA titer was found in the highest vaccine dose of 1.5 µg per PorA compared 
to the lower dose (0.75 µg/PorA). Strikingly, no potentiating immunogenic effect of aluminum 
phosphate adjuvant was observed for the 9 PorA antigens, except for a small, but statistically 
significant, increase in SBA titer against the P1.5-1,2-2 subtype in rabbits (Figure 3B).
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Table 1. 
Average body temperature in °C (± standard deviation) of rabbits measured after vaccination. */** Dunnett-
test based on pooled variance significance at 5% (*) or 1% (**) level. Body temperature of animals vaccinated 
with next-generation NonaMen (next-Nona) was compared with aluminum-phosphate adjuvated placebo 
(adj. placebo) treated animals. Body temperature 24 hours after vaccination was only measured if one of 
the animals had a body temperature ≥ 40.0 °C.
time 
after 
vacc.
Female treatment groups Male treatment groups
adj. 
placebo
next-Nona
(7.5)
next-Nona
(15)
adj. next-
Nona (15)
adj.
placebo
next-Nona
(7.5)
next-Nona
(15)
adj. next-
Nona (15)
Day 1 (1st vaccination)
4 hrs 39.3 ± 0.1 39.8** ± 0.2 40.0** ± 0.3 39.7** ± 0.2 39.1 ± 0.2 39.9** ± 0.2 40.0** ± 0.4 39.9** ± 0.3
24 hrs 39.1 ± 0.2 39.2 ± 0.1 39.1 ± 0.2 39.1 ± 0.1 39.0 ± 0.1 39.0 ± 0.2 39.1 ± 0.1 39.2 ± 0.3
Day 15 (2nd vaccination)
4 hrs 39.2 ± 0.2 39.6* ± 0.2 39.7** ± 0.4 39.5* ± 0.1 39.0 ± 0.2 39.5** ± 0.2 39.7** ± 0.2 39.6* ± 0.2
24 hrs 39.1 ± 0.2 39.2 ± 0.1 39.1 ± 0.3 39.1 ± 0.1 - - - -
Day 29 (3rd vaccination)
4 hrs 39.1 ± 0.1 39.4* ± 0.1 39.4* ± 0.2 39.3 ± 0.2 39.0 ± 0.1 39.4* ± 0.3 39.5** ± 0.2 39.6** ± 0.4
24 hrs - - - - 39.0 ± 0.2 39.0 ± 0.2 39.1 ± 0.2 39.1 ± 0.2
Day 43 (4th vaccination)
4 hrs 39.3 ± 0.1 39.4 ± 0.2 39.5 ± 0.3 39.5 ± 0.2 39.1 ± 0.1 39.5** ± 0.2 39.6** ± 0.2 39.7** ± 0.3
24 hrs - - - - 39.0 ± 0.2 39.0 ± 0.2 39.1 ± 0.2 39.1 ± 0.1
Day 57 (5th vaccination)
4 hrs 39.3 ± 0.1 39.6** ± 0.1 39.5* ± 0.2 39.4 ± 0.1 39.0 ± 0.2 39.6** ± 0.3 39.7** ± 0.2 39.6** ± 0.2
24 hrs - - - - - - - -
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Figure 3.
Serum bactericidal antibody responses to monovalent isogenic MenB test strains each expressing a single 
PorA subtype present in the vaccine strains, i.e. P1.5-1,2-2; P1.7,16; P1.19,15-1; P1.5-2,10; P1.12-1,13; P1.7-
2,4; P1.22,14; P1.7-1,1; P1.18-1,3,6 are presented for immunized in rabbits (A) and mice (B). Animals were 
four times immunized with low dose next-generation NonaMen (7.5 μg and 0.75 μg per PorA resp. for 
rabbits and mice; black bars), high dose next-generation NonaMen (15 µg and 1.5 µg per PorA resp. for 
rabbits and mice; dark gray bars), and next-generation aluminum phosphate adjuvated NonaMen (15 µg 
and 1.5 μg per PorA resp. for rabbits and mice; light gray bars). Geometric mean SBA titers and standard 
deviation are presented for each PorA sero-subtype per treatment group.
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Discussion
The present study evaluated the safety and immunogenicity of next-generation NonaMen 
vaccine in rabbits and mice. Next-generation NonaMen contains nine different PorA subtypes 
to provide broad coverage against MenB disease [5, 7, 62]. Previously, deoxycholate-extracted 
OMV (dOMV) NonaMen vaccine was shown to be well-tolerated in healthy adults [273]. dOMV 
NonaMen (15 µg per PorA/per dose; > 60% PorA of protein content) had low LPS content (2-8% 
of protein content). However, the use of detergents to remove toxic LPS resulted in a vaccine 
with lower quality caused by partially disintegrated and aggregated vesicles. For this reason, 
next-generation NonaMen, containing attenuated lpxL1 LPS, was developed with an optimized 
detergent-free and animal-free production process [275]. Next-generation NonaMen (15 μg per 
PorA/per dose; > 60% PorA of protein content), with no need to remove LPS with detergent 
extraction, had consequently higher (lpxL1-)LPS content (10-20% of protein content). The (lpxL1-)
LPS content of next-generation NonaMen may be relatively low compared to other native OMV 
vaccine concepts containing (lpxL1-)LPS, which can be explained by the fact that the EDTA 
extraction step in our vaccine production process have shown to remove a (minor) portion of 
(lpxL1-)LPS [185].
In order to evaluate the safety of next-generation NonaMen, a GLP toxicology study in rabbits 
was performed. No relevant findings regarding clinical signs or biochemical/hematology safety 
parameters were noted after five immunizations. Some animals receiving adjuvated NonaMen 
but not plain NonaMen had localized inflammations at the injection site that were sometimes 
accompanied with granulomatous areas with central necrosis. With respect to body temperature, 
only a minimal and transient increase (≤ 0.9 ˚C) was observed after vaccination with NonaMen 
compared to placebo. These results are in agreement with a pilot study performed prior to the 
GLP toxicology study using implanted data loggers for continuous body temperature monitoring 
in rabbits after vaccination with next-generation NonaMen [274].
Pharmaceutical products intended for parenteral administration, including vaccines, have to be 
tested for its pyrogenic risk. Until recently, the rabbit pyrogen test and the Limulus Amebocyte 
Lysate (LAL) test were the standard methods accepted by regulatory authorities for the detection 
of pyrogens [278, 279]. Since both tests are intended to detect minimal pyrogen contamination, 
they are less suitable for bacterial vaccines that contain considerable amount of LPS. The monocyte 
activation test (MAT) represents a more suitable alternative method for estimating pyrogenicity 
of pharmaceuticals [278-280] and has recently been accepted by regulatory authorities and 
included within the European Pharmacopoeia (Chapter 2.6.30 Monocyte Activation Test). The 
MAT, measuring the release of pro-inflammatory cytokines by monocytic cells, is expected to 
reflect the reactions of the human innate immune system better than the other two conventional 
methods. In the present study, monocytic cells released less IL-6 following incubation with 
next-generation NonaMen than DTwcP-IPV vaccine or aluminum-phosphate adjuvated dOMV 
NonaMen vaccine. Previously, adjuvated dOMV NonaMen was well-tolerated in healthy adults 
without any cases of fever in the treatment groups receiving only the NonaMen vaccine [273]. 
MAT results therefore indicate that the pyrogenic activity of next-generation NonaMen is likely 
to be low, which is in line with the limited effect observed on body temperature of the rabbits in 
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the toxicology study. In agreement, studies with other OMV products from lpxL mutant strains 
have shown reduced toxicity based on MAT data [6, 63, 94, 185]. Adjuvated next-generation 
NonaMen induced considerably more IL-6 release than plain NonaMen, which was comparable 
to adjuvated dOMV NonaMen and DTwcP-IPV vaccine. Apparently, OMV product together with 
aluminum phosphate adjuvant resulted in an increased release of IL-6. This difference between 
plain and adjuvated NonaMen was not reflected in the effects on body temperature in the rabbits 
of the toxicology study, however, the rabbits that received adjuvated NonaMen did show more 
local reactions compared to plain NonaMen.
Currently, the SBA assay is the primary serological assay for the evaluation of the immunogenicity 
of vaccines against N. meningitidis and has generally been accepted as surrogate endpoint of 
group B meningococcal vaccine efficacy [46, 281, 282]. The present study showed that next-
generation NonaMen, even without adjuvant, was immunogenic in both rabbits and mice (Figure 
3). SBA titers in rabbits were generally high, while the SBA titers in mice varied more between 
the different PorA subtypes. It should be taken into account that mice received only one-tenth 
of the vaccine dose (1.5 μg per PorA subtype) that was given to the rabbits in the toxicology 
study, i.e. the highest intended human dose (15 μg per PorA subtype). Nevertheless, differences 
in immunogenicity between PorA subtypes have been observed in other preclinical and clinical 
studies as well. In agreement with our findings in mice, in clinical studies with MenB OMV 
vaccines the immunogenicity of PorA subtype P1.19,15 was lower than the P1.7,16 subtype [55, 
283, 284]. Our results were also in accordance with previous studies in mice with our nonavalent or 
hexavalent PorA dOMV vaccines showing variable SBA titers among the different PorA subtypes 
[5, 118]. Previously, it has been shown that PorA dOMV vaccines from Intravacc induced SBA 
responses against wild-type isolate strains with PorA vaccine subtypes at the same magnitude as 
the isogenic vaccine strains in vaccinated toddlers and school children [285]. In addition, cross-
reactivity against several patient isolates from non-vaccine PorA sero-subtypes was observed in 
this clinical study [285].
In the present preclinical study, aluminum-phosphate adjuvant did not further potentiate the 
immunogenicity of the PorA subtypes significantly, indicating that there is probably no need for 
an adjuvant for next-generation NonaMen containing lpxL1-LPS. The majority of lipoproteins that 
have shown to be removed by detergent-extraction in dOMV NonaMen are preserved in next-
generation NonaMen (nOMV) as determined by proteomic technologies (manuscript submitted 
for publication). Additionally, we showed that a trivalent PorA native OMV (nOMV) vaccine 
product, prepared with a detergent-free production process, elicited cross-protection against 
meningococcal serogroup B strains of non-vaccine PorA sero-subtypes [185]. This suggests that 
other minor conserved antigens with the potential to induce bactericidal activity, such as NadA 
or factor H binding protein (fHbp), are retained in next-generation NonaMen, but also (lpxL1)LPS 
may induce bactericidal activity [63, 286-288]. This is in accordance with preclinical and clinical 
study results from another group with nOMV vaccine made from a meningococcal serogroup 
B strain with deleted lpxL1 gene [63, 286-288]. This vaccine was also prepared with a detergent-
free process, but with several undesirable process steps, such as phenol inactivation. The 
vaccine induced higher SBA titers against a PorA heterologous strain than against the parental 
vaccine strain [63, 286]. Furthermore, this experimental nOMV vaccine induced bactericidal 
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antibodies against clinical isolates of other N. meningitidis serogroups C, Y, W, X, and NadA-
expressing serogroup A strains [287, 288]. This underlines that the nOMV vaccine has a broad 
cross-protective potential with a good safety profile [286-288]. Another group has developed an 
experimental nOMV vaccine based on detoxified LPS with L3 immunotype without expression 
of PorA proteins and iron-binding FrpB proteins. This vaccine was produced with detergent 
treatment. Even though the vaccine appeared to be safe and well-tolerated in healthy adults, the 
immunogenicity was disappointing [289]. 
Summarizing, NonaMen has the potential to prevent the majority of serogroup B infection in 
Europe [5, 62, 70]. The present study showed that next-generation NonaMen has a good safety 
profile in rabbits. In agreement with this, the MAT data indicated an acceptable pyrogenicity 
of next-generation NonaMen. The vaccine induced a good functional immune response in both 
rabbits and mice against different PorA proteins. Strikingly, adding aluminum phosphate to next-
generation NonaMen resulted in increased toxicity with respect to local reactions in rabbits 
and in vitro IL-6 release, while the immunogenicity was not further enhanced. Therefore, the 
balance of risks and benefits favors the use of plain next-generation NonaMen instead of the 
adjuvated vaccine. At present, a fully scalable, animal-free, optimized production process has 
been developed, which allows production of GMP clinical batches of next-generation NonaMen 
(manuscript submitted for publication). The presented preclinical results support the start of the 
first clinical studies with this next-generation NonaMen containing lpxL1-LPS, in which, safety 
in humans and the broad potential coverage against wild-type strains can be further explored.
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Abstract
OMV vaccines successfully stopped N. meningitidis serogroup B outbreaks but have limited 
coverage and are difficult to produce, due to a detergent-extraction step with deoxycholate [3, 
61]. The detergent-extraction removes toxic lipopolysaccharide (LPS), but compromises OMV 
integrity [185, 290]. Meningococcal LPS can be attenuated with the lpxL1 mutation, which may 
allow a detergent-free approach [6, 94]. This thesis explores the impact of such an alternative 
approach with the goal to develop an improved, next-generation OMV vaccine. The designation 
‘next-generation’ refers to the combination of OMV with attenuated lpxL1-LPS and a detergent-
free process [70]. Mutations that improve OMV yield (i.e. ΔrmpM) may also be beneficial [75]. 
This thesis covers the full preclinical development phase through evaluation of five hypotheses 
(Figure 1). After strain selection and optimization of specific process steps, a robust pilot-scale 
production process has been developed. The quality of OMV from this optimized process is stable 
and within pre-set specifications for nine consecutive batches. Studies in mice and rabbits suggest 
that next-generation OMV are immunogenic and safe for parenteral use in humans. Therefore 
these vaccines are now ready for clinical evaluation. In addition to N. meningitidis serogroup 
B, other meningococcal serogroups and several gram-negative pathogens were found to release 
immunogenic OMV [229]. It should require only minor adjustments to produce these other OMV 
with the pilot-scale production process described in this thesis. Therefore the current results are 
likely to be relevant for the broader field of vaccinology.
Figure 1. Preclinical vaccine development stages.
This thesis covers all stages of preclinical vaccine development for next-generation OMV vaccine. Concept 
discovery is described in chapter 2, while chapters 3–6 evaluate important characterization and optimization 
aspects. Chapter 7 describes the development of a robust pilot-scale production process, which has been 
used to produce next-generation NonaMen vaccine with broad potential coverage against serogroup B 
meningococcal disease. Safety and immunogenicity of this product has been confirmed in mice and rabbits 
(chapter 8). The results of these different chapters have generated a scientific basis for the hypotheses and 
central research question of this thesis, confirming that next-generation OMV vaccines provide improved 
quality and process robustness. 
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Hypothesis 1: Next-generation OMV vaccines provide improved quality compared to 
detergent-extracted OMV
Previous studies have identified important but separate aspects of next-generation OMV, like 
a detergent-free process [100], attenuated LPS toxicity [6] or a hypothesized positive effect of 
rmpM deletion on OMV yield [75]. Chapter 2 systematically combines these aspects to assess 
feasibility for further development. Three OMV purification processes have been compared, 
referred to as dOMV, nOMV and sOMV (Figure 2). The dOMV process uses bacterial extraction 
with deoxycholate buffer (detergent) to release vesicles and remove most of the LPS [2, 49], while 
nOMV uses a buffer which retains LPS (detergent-free extraction) [100, 101]. The sOMV process 
purifies spontaneously released vesicles without additional treatments (detergent-free, no 
extraction) [97]. These processes have been tested on vaccine strains with mutations to attenuate 
LPS toxicity (ΔlpxL1) or improve OMV yield (ΔrmpM). 
Despite a beneficial effect of ΔrmpM, the sOMV yield is much lower than other processes. During 
clinical trials this difference may not be problematic, but for commercial production sOMV 
will be the more expensive option. Therefore adjustments that further increase sOMV release 
yield will improve feasibility. A promising example of such an adjustment is cysteine starvation 
during the stationary growth phase, which is explored in chapter 6 of this thesis. Chapter 2 also 
demonstrates that detergent-free processes, sOMV in particular, produce vaccines with improved 
immunological properties compared to dOMV (Table 1). The improved immunogenicity has been 
confirmed by Zollinger et al. and substantiates hypothesis 1 [63]. In addition, next-generation 
nOMV and sOMV vaccines have superior biochemical properties and are likely to be safe for 
Figure 2. Differences between OMV production processes.
(A) Production harvest can be purified to OMV with three different processes, referred to as dOMV, 
nOMV or sOMV. First, the bacteria are separated from the culture broth. Bacteria can be extracted with 
a deoxycholate buffer (detergent). This dOMV process releases detergent OMV and removes most of the 
lipopolysaccharide (LPS), but requires extensive downstream purification for deoxycholate removal. The 
nOMV process uses a detergent-free buffer with EDTA to stimulate native OMV release. This approach 
retains LPS and allows simplified purification. The sOMV process purifies spontaneous OMV directly 
from the culture broth, without any treatments to increase vesicle release. This alternative detergent-free 
approach also retains LPS. The sOMV process is the most straightforward, but the vesicle yield is typically 
lower than for dOMV or nOMV. (B) Effects of the different OMV purification processes at the bacterium, 
OMV and LPS level. Most of the descriptions refer to section A. The bacterial cell envelope consists of IM 
(inner membrane), PG (peptidoglycan layer) and OM (outer membrane). The LPS and PorA antigen (outer 
membrane porin A protein) are located in the OM.
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parenteral use in humans [185]. These results provide justification for further development of a 
pilot-scale production process for clinical trials (chapters 5-8).
Hypothesis 2: Biomass extraction during processing changes the immunogenic 
protein content of OMV vaccines
The effect of different purification processes on protein composition of OMV has been investigated 
with a novel proteomics method. The method uses selective purification of N-terminal peptides 
with phospho-tagging (PTAG). Chapter 3 demonstrates that the PTAG strategy is effective and 
broadly applicable [204]. Chapter 4 adds a robust quantification protocol and the protein content 
of sOMV, nOMV and dOMV vaccines has been analyzed. Due to a milder purification process, 
both detergent-free OMV vaccines (nOMV and sOMV) contain less lysis proteins and are enriched 
with potentially immunogenic membrane (lipo)proteins. Serum blot proteomics confirms that 
biomass extraction with detergent (dOMV) indeed removes immunogenic proteins, including 
factor H binding protein [298]. The results of chapter 3–4 therefore confirm hypothesis 2, but 
there are other aspects likely to be relevant for immunogenicity. This includes a differential LPS 
content, which may change the adjuvanting capacity of the vaccine [63, 93]. In dOMV vaccine 
almost all LPS is removed, but this thesis also reveals a difference in LPS content between both 
detergent-free alternatives. Apparently the EDTA treatment removes a small portion of the 
LPS as well. Together with the observed differences in immunogenic protein content, this may 
explain the increasing cross-protection from dOMV, through nOMV to sOMV vaccine observed 
in chapter 2. The proteome analyses in chapter 4 have provided detailed insight in the effects of 
biomass extraction on OMV protein content. It is demonstrated that next-generation OMV, sOMV 
in particular, have a preferred composition.
OMV vaccine
properties OMV quality
strain process yield toxicity morphology immunogenicity cross-protection
reference ΔR dOMV + + + low partly aggregated + –
next-generation 1 ΔR ΔL sOMV + – low defined Ø80 nm + + + + + +
next-generation 2 ΔR ΔL nOMV + + low defined Ø80 nm + + +
Table 1. Quality characteristics of reference and next-generation OMV vaccines.
Reference dOMV vaccine is prepared with detergent-extraction to remove toxic LPS [61]. Next-generation 
OMV vaccines use strains with attenuated lpxL1-LPS (ΔL mutation) and a detergent-free process (either 
sOMV or nOMV). The rmpM mutation (ΔR) improves OMV yield [3]. The vaccines have a different quality 
with respect to yield, toxicity, morphology, immunogenicity and cross-protection. Undesired characteristics 
are depicted in grey. Table 1 indicates that next-generation nOMV vaccine has the best quality, closely 
followed by next-generation sOMV due to a low yield. The dOMV reference has limited cross-protection 
and is partly aggregated, which complicates processing.
155
Chapter 9
Hypothesis 3: Biological stimuli can trigger OMV release by N. meningitidis and can be 
applied to improve vaccine production
Based on the result of chapters 2–4, next-generation nOMV vaccine was selected as the primary 
candidate for further development towards clinical trials. The sOMV vaccine had slightly better 
immunogenicity and a more straightforward large-scale process, but these advantages were 
outweighed by a low yield for which no obvious solution was available. During optimization 
of the nOMV process, it became clear that spontaneous OMV release increased significantly 
during the stationary growth phase, most likely caused by nutrient limitation [186]. This effect 
was also suggested in another recent study by Santos et al. and may improve the sOMV yield 
[291]. In agreement with these observations, chapter 6 has identified cysteine depletion as the first 
known vesiculation stimulus for N. meningitidis. Cysteine depletion causes stationary growth and 
sufficient sOMV release for feasible vaccine production [292]. These results confirm hypothesis 
3. However, minor quality concerns remain, most likely due to a non-optimized sOMV process. 
Measures to prevent cell lysis during the stationary phase would be beneficial. It would also 
be interesting to assess potential differences in  immunogenicity and proteomes of sOMV 
vaccines before and after cysteine depletion. The effect of cysteine on a panel wild-type strains 
would demonstrate whether the observed vesiculation is unique for ΔrmpM–ΔlpxL1 strains. In 
addition, there may be other effective vesiculation triggers for N. meningitidis like heat shock [41, 
80, 81]. Despite these unknown aspects, chapter 6 demonstrated that cysteine depletion can be 
successfully applied to solve the yield issues associated with sOMV production.
Hypothesis 4: Next-generation OMV vaccines allow a more consistent and efficient 
large-scale production process
Chapter 5 has optimized the central processing step of next-generation nOMV vaccine: detergent-
free biomass extraction with EDTA. Out of five process parameters, only harvest point of the 
cultivation and extraction pH are critical and have subsequently been optimized. With the 
optimized EDTA extraction in place, a pilot-scale nOMV production process with 40 L cultivation 
volume has been developed in chapter 7. Scalable aseptic equipment is implemented throughout 
the process, replacing undesirable steps like ultracentrifugation, inactivation with phenol and 
the use of preservatives. The improved process is robust, scalable to at least 800 L cultivation 
volume [4] and with 9–21 fold higher average PorA yield than reference processes [49, 61, 253]. 
In addition, quality of the nOMV vaccines is stable and within preset specifications for nine 
consecutive batches [299]. Chapter 7 therefore supports hypothesis 4. The current improvements 
are expected to enable next-generation nOMV production at commercial scale.
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Hypothesis 5: Despite a high LPS content, next-generation OMV vaccines are safe for 
parenteral use in humans.
Next-generation NonaMen vaccine consists of nOMV from three ΔrmpM–ΔlpxL1 strains, each 
expressing three different PorA’s [5, 7]. The vaccine has been produced with the pilot-scale 
production process from chapter 7, which retains potentially toxic LPS. In vitro analyses already 
suggested that lpxL1-LPS is safe for human use [6, 63, 94], but animal testing is an obligatory 
prerequisite for safety evaluation in humans. Therefore chapter 8 assessed repeated-dose toxicity 
and immunogenicity of next-generation NonaMen in mice and rabbits. The vaccine induced 
high bactericidal titers without signs of toxicology or histopathology. Bactericidal activity may 
however be sligthly overestimated, due to the use of rabbit complement. Notably there is no 
need for an adjuvant, confirming the intrinsic adjuvanting capacity of lpxL1-LPS [93]. The TLR4-
mediated adjuvanting capacity observed in mice may not be fully representative for humans [300], 
but OMV with lpxL1-LPS were found to elicit broad functional immunogenicity in non-human 
primates as well [190]. The results of this thesis therefore encourage clinical safety evaluation, 
as successfully performed for a related next-generation OMV vaccine [187], and provide strong 
additional evidence for hypothesis 5.
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Perspectives
At present, next-generation nOMV vaccine is the best option for clinical testing. The choice for 
nOMV vaccine is arguable and mainly based on the low yield of sOMV vaccine. Both options are a 
significant improvement, but sOMV vaccine has the better immunogenicity and cross-protection 
(Table 1) [185]. However, implementation of an effective vesiculation trigger would greatly 
improve feasibility [292]. Future sOMV process optimization should focus on the upstream 
process, especially the stationary phase in which vesiculation occurs. A robust upstream process 
requires a stable stationary phase with cysteine as the sole depleted nutrient. To prevent additional 
nutrient depletions, a cysteine-free feed that supports maintenance metabolism may be required. 
This minimizes bacterial lysis and allows a clean harvest for downstream processing. Vesiculation 
monitoring would be another beneficial improvement. The fluorescent, phospholipid-specific 
probe described in chapter 6 is well-suited for this purpose. This fast phospholipid assay can 
be automated for monitoring of sOMV release, to pinpoint the optimal harvest point. With 
these improvements a highly reproducible upstream process is obtained, which facilitates a 
straightforward downstream process. 
Several groups are now developing innovative next-generation OMV concepts. The main focus 
remains N. meningitidis serogroup B, but OMV concepts with broad potential coverage against 
other serogroups and concepts against other gram-negative pathogens are emerging [64, 82, 188, 
190, 231]. These include E. coli vesicles with insertion sites for heterologous proteins [269, 270]. 
Recent work also suggests that OMV can enhance the immunogenicity of purified recombinant 
proteins and stimulate Th1-oriented cellular immunity [264, 293]. These findings demonstrate 
that OMV have the potential to become a versatile technology platform for prophylactic and 
therapeutic vaccines. Such a platform requires a reliable production process to generate substantial 
quantities of high quality product. The next-generation nOMV process described in chapter 7 is 
well-suited for this purpose. OMV concepts that are potentially compatible with this process are 
listed in Table 2. 
Most OMV concepts in Table 2 are still in the early preclinical development phase, with the primary 
goal to obtain immunogenic vesicles. Assessment of LPS toxicity, cross-protection or yield is often 
incomplete, even though these aspects are essential for final feasibility. Like meningococcal LPS, 
the LPS of other gram-negative pathogens can cause adverse events. This is illustrated by the 
whole cell pertussis vaccine, which has been used for decades but was recently replaced with a 
less reactogenic, purified protein vaccine [261, 262]. Toxicity of B. pertussis LPS can be attenuated 
with the ΔpagL mutation [119]. For E. coli a comparable mutation is available (ΔlpxM) [270, 295]. 
Like the ΔlpxL1 mutation in N. meningitidis, these mutations target acyl chain biosynthesis. Since 
the next-generation nOMV process retains LPS, the other gram-negative pathogens in Table 2 will 
likely require a comparable modification. 
Potential LPS toxicity, cross-protection or yield issues must be properly addressed for new OMV 
concepts. Once this is done, it should require only minor adjustments to adopt these concepts to 
the next-generation nOMV process. The organisms in Table 2 are all gram-negative pathogens 
with comparable nutritional requirements. The growth medium used in this thesis is developed 
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for N. meningitidis and is chemically defined without components of animal origin [4, 246]. It 
supports high biomass densities for other vesiculating pathogens as well, which has recently 
been confirmed for Shigella dysenteriae, Vibrio cholerae, Klebsiella pneumoniae and Acinetobacter 
baumannii (unpublished data). Demanding pathogens like B. pertussis will likely require fed-
batch cultivation to obtain sufficient biomass for feasible OMV processing [296]. This may be 
beneficial for N. meningitidis as well, since nOMV yield correlates directly to biomass yield in this 
thesis [292]. The downstream process can be uniform regardless the pathogen that is used. All 
studies in Table 2 have obtained vesicle sizes between 20–200 nm with comparable biochemical 
characteristics. The vesicle size distribution is well within the pore size range of the various filters 
that are used for pilot-scale processing. This allows easy pore size adjustment and the use of 
identical gel filtration matrices. Therefore compatibility issues with the next-generation nOMV 
downstream process are not expected.
OMV concept Target organism Required modifications
nOMV nonavalent PorA [258] N. meningitidis serogroup B none (this thesis)
sOMV over-expressed fHbp [190]* N. meningitidis serogroup B ΔrmpM; biomass extraction
dOMV enriched with lpxL1-LPS [231] N. meningitidis serogroup B ΔrmpM; omit detergent
strains with PorA/FetA variants [64] N. meningitidis serogroup B ΔrmpM; ΔlpxL1; omit detergent
nOMV multiple PorA, fHbp, LPS antigens [188] N. meningitidis serogroup B, C, W, X, Y ΔrmpM
sOMV cross-protective fHbp [82]* N. meningitidis serogroup A, B, W, X ΔrmpM; biomass extraction
dOMV from different serogroups [294] N. meningitidis serogroup A, W ΔrmpM; ΔlpxL1; omit detergent
sOMV from high-density cell culture [254]‡ Shigella sonnei growth medium; biomass extraction
cross-protective sOMV [83]*Δ Vibrio cholerae growth medium; biomass extraction
sOMV protein expression platform [270]*‡ heterologous expression (E. coli) growth medium; biomass extraction
sOMV protein expression platform [269]*Δ‡ heterologous expression (E. coli) growth medium; biomass extraction
sOMV [263]*Δ‡ Acinetobacter baumannii growth medium; biomass extraction
dOMV [84]*Δ‡ Bordetella pertussis growth medium; omit detergent
sOMV [265]*Δ‡ Escherichia coli (enterotoxigenic) growth medium; biomass extraction
sOMV [266]*Δ‡ Francisella novicida growth medium; biomass extraction
sOMV [264]*Δ‡ Burkholderia pseudomallei growth medium; biomass extraction
Table 2. OMV vaccine concepts that are potentially compatible with the next-generation nOMV 
process.
The table provides a concept description, the target organism and required modifications. Most concepts 
are still in early preclinical development, where assessment of yield, cross-protection and toxicity is often 
incomplete. These aspects need to be addressed before further development. 
*OMV yield assessment not performed. 
ΔLPS toxicity assessment not performed. 
‡Cross-protection assessment not performed.
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Conclusions 
This thesis describes the full preclinical development and characterization of next-generation 
OMV vaccine, based on strains with attenuated LPS and a detergent-free process [70]. The new 
production process is fully scalable and in agreement with current regulatory requirements. This 
is expected to resolve the production difficulties associated with dOMV technology. In addition, 
next-generation OMV vaccines provide good preclinical safety and immunogenicity [258]. Clinical 
evaluation of broadly protective OMV against N. meningitidis serogroup B is a logical next step, 
due to the extensive experience with this organism [187]. In the meanwhile, the results of this 
thesis can be applied for other meningococcal serogroups and for other pathogens. OMV with 
heterologous antigens may also be within reach. These developments are likely to be compatible 
with the robust OMV production platform described in this thesis. Due to a substantial public 
health interest, this work was funded by the Dutch Ministry of Health, Welfare and Sport [1]. The 
results encourage technology transfer to a commercial partner, with the goal to translate next-
generation OMV technology into actual vaccines and improve global public health.
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Summary
Summary
The development of a vaccine against Neisseria meningitidis serogroup B is of major importance 
for public health. At present only vaccines containing outer membrane vesicles (OMV) have 
proven efficacy. OMV vaccines, however, have limited coverage and are difficult to produce, 
due to a detergent-extraction step with deoxycholate. The detergent-extraction removes toxic 
lipopolysaccharide (LPS), but also compromises OMV integrity. The lpxL1 mutation attenuates 
meningococcal LPS and may allow detergent-free OMV production process. The impact of such 
an alternative approach is explored in this thesis, with the goal to develop an improved, next-
generation OMV vaccine. The designation ‘next-generation’ refers to the combination of OMV 
with attenuated LPS and a detergent-free process. 
Chapter 2 systematically compares three different OMV purification processes (dOMV, nOMV 
and sOMV) in combination with genetic modifications that are expected to attenuate LPS toxicity 
(ΔlpxL1) or improve OMV yield (ΔrmpM). The sOMV purification has yielded significantly less 
OMV than the other processes due to the absence of biomass extraction. Approximately 50% of 
this yield loss can be compensated with the rmpM mutation. Chapter 2 also gives strong evidence 
that next-generation nOMV and sOMV vaccines from ΔrmpM-ΔlpxL1 mutant strains provide 
superior vaccine quality, in terms of vesicle morphology and functional immunogenicity. These 
results justify further development towards clinical trials (chapters 5–8).
Chapter 3–4 describes the development of a novel quantitative proteomics method, which has 
been used to assess the effect of different purification processes on protein content of OMV. The 
method uses the phospho-tag strategy (PTAG) to selectively purify N-terminal peptides after 
proteolytic cleavage. Chapter 3 demonstrates that the PTAG strategy is effective and broadly 
applicable. Chapter 4 adds a quantification protocol and the proteomes of sOMV, nOMV and 
dOMV vaccines have been analyzed. Due to a milder purification process, both detergent-free 
OMV vaccines (nOMV and sOMV) contain less lysis proteins and are enriched with potentially 
immunogenic membrane (lipo)proteins. Serum blot proteomics confirmed that biomass extraction 
with detergent (dOMV) indeed removes immunogenic proteins. Therefore, next-generation OMV 
vaccines, sOMV in particular, have a preferred protein composition.
Based on the result of chapters 2–4, next-generation nOMV vaccine has been selected as the 
primary candidate for further development towards clinical trials, mainly due to the low yield of 
the sOMV process. Later on, it became clear that vesiculation increases significantly during the 
stationary phase. Chapter 6 demonstrates that the vesiculation is caused by cysteine depletion 
and that this stimulus is applicable for sOMV vaccine production. The sOMV yield became 
comparable to nOMV reference yield after approximately 8 hours of cysteine-limited stationary 
phase, therefore this approach may solve the yield issues associated with next-generation sOMV 
vaccine.
Chapter 5 optimizes the central processing step of next-generation nOMV vaccine: detergent-
free biomass extraction with EDTA. Out of five process parameters, only harvest point of the 
cultivation and extraction pH are critical and have subsequently been optimized. Next, a pilot-
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scale nOMV production process with 40 L cultivation volume has been developed in chapter 
7. The new process is robust, scalable and with 9–21 fold higher PorA yield than reference 
processes. In addition, quality of the nOMV vaccines is stable and within preset specifications 
for 9 consecutive batches. These improvements are expected to enable next-generation nOMV 
production at commercial scale. Chapter 8 assesses repeated-dose toxicity and immunogenicity 
of next-generation NonaMen, consisting of nOMV from three vaccine strains, each expressing 
three different PorA antigens. The vaccine induces high bactericidal titers in mice and rabbits 
and none of the rabbits developed signs of toxicity or pathology. These results suggest that next-
generation NonaMen is broadly immunogenic and safe for parenteral use in humans. 
This thesis shows that next-generation OMV have significantly improved quality characteristics 
and are now ready for clinical evaluation. The new, pilot-scale production process is expected 
to resolve the difficulties associated with dOMV technology. Clinical evaluation of broadly 
protective OMV against N. meningitidis serogroup B is a logical next step, but promising OMV 
concepts for other meningococcal serogroups and for other pathogens are also emerging. These 
concepts are likely to be compatible with the nOMV production platform described in this thesis.
165
Samenvatting
Samenvatting
De ontwikkeling van een vaccin tegen Neisseria meningitidis serogroep B (meningokokken) is 
belangrijk voor de volksgezondheid. Op dit moment geven alleen vaccins die gebaseerd zijn 
op ‘outer membrane vesicles’ (OMV’s, ofwel buitenmembraan deeltjes) bescherming tegen deze 
ziekte. De breedte van de bescherming is bij OMV vaccins echter beperkt en ze zijn moeilijk 
te produceren, door een extractie stap met het detergens deoxycholaat. Deze detergens-
extractie verwijdert toxisch lipopolysaccharide (LPS), maar beschadigt daarbij de OMV’s. De 
lpxL1 mutatie zorgt ervoor dat het LPS niet langer toxisch is en maakt daarmee wellicht een 
detergens-vrij productieproces mogelijk. Dit proefschrift verkent de implicaties van zo’n 
alternatief productieproces, met als doel een 2e generatie OMV vaccin te ontwikkelen. De 
benaming ‘2e generatie’ verwijst naar de combinatie van niet-toxisch LPS met een detergens-vrij 
productieproces. 
Hoofdstuk 2 is een systematische vergelijking van drie verschillende OMV productieprocessen 
(dOMV, nOMV en sOMV), die zijn toegepast op genetisch gemodificeerde meningokokken 
met niet-toxisch LPS (ΔlpxL1) en/of een verbeterde OMV opbrengst (ΔrmpM). Het sOMV 
purificatieproces blijkt een significant lagere OMV opbrengst te hebben dan de andere twee 
processen, doordat er geen biomassa-extractie stap wordt gebruikt. Ongeveer 50% van het 
opbrengst verlies kan gecompenseerd worden door de rmpM mutatie te introduceren. Hoofdstuk 
2 bewijst bovendien dat 2e generatie nOMV en sOMV vaccins, geproduceerd met genetisch 
gemodificeerde ΔrmpM-ΔlpxL1 stammen, een sterk verbeterde vaccinkwaliteit bieden. Dit geldt 
zowel voor de morfologie van de OMV’s, als voor de functionele immunogeniciteit van het vaccin. 
Deze resultaten verantwoorden verdere ontwikkeling richting klinische studies (hoofdstukken 5 
t/m 8).
Hoofdstuk 3 en 4 beschrijven de ontwikkeling van een nieuwe kwantitatieve proteomics methode, 
die is gebruikt om het effect van verschillende productieprocessen op de eiwitsamenstelling van 
het vaccin te onderzoeken. De methode is gebaseerd op de ‘phospho-tag strategie’ (PTAG), die 
N-terminale peptiden na proteolyse selectief kan zuiveren. Hoofdstuk 3 laat zien dat PTAG effectief 
is en bovendien breed inzetbaar. In hoofdstuk 4 wordt een kwantificeringsprotocol ontwikkeld, 
waarna de eiwitsamenstelling van sOMV, nOMV en dOMV vaccins is geanalyseerd. Dankzij 
een milder zuiveringsproces, bevatten beide detergens-vrije vaccins (nOMV en sOMV) minder 
celdood eiwitten. Daarnaast zijn deze vaccins verrijkt met potentieel immunogene membraan- 
en lipoproteïnen. Serumblot analyse bevestigt deze bevindingen door aan te tonen dat biomassa 
extractie met detergens (dOMV proces) inderdaad immunogene eiwitten verwijdert. Om deze 
redenen hebben 2e generatie OMV vaccins, sOMV vaccin in het bijzonder, de meest geschikte 
eiwitsamenstelling. 
Gebaseerd op de resultaten van hoofdstuk 2–4, is 2e generatie nOMV vaccin geselecteerd voor 
verdere ontwikkeling richting klinische studies, vooral vanwege de lage opbrengst van het 2e 
generatie sOMV vaccin. Later werd duidelijk, dat spontane OMV vorming sterk toeneemt 
tijdens de stationaire kweekfase. Hoofdstuk 6 laat zien dat de spontane OMV vorming wordt 
veroorzaakt door cysteine limitatie en dat een dergelijke stimulus kan worden gebruikt om de 
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opbrengst van sOMV vaccin productie te verbeteren. Na ongeveer 8 uur cysteine-gelimiteerde 
stationaire fase werd de sOMV opbrengst namelijk vergelijkbaar met die van het nOMV proces. 
Deze cysteine limitatie aanpak kan mogelijk de lage OMV opbrengst van het 2e generatie sOMV 
vaccin verhelpen.
Hoofdstuk 5 optimaliseert de meest centrale processtap van het 2e generatie nOMV vaccin: 
detergens-vrije biomassa extractie met behulp van EDTA. Van de vijf geteste procesparameters, 
bleken alleen het oogstmoment van de kweekstap en de pH kritisch te zijn voor het eindresultaat. 
Deze kritieke procesparameters zijn daarna succesvol geoptimaliseerd. In hoofdstuk 7 is 
een pilot-schaal nOMV productieproces met 40 L kweekvolume ontwikkeld. Dit nieuwe 
productieproces bleek robuust en opschaalbaar, met een 9–21 keer hogere OMV opbrengst dan 
gepubliceerde referentie processen. Bovendien bleek de kwaliteit van de nOMV vaccins stabiel te 
zijn en voor 9 achtereenvolgende producties te voldoen aan vooraf gestelde specificaties. Dankzij 
deze verbeteringen is een nOMV productie proces op commerciële schaal binnen handbereik. 
Hoofdstuk 8 meet de toxiciteit en immunogeniciteit van 2e generatie NonaMen vaccin, wat is 
samengesteld uit OMV’s van 3 vergelijkbare serogroep B meningokokken, die elk 3 unieke PorA 
antigenen tot expressie brengen. Het vaccin induceerde hoge bactericide titers in het serum van 
muizen en konijnen. Bovendien konden er geen relevante tekenen van toxiciteit of pathologie 
worden ontdekt in konijnen die werden geïmmuniseerd met vijf humane doses vaccin. Deze 
resultaten suggereren, dat 2e generatie NonaMen vaccin breed beschermend is en veilig voor 
humane toepassingen.
Dit proefschrift toont aan dat 2e generatie OMV vaccins een sterk verbeterde kwaliteit hebben 
en geschikt lijken voor gebruik in klinische studies. Het nieuwe, pilot-schaal productie proces 
ondervangt naar verwachting alle belangrijke nadelen van dOMV technologie. Klinische 
evaluatie van breed beschermende OMV vaccins tegen serogroep B meningokokken is een 
logische volgende stap. Veelbelovende OMV concepten voor vaccins tegen andere serogroepen 
en andere pathogenen zijn echter ook in opkomst. Het nOMV productieplatform beschreven in 
dit proefschrift is naar verwachting inzetbaar om ook deze nieuwe vaccins te produceren. 
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